



# Lessons learned from intervertebral disc pathophysiology to guide rational design of sequential delivery systems for therapeutic biological factors

Leslie Frapin <sup>a,b</sup>, Johann Clouet <sup>a,b,c,d</sup>, Vianney Delplace <sup>a,b</sup>, Marion Fusellier <sup>a,e</sup>, Jérôme Guicheux <sup>a,b,f,1</sup>, Catherine Le Visage <sup>a,b,\*,1</sup>

<sup>a</sup> Inserm, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRIS, Nantes F-44042, France

<sup>b</sup> Université de Nantes, UFR Odontologie, Nantes F-44042, France

<sup>c</sup> CHU Nantes, Pharmacie Centrale, PHU 11, Nantes F-44093, France

<sup>d</sup> Université de Nantes, UFR Sciences Biologiques et Pharmaceutiques, Nantes F-44035, France

<sup>e</sup> Department of Diagnostic Imaging, CRIP, National Veterinary School (ONIRIS), Nantes F-44307, France

<sup>f</sup> CHU Nantes, PHU 4, OTONN, Nantes F-44093, France

## ARTICLE INFO

### Article history:

Received 8 February 2019

Received in revised form 5 August 2019

Accepted 18 August 2019

Available online 21 August 2019

### Keywords:

Drug delivery systems

Degenerative disc disease

Anti-catabolic factors

Pro-anabolic factors

Cell supplementation

Endogenous repair

## ABSTRACT

Intervertebral disc (IVD) degeneration has been associated with low back pain, which is a major musculoskeletal disorder and socio-economic problem that affects as many as 600 million patients worldwide. Here, we first review the current knowledge of IVD physiology and physiopathological processes in terms of homeostasis regulation and consecutive events that lead to tissue degeneration. Recent progress with IVD restoration by anti-catabolic or pro-anabolic approaches are then analyzed, as are the design of macro-, micro-, and nano-platforms to control the delivery of such therapeutic agents. Finally, we hypothesize that a sequential delivery strategy that i) firstly targets the inflammatory, pro-catabolic microenvironment with release of anti-inflammatory or anti-catabolic cytokines; ii) secondly increases cell density in the less hostile microenvironment by endogenous cell recruitment or exogenous cell injection, and finally iii) enhances cellular synthesis of extracellular matrix with release of pro-anabolic factors, would constitute an innovative yet challenging approach to IVD regeneration.

© 2019 Elsevier B.V. All rights reserved.

## Contents

|   |    |
|---|----|
| 1. Introduction . . . . .   | 50 |
| 2. IVD physiology . . . . .                                       | 50 |
| 2.1. IVD structure . . . . .                                      | 50 |
| 2.2. IVD extracellular matrix homeostasis. . . . .                | 52 |
| 2.3. IVD function. . . . .  | 52 |
| 3. The pathophysiology of IVD degeneration. . . . .               | 52 |
| 3.1. Cellular and molecular changes . . . . .                     | 52 |
| 3.2. Structural and mechanical changes . . . . .                  | 53 |
| 3.3. Diagnosis and current treatments of discogenic LBP . . . . . | 53 |
| 4. Innovative bioinspired therapeutic strategies . . . . .        | 53 |
| 4.1. Anti-catabolic and anti-inflammatory strategies. . . . .     | 54 |
| 4.2. Pro-anabolic strategies . . . . .                            | 55 |
| 4.2.1. Pro-anabolic molecules. . . . .                            | 55 |
| 4.2.2. Cell supplementation. . . . .                              | 58 |
| 5. Sequential delivery systems for IVD regeneration . . . . .     | 59 |
| 5.1. Sequential delivery of biological factors . . . . .          | 60 |

\* Corresponding author at: Inserm, UMR 1229, RMeS, Regenerative Medicine and Skeleton, 1 Place Alexis Ricordeau, 44042 Nantes Cedex, France.

E-mail address: [catherine.levisage@inserm.fr](mailto:catherine.levisage@inserm.fr) (C. Le Visage).

<sup>1</sup> These authors contributed equally.

|   |    |
|---|----|
| 5.2. Cell and biological factors combined strategies . . . . .                    | 61 |
| 5.3. On-demand release strategies . . . . .                                       | 63 |
| 5.4. Sequential release strategies as a function of disease progression . . . . . | 63 |
| 6. Conclusion . . . . .   | 63 |
| Acknowledgments . . . . .   | 63 |
| References . . . . .  | 63 |

## 1. Introduction

Low back pain (LBP) is a particularly common affliction in the 21st century, with 80% of the world population experiencing it at some point in their life [1,2]. It is the second most common reason for a medical consultation in industrialized countries and one of the costliest diseases for the healthcare system [3–5]. LBP consists of pain in the lumbar part of the spine that can also extend to the legs, with patients suffering from impaired mobility in the most severe cases. Thus, management of LBP patients, estimated to be 600 million worldwide, presently constitutes a major socio-economic problem [6]. It is now well established that 40% of the chronic LBP cases are due to degeneration of the intervertebral disc (IVD) [7,8], which is the fibrocartilaginous joint situated between two vertebrae. The IVD is a complex tissue composed of three distinct components that assume a unique structural organization essential for its function as a shock absorber. A healthy IVD, which is a key requirement for spine movements, exhibits mechanical properties such as high compressive and tensile strength that are tightly linked with its complex structural organization. For reasons that are not yet fully understood, very early after skeletal maturity, the IVD can undergo a degenerative process that manifests as cell death, extracellular matrix (ECM) changes and dehydration, culminating in failure of its biomechanical properties, thereby leading to pain and disability [9]. This progressive natural aging process can be accelerated and amplified by the occurrence of various traumatic, environmental or genetic factors. Conventional treatments for degenerative disc disease (DDD) are focused only on pain or inflammatory relief, with pharmacological approaches as the first intention, followed by invasive surgical procedures as the last option for treatment of resistant and severe disease. Ultimately, none of these treatments restore disc function. Consequently, the development of innovative therapeutic strategies has become a high-priority issue in the scientific community, with the main view being that these strategies should be based on therapeutic agents that allow reversal of the degenerative processes so as to fully restore the healthy tissue physiology in terms of its structural and functional complexity. Thus, therapeutic strategies are now focused on the mechanisms of IVD degeneration, primarily with the aim of correcting the anabolic/catabolic balance, albeit only one at a time. However, IVD degeneration occurs at different levels, with the occurrence of three main events that are intertwined and that work in a vicious circle: i) inflammation and catabolic cascades, ii) progressive loss of cells, and iii) decline in cellular functions and anabolic activities. Thus, although strategies based on rectifying only one of these events, by delivering either anti-inflammatory cytokines, growth factors, or cells, have shown promising results, they have so far not been sufficiently robust to allow for full IVD restoration.

In this review, we formulate and support the notion that all three of the main events of IVD degeneration need to be addressed in order to achieve complete reversal of DDD. Thus, we hypothesize that a combination of strategies that may have already been assessed individually is likely to stimulate the degenerated IVD microenvironment to the point where full regeneration of disc tissue may occur. Local delivery of therapeutic agents of various natures (e.g., cytokines, growth factors, nucleic acids, and cells) into a tissue constitutes a challenge, as does the need to avoid an invasive surgical procedure, as the spine is a particularly delicate entity. Thus, one of the crucial parameters for designing a drug delivery system (DDS) specifically for IVD regeneration is the

requirement for an injectable biomaterial that can both protect the therapeutic agents and allow for their sustained delivery, while avoiding repeated injections as these are deleterious to the structure of the IVD. Being able to act on the different stages of disc degeneration in a consecutive and controlled manner by use of a single injection would therefore be optimal. Such a sequential DDS must allow effects on i) firstly, the inflammatory, pro-catabolic, and hostile microenvironment by the release of anti-apoptotic and anti-catabolic or anti-inflammatory cytokines; ii) secondly, on the cell density by increasing the number of cells in this healed microenvironment; and then iii) thirdly, the cellular functions, mostly the synthesis of adequate ECM, by the release of pro-anabolic factors. Nevertheless, before considering the clinical application of such sequential strategies, many design issues need to be addressed. Indeed, the optimal timing and profiles of release, as well as adequate doses of the various therapeutic agents still need to be properly determined. Further studies are needed to define these various issues before the establishment of such sequential DDS for full IVD reparation.


Here, we first review the current knowledge of IVD physiology and physiopathological processes in terms of homeostasis regulation and consecutive events that lead to tissue degeneration. Recent advances to restore the IVD by anti-catabolic or pro-anabolic approaches are then analyzed, as are the design of smart macro-, micro- and nano-platform biomaterial to control the delivery of such therapeutic agents. Finally, a single-injection-based sequential regeneration strategy that aims to act in a time-dependent manner on all three of the main events of IVD degeneration is discussed.

## 2. IVD physiology

### 2.1. IVD structure

The IVD is a fibrocartilaginous tissue located between two adjacent vertebral bodies, in a ventral position with respect to the spinal cord [10]. By maintaining the stability and dynamics of the spine, this amphiarthrosis plays an important role in spinal kinematics, as it absorbs the shocks produced during movement of the entire body and it distributes mechanical loads along the spinal column [11–13]. Each IVD is composed of three distinct regions that ensure a unique internal organization while also providing elasticity and strength. At the center of the IVD, the nucleus pulposus (NP) is a gelatinous and highly-hydrated tissue; at the IVD periphery, surrounding the NP, there is the annulus fibrosus (AF), which is a highly-organized fibrous structure, while cartilage endplates (CEP) are present at the top and bottom of the vertebral bodies and they interface the IVDs with the adjacent vertebrae. Each region represents a structural and biological entity that participates jointly in disc homeostasis.

The NP has a low cell density of approximately 3000 cells/mm<sup>3</sup> [14,15]. Young and healthy human IVDs have been reported to have two types of cells: notochordal cells, which are large vacuolated cells that originate from the embryonic notochord, and nucleolpocytes (NPCy), which are small spherical cells with a singular phenotype resembling that of articular chondrocytes but that express specific markers (OVOS2, CA12, CD24, HIF- $\alpha$ , and cytokeratin 8/18/19, amongst others) [16–18]. NPCy synthesize the ECM, which is rich in aggrecan, type II collagen (with a 27:1 ratio vs. 2:1 for articular chondrocytes) and hyaluronic acid (HA) that retains water and contributes to the



**Fig. 1.** Internal structure and the network of biological factors involved in homeostasis of young and healthy intervertebral discs (IVDs). The IVD is a hypovascular tissue that has three distinct components: the nucleus pulposus (NP), which is a gelatinous and hydrated structure at the center of the IVD; the annulus fibrosus (AF), which is a lamellar collagenic region that surrounds the NP; and finally two cartilaginous endplates (CEPs) that interface with the vertebral bodies. All of these components play a significant role in maintaining disc homeostasis. CEPs contain chondrocytes and enable oxygen, nutrient, and waste metabolite diffusion. The AF contains fibroblasts that are organized into a complex multilayer structure that constrains the NP and that provides the IVD with elastic properties. In the early years of human life, notochordal cells and nucleolipocytes (NPCy) communicate by secreting specific growth factors: CTGF, Shh, and TGF-β1, which regulate the anabolic/catabolic balance. Notochordal cells secrete CTGF and Shh to stimulate cell proliferation and the synthesis of ECM components such as aggrecan and type II collagen fibers. The TGF-β1 synthesized by NPCy acts in a self-regulatory loop that enhances CTGF expression by notochordal cells. Others biological factors synthesized by NPCy also play crucial roles in IVD physiology. Among them, GDF-5 boosts the proliferation and functions of the NPCy and ensures the balance of anabolic/catabolic events. **CTGF**: Connective tissue growth factor; **Shh**: Sonic hedgehog; **TGF-β**: Transforming growth factor β; **ECM**: Extracellular matrix; **CCL5**: C-C motif ligand 5, also called Regulated And Normal T cell Expressed and Secreted (RANTES); **CXCL12**: C-X-C motif chemokine Ligand 12, also called, stromal cell-derived factor-1 (SDF-1); **VEGF**: Vascular endothelium growth factor; **IL-6 and -8**: Interleukin 6 and 8, **TIMPs**: Tissue inhibitors of metalloproteinases; **MMPs**: Metalloproteinases; **GDF5**: Growth differentiation factor-5.

osmotic pressure responsible for NP biomechanical properties [19]. These two cell types coexist only during the first few years of life due to the gradual post-natal disappearance of notochordal cells that ultimately disappear permanently prior to skeletal maturity in humans [20]. This short-lived cohabitation of notochordal cells and NPCy appears to be fundamental for disc homeostasis and the synthesis of a functional ECM [21,22] (Fig. 1). A cellular dialogue between notochordal cells and NPCy occurs as a result of the secretion of growth factors: connective tissue growth factor (CTGF), transforming growth factor (TGF-β), and sonic hedgehog (Shh), which together limit enzymatic degradation of the ECM by both inhibition of matrix metalloproteinases (MMPs) production and stimulation tissue inhibitors of metalloproteinases (TIMPs) production [23,24]. This cellular dialogue also protects the NPCy from apoptosis and it prevents tissue neovascularization through inhibition of the expression of vascular endothelium growth factor (VEGF), interleukins 6 and 8 (IL-6 and IL-8). Aside from these anti-catabolic actions, notochordal cells, primarily as a result of CTGF and Shh production, stimulate the synthesis of ECM components by NPCy, which in turn secrete TGF-β1 to stimulate CTGF synthesis by notochordal cells [23,25–27]. This molecular exchange between notochordal cells and NPCy, which is responsible for all of these anti-catabolic and pro-anabolic effects, is therefore strongly involved in the metabolic balance and matrix integrity of the tissue and is not limited to NP cells. Indeed, it has been reported that notochordal cells, through Shh, also have

a beneficial effect on the proliferation and anabolic activities of AF cells and endplate chondrocytes [27–29].

While the NP is a network of randomly oriented type II collagen fibers within an amorphous matrix of glycosaminoglycans (GAGs), the AF is organized into 15–25 concentric lamellae composed essentially of type I collagen fibers [12,30]. Within the same lamella, the collagen fibers are arranged at an angle to each other and have a specific orientation of 30° relative to the transverse plane [31]. This structurally organized ECM is also composed to a lesser extent of type II collagen, proteoglycans (PGs), and elastin [32]. The AF can be divided into two parts: the outer AF, which is mainly composed of organized type I collagen fibers and exhibits a high level of resistance to tensile strength; and the inner AF, which is a transitional zone between the outer AF and the NP and is less dense and less organized [33]. The entire AF tissue contains fibroblast-like cells at a density of approximately 9000 cells/mm<sup>3</sup> [14].

On both sides of the IVD, CEPs, which interface with the adjacent vertebral bodies, are composed of hyaline cartilage cells and chondrocytes that synthesize an ECM rich in type II collagen and PGs [14]. The diffusion of oxygen and glucose in the IVD, which is necessary for growth and nutrition of the tissue as well as for metabolite excretion, takes place through the CEPs [34], via their network of fine blood vessels [35]. This diffusion route is particularly important since the IVD is the most avascular tissue in the human body [12,36,37]. IVD cells

consequently have to adapt to a hypoxic environment and thus preferentially engage in anaerobic metabolism. This adaptation of disc cells is partially due to the stabilization of the hypoxia-inducible factor- $\alpha$  (HIF $\alpha$ ), which is constantly expressed by NP cells irrespective of the oxygen content [38,39]. Furthermore, it has been reported that the IVD environment is acidic, due to the anaerobic lactic acid metabolic pathway used by cells [40]. Interestingly, NP is immune privileged, like brain, retina, testicles, and fetus. This means that the NP environment should be amenable to the introduction of foreign antigens without this necessarily causing an inflammatory immune response.

## 2.2. IVD extracellular matrix homeostasis

Under physiological conditions, the IVD dynamic structure is characterized by an anabolic/catabolic balance that ensures slow physiological turnover of the ECM by synthesis and degradation [41]. As mentioned above, this homeostasis is particularly dependent on a cellular dialogue between notochordal cells and the other disc cells that involves the following growth factors: CTGF, TGF- $\beta$ , and Shh, as well as by other molecules such as growth factors that belong to the bone morphogenetic protein (BMP) family: BMP-2, osteogenic protein-1 (OP-1, also called BMP-7), and growth differentiation factor 5 (GDF5, also called BMP14), which promote the synthesis of ECM components and regulate MMPs production by NPCy. Catabolic factors, including MMPs and aggrecanases, a type of A disintegrin and metalloproteinase with thrombospondin (ADAMTS) motif enzyme, participate in metabolic regulation of the tissue, along with TIMPs that regulate the action of these matrix-degrading enzymes [42].

## 2.3. IVD function

Physiological compressive loads applied to the spine are first distributed over the vertebral bodies and then transmitted to the IVDs along the spine. Indeed, in a healthy lumbar disc, the NP pressure varies between 91 kPa to 1300 kPa, depending on the lying, seated, or standing position [43]. As their biological and physical characteristics are highly related, the three specific regions of the IVD have complementary mechanical properties. In addition to its gelatinous aspect and hydrated nature, the NP is a highly deformable tissue that acts as a viscoelastic liquid that can absorb compression forces by variation of the osmotic pressure. This osmoregulation depends particularly on proteoglycans in the ECM and the water content that can both alter the height of the IVD [44,45]. The primary function of the AF is to contain and maintain the osmotic pressure imposed by the NP with its tensile strength. The structure of the concentric collagen lamellae of the AF provides natural resistance to flexion, torsion, and shearing [33,40]. Finally, as a result of their cartilaginous structure, the endplates provide a flexible entity that can support substantial loads and distribute the intradiscal pressure toward the adjacent vertebrae [46,47].

IVD is therefore a complex tissue with specific biological, physicochemical and mechanical properties, all possibly affected by degeneration mechanisms, making it particularly difficult to fully regenerate.

## 3. The pathophysiology of IVD degeneration

IVD degeneration or degenerative disc disease (DDD) is a multifactorial condition caused by aging, genetics, biomechanics, and environmental factors [48–54]. In all cases, a degenerated IVD exhibits dysregulation of its anabolic/catabolic balance and a decline in NP cell density [55,56]. Clinically, DDD is a progressive and chronic affliction, manifesting as low back and leg pains that result in a substantial degree of disability [57]. In severe cases, the DDD results in radiculopathies, stenosis, or hernia [45]. These painful symptoms are due to molecular and cellular changes in the tissue that compromise the mechanical properties of the IVD.


### 3.1. Cellular and molecular changes

With aging, the physiological processes of the IVD change naturally and the ability of the IVD to withstand mechanical stresses is reduced. Nevertheless, some factors accelerate these pathophysiological processes toward degeneration and drive aberrant responses in IVD cells [45].

On the one hand, several studies have highlighted the pivotal role of the disappearance of notochordal cells and the breakdown of their dialogue with NPCy in the establishment of a degenerative process, which correlates particularly with a low level of NPCy survival [23,58,59]. The NPCy undergo phenotypic changes, leading to an increase in factors that degrade the ECM and the production of pro-inflammatory cytokines, while, in parallel, there is a decrease in the level of anabolic factors and the synthesis of healthy ECM (Fig. 2) [60–62]. NPCy synthesize MMP-1, MMP-3, and ADAMTS, which inhibit aggrecan and type II collagen synthesis, thus leading to alteration of the ECM integrity [42,63,64]. Furthermore, an increase in IL-6, IL-8, and prostaglandin E2 (PGE2) synthesis by NPCy results in the stimulation of nerve growth factor (NGF) production. Combined with upregulation of VEGF in the degenerated NP, this generates abnormal nerve ingrowth and vascularization in this formerly avascular and non-innervated tissue that can lead to the generation of pain [65]. The induction of vascularization and the increase in chemokine synthesis by NP cells, particularly CCL2, 3, 4, 5, 7, and 13, CXCL10, and IL-8, stimulate the recruitment of immune cells that can populate the NP and produce IL-1 $\beta$  and tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) [65]. Together, these two major pro-inflammatory cytokines mediate catabolism and anti-anabolic metabolism inside the NP and participate greatly to the establishment and progression of the degenerative state of disc tissue [66,67]. IL-1 $\beta$  and TNF $\alpha$ , which are synthesized by immune and IVD cells under degenerative conditions, are responsible for several metabolic impairments [68–70]. Indeed, IL-1 $\beta$  and TNF $\alpha$  stimulate the production of MMPs and ADAMTS by NPCy and they suppress the expression of TIMPs (reviewed in [65]). In addition to these pro-catabolic actions, the alteration of matrix integrity is amplified by down-regulation of GDF-5 by IL-1 $\beta$  and TNF $\alpha$ , thus reducing the synthesis of essential ECM components such as aggrecan and type II collagen. The decline in aggrecan and type II collagen content is associated with concomitant enhancement of the expression of type I collagen. The NP gradually loses its gelatinous and highly-hydrated aspect to become more fibrous and less elastic, thereby compromising its ability to exert its role as a hydraulic shock absorber [9,45,71,72].

On the other hand, calcification of CEPs (Fig. 2) has been observed with hypertrophy of chondrocytes, the occlusion of marrow spaces, and sclerosis, altering the energy supply/demand balance and reducing the rate of nutrient and metabolite diffusion [73–75]. The nutrient supply decreases whereas the demand increases with the recruitment of immune cells. This imbalance between demand and supply decreases the availability of nutrients to disc cells, thereby leading to adverse effects on cellular activity and viability (reviewed in [76], [77]). In addition, a reduction of metabolite excretion and acidification of the IVD microenvironment occurs with the calcification of CEPs, thus resulting in cellular stress that stimulates the apoptosis and senescence of NPCy [78]. The accumulation of metabolites in the NP boosts the production of MMPs and ADAMTS, thereby further increasing the degradation of ECM components.

Eventually, the ECM of the AF also becomes weaker as collagen fibers become irregular and thinner, and disorganization of its concentric structure occurs with the possible formation of fissures. Finally, these matrix changes lead to disruption of the mechanical forces sensed by the surface mechanoreceptors of AF cells, thereby leading to their apoptosis [79,80].



**Fig. 2.** Pathophysiological cascade in IVD degeneration. The dysregulation of homeostasis is a key element of IVD degeneration, with a significant decrease in the nucleolpocyte (NPCy) number combined with qualitative and quantitative changes in ECM components. Endplate calcification impedes diffusion paths, decreasing the nutrient supply to IVD cells and increasing the accumulation of metabolic waste within the tissue and it leads to NPCy phenotypic changes and ultimately senescence and apoptosis. Meanwhile, NPCy produce pro-inflammatory cytokines such as IL-1 $\beta$  and TNF $\alpha$  that boost the synthesis of MMPs and ADAMTSs, which in turn inhibit the production of ECM components and drive changes in the ECM integrity. In parallel, the overexpression of IL-6, IL-8, and PGE2 by NPCy stimulates innervation and vascularization by NGF and VEGF, thereby generating IVD pain. This neo-innervation and neo-vascularization favor the recruitment of immune cells, which amplifies degeneration by stimulating the pro-inflammatory and anti-catabolic effects of TNF $\alpha$  and IL-1 $\beta$ . The IVD degeneration processes thus amount to a self-perpetuating vicious circle that amplifies degeneration. **ECM:** Extracellular matrix; **IL-6 and IL-8:** Interleukin 6 and 8; **PGE2:** Prostaglandin 2; **MMP-1 and -3:** Metalloproteinases 1 and 3; **ADAMTS:** A disintegrin and metalloproteinase with thrombospondin motifs; **NGF:** Nerve growth factor; **TIMPs:** Tissue inhibitors of metalloproteinases; **TNF- $\alpha$ :** Tumor necrosis factor  $\alpha$ ; **IL-1 $\beta$ :** Interleukin 1 $\beta$ ; **GDF5:** Growth differentiation factor 5; **VEGF:** Vascular endothelium growth factor; **NPCy:** Nucleolpocytes.

### 3.2. Structural and mechanical changes

IVD degeneration involves cellular, molecular, and inflammatory mechanisms that lead to pronounced structural, physical, and mechanical changes that give rise to the patient's pain. Dehydration of the NP results in loss of its mechanical properties and an increase in the tensile forces exerted on the AF [81]. Consequently, the AF can tear, while in severe cases expulsion of the NP (disc herniation) can occur, which is often accompanied by significant low back and leg pain due to compression of the adjacent nerve root [78,82]. The inner AF can also suffer damage, followed by nerve ingrowth and secretion of inflammatory factors that amplify the degenerative cascade and the patient's pain. Finally, calcification of CEPs alters their mechanical characteristics and makes them less flexible [74].

### 3.3. Diagnosis and current treatments of discogenic LBP

The diagnosis of DDD is mainly based on the occurrence of low back pain, and is then confirmed by complementary imaging analysis (e.g., X-rays, CT scan, or magnetic resonance imaging (MRI)) to evaluate the severity of the degeneration by assignment of a score [83–85]. This scoring is based on the hydration state of the NP and the IVD height (Pfirrmann) or on the CEP aspect (Modic) [86–88]. The currently available treatments for IVD degeneration are conservative and focused on reduction of the pain by physical therapy, analgesia, or anti-inflammatory drugs and, in severe cases, by invasive surgical procedures such as spinal fusion or arthroplasty [89–94]. Despite positive effects on the patient's pain, the long-term efficacy of these pharmaceutical and surgical therapeutic strategies remains moderate and unreliable, with a high risk of vertebral body fractures and degeneration of adjacent levels [95,96].

Hence, based on recent improvements in the understanding of disc pathology, innovative therapeutic approaches have been devised with the aim to prevent, reduce the rate, or even reverse the IVD degenerative cascade.

## 4. Innovative bioinspired therapeutic strategies

IVD degeneration is the result of complex pathological processes involving cellular, molecular, inflammatory, structural, and mechanical mechanisms that cause dysregulation of the tissue homeostasis, as evidenced by alteration of ECM components, abnormal enzymatic activity, the production of pro-inflammatory factors, and a dramatic decrease in cell density. The ECM profoundly affects the phenotype and behavior of cells through various signaling pathways. Unhealthy cells and unhealthy ECM are interconnected, leading to a vicious circle of degeneration (reviewed in [97,98]). Thus, restoring a healthy cell-ECM dialogue appears to be paramount to reverse or reduce the rate of IVD degeneration. The main common hypothesis for innovative therapeutic strategies for regenerating IVDs is based on restoration of the homeostatic mechanism by readjustment of anabolic/catabolic events in the NP [14,99]. With this aim in mind, the regenerative potential of various minimally-invasive approaches based on the injection of specific therapeutic agents in the NP microenvironment to counteract the degeneration have been evaluated. Almost all the studies have been performed using the trans-annular route to directly inject therapeutics into the NP, with reported issues of material leakage after needle removal, permanent AF lesions, osteophyte formation and accelerated degeneration. The transpedicular approach has been recently described as an alternative route, but long term effect on the endplate integrity has not been evaluated yet [100,101]. Anti-catabolic and/or anti-inflammatory strategies have been investigated, such as halting or minimizing the

inflammation and the degradation of the ECM. Conversely, pro-anabolic treatments to repopulate the NP with specific cells and/or stimulation of the production of healthy ECM by cells have been tested, with the aim of re-establishing a healthy cell/ECM synergy.

#### 4.1. Anti-catabolic and anti-inflammatory strategies

Inhibition of both the catabolic and the inflammatory cascades could be a promising therapeutic approach to prevent the degradation of the ECM and the alteration of resident IVD cells, thus attenuating the adverse effects of the degenerated IVD microenvironment. The regenerative effect derived from the injection of anti-catabolic or anti-inflammatory factors has been investigated by *in vitro*, *ex vivo* and *in vivo* studies, as summarized in Table 1. Inhibition of catabolic enzymes (i.e., MMPs and ADAMTS) has been carried out either by direct suppression of their activities or by regulation of their inflammatory mediators (i.e., TNF- $\alpha$  and IL-1 $\beta$ ). The use of short non-coding

sequences of nucleotides that control ribonucleic acid (RNA) silencing, translation, or degradation, appears to be an attractive option for IVD regeneration as the dysregulation of many processes during IVD degeneration includes micro-RNAs (miRNAs) involved in MMPs overexpression, pro-inflammatory cytokine upregulation, and other catabolic events. However, the potential of such therapeutic small interfering RNAs (siRNAs) and miRNAs (reviewed in [102]) may be limited due to their *in vivo* degradation by endonucleases. On the other hand, suppression of the ADAMTS5 gene by injection of anti-ADAMTS5 siRNA oligonucleotide in the lumbar IVDs of a rabbit annular needle-puncture model revealed improvement of both the Thompson and histological grade scores at two months [103]. Direct injection, in a rabbit annulotomy model, of adeno-associated virus serotype 2 (AAV2) carrying the gene for TIMP-1, which is an MMPs inhibitor that is downregulated in disc disease, resulted in less MRI and histological evidence of degeneration, albeit without statistical significance, compared to the puncture group at three months, combined with a significant decrease

**Table 1**  
Anti-catabolic/anti-inflammatory strategies for the regeneration of IVD.

|  | Factor  | Model  | Study design  | Effects  | Ref   |
|--|---|--|---|--|---|
| <b>Anti-cytokines</b>  | anti-TNF $\alpha$ : Infliximab  | Human IVD cells cultured with TNF $\alpha$ [114]   | In vitro study [114]  | Reduction of IL-6, IL-8, IL-1 $\beta$ expression levels [114]  | [114,313]   |
|  |   | Induced IVD degeneration rat model [313]   | In vivo study of 6 weeks – by intradiscal injection [313]   | Decrease of pain and semi-quantitative IVD degeneration grading scale [313]  |   |
|  | anti-TNF $\alpha$ : Infliximab [110]<br>Etanercept [53,105,109]<br>Adalimumab [106,107] | Chronic discogenic low back pain patients with severe sciatic [105,110] or radicular pain [53,106,107]                               | Clinical study from few months [53,105,107,109,110] to 3 years [106]<br>follow-up about 20, 50, 143 or 265 patients – by single intravenous [110], 2 or 3 subcutaneous [105–107], 1 perispinal [109] or 2 transforaminal epidural injections [53] | Reduction of patient's pain and VAS intensity [105,109]<br>Small decrease [106,107] or no reduction of the need of surgical procedures [110]   | [53,105–107, 109,110]   |
|  | Anti-IL-6 receptor: Tocilizumab   | Patients with discogenic LBP [314,315] and spinal stenosis [314]   | Clinical study of few month follow-up on 60 patients – by epidural infiltration into the spinal nerve [314] or intradiscal injection [315]  | Reduction of LBP, leg pain and leg numbness without adverse event [314]<br>Improvement of ODI and NRS [315]  | [314,315]   |
| <b>Anti-proteases</b>  | anti-ADAMTS5 oligonucleotide<br>TIMP-1  | Induced IVD degeneration rabbit model<br>Induced IVD degeneration rabbit model   | In vivo study of 8 weeks - delivered by intradiscal injection<br>In vivo study of 12 weeks - delivered by AAV vector intradiscally injected   | Improvement of MRI and histologic grades<br>Improvement of MRI grades, histological observations, serum biochemical analysis and biomechanical properties  | [103]<br>[104]  |
|  | <b>Inhibitors of signaling pathways</b>   | anti-TNF $\alpha$ : soluble TNF receptor type II   | Human IVD cells cultured with TNF $\alpha$  | In vitro study   | Attenuation of the inflammation<br>Reduction of TNF $\alpha$ , NO and PGE2 levels |
| IL-1 receptor antagonist: IL-1Ra                                   |   | Degenerated human IVDs from surgical patients  | Ex vivo study of 2 weeks - delivered directly or by AAV intradiscally injected  | Attenuation of the matrix degradation  | [112]   |
| Inhibition of p38 MAPK activity                                    |   | Human degenerated NP cells cultured with IL-1 $\beta$ or TNF $\alpha$  | In vitro study with alginate beads  | Reduction of PGE2 and IL-6 production<br>Increase in the TIMP-1 / MMP3 ratio   | [316]   |
| Triptolide [116]<br>Bovine lactotransferrin [317]                  |   | Human [116,317] or bovine [317] degenerated IVD cells pre-treated by IL-1 $\beta$ or rabbit IVD organ model cultured with IL-1 [317] | In vitro studies [116,317] – cultured with cells in alginate beads [317] or ex vivo study [317] – by intradiscal injection  | Inhibition of IL-6 [116,317], IL-8 [116], PGE2 [116], MMPs [116,317], ADAMTS [317], toll-like receptors -2 and -4 expression [116,317]<br>Increase in PGs [317], aggrecan and collagen II [116] expression | [116,317]   |
| Lovastatin   |   | Induced IVD degeneration rat model   | In vivo study of 4 weeks - by intradiscal injection   | Up-regulation of GAG, aggrecan, collagen type II, Sox9 and BMP-2 expression<br>Decrease in collagen type I   | [117]   |
| Wogonin  | Rat NP cells treated with IL-1 $\beta$<br>Induced IVD degeneration rat model            | In vitro study<br>In vivo study of 8 weeks   | Suppression of iNOS, IL-6, COX2, MMPs and ADAMTSs expression<br>Up-regulation of collagen type II   | [318]  |   |
| Inhibitors of NF- $\kappa$ B: Nemo Binding Domain (8K-NBD) peptide | DNA repair-deficient mouse model of accelerated aging (Ercc1- $\Delta$ mice)            | In vivo study of 25 months- by 3 intraperitoneal injections per week   | Increase in disc cellularity and PGs synthesis  | [119]  |   |

**TNF $\alpha$** : Tumor necrosis factor  $\alpha$ , **IL-6**: Interleukin 6, **VAS**: Visual analogue scale, **ODI**: Oswestry disability index, **NRS**: Numeric rating scale, **ADAMTS5**: A disintegrin and metalloproteinase with thrombospondin Motifs 5, **MRI**: Magnetic resonance imaging, **TIMP-1**: Tissue Inhibitor of Metalloproteinases, **NO**: nitric oxide, **PGE2**: Prostaglandin E2, **IL-1Ra**: Interleukin 1 receptor antagonist, **AAV**: Adeno-associated viral vector, **MAPK**: Mitogen-activated protein kinases, **COX2**: Cyclooxygenase 2, **PGs**: Proteoglycans, **LBP**: Low back pain

in the degradation of type II collagen [104]. Other strategies that are focused on the inflammatory pathway have sought to reduce the expression and activity of inflammation mediators such as TNF and interleukins. Clinical studies have been performed on LBP patients with or without sciatica, radiculopathy or IVD herniation, to evaluate the role of anti-TNF $\alpha$  intradiscal injections, which are used clinically in polyarthritis rheumatoid treatments. Etanercept (Enbrel®, a recombinant TNF receptor), adalimumab (Humira®, a human monoclonal antibody directed against TNF $\alpha$ ) and infliximab (Remicade®, a chimeric monoclonal antibody directed against TNF $\alpha$ ) can neutralize the biological activity of TNF $\alpha$  and have been shown to reduce pain based on a reduction on visual analog scales (VAS) of intensity and Oswestry disability indexes (ODI) [105–110]. Nevertheless, no significant reduction of the need for surgical procedures has been shown to date. The antagonist of IL-1 receptor, IL-1Ra, has also been investigated due to its ability to inhibit IL-1 $\beta$  inflammatory activity, and an attenuation of the degradative effects of MMPs was observed in vitro and by ex vivo analysis performed on human degenerated IVD. [111,112].

IL-6, IL-8, and PGE2 pathways are also promising targets for anti-catabolic treatment of IVD degeneration. Firstly, in vitro studies performed on human IVD cells cultured with anti-TNF $\alpha$  found that there was a decrease in IL-6, IL-8, and PGE2 expression levels, hence suggesting that therapeutic effects of anti-TNF $\alpha$  could be mediated by these cytokines [113,114]. In LBP patients, intradiscal injection of tocilizumab, which is a humanized monoclonal antibody directed against the IL-6 receptor, has been shown to result in similar effects as those observed with anti-TNF $\alpha$  injections, with a reduction in pain without any adverse effects. On the other hand, blocking p38 mitogen-activated protein kinases (MAPKs) that are involved in IVD cell apoptosis appears to have potential to help reduce the vicious catabolic circle in human degenerated NP cells, including a decrease in PGE2 levels and IL-6 induction by IL-1 $\beta$  and TNF $\alpha$  [115]. Of note, some molecular entities, such as triptolide from traditional Chinese medicines [116], lovastatin [117], and the synthetic NSAID diclofenac [118], have exhibited encouraging effects on catabolism, with down-regulation of pro-inflammatory cytokines and proteolytic enzymes, combined with a pro-anabolic action on the NP microenvironment [117,118]. Moreover, inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B), which is involved in the control of cell survival and cellular responses to stress, has been reported to lead to an increase in cell density and proteoglycan synthesis after intraperitoneal injection in a mouse model of accelerated aging [119].

Overall, these results indicate that while anti-catabolic and anti-inflammatory therapeutic approaches appear to have ample potential, they are not yet sufficiently robust to result in full regeneration of the IVD. Indeed, the reduction of catabolic events did not restore the anabolic function of the tissue, nor has rehydration or restoration of IVD height been observed. Despite the improvement in the IVD microenvironment and the decrease in tissue inflammation, resident cells failed to fully restart the disc biological machinery and synthetic activities.

## 4.2. Pro-anabolic strategies

### 4.2.1. Pro-anabolic molecules

The induction of ECM biosynthesis may also prove to be an effective strategy, as shown by studies in which the disc was supplemented with anabolic agents, mostly growth factors, that regulate the survival, proliferation, and fate of cells (Table 2). Numerous in vitro studies have focused on the effect of OP-1 (BMP-7) on degenerated rabbit or human IVD cells, and they have reported a consistent increase in proteoglycans, aggrecan and type II collagen gene expression levels [120–124]. These in vitro results have been confirmed by in vivo investigations over periods of up to 6 months in various preclinical models, including induced IVD degeneration models in rabbits and rats, as indicated in Table 2 [125–130]. Partial improvement in the disc height index (DHI) has

often been noted, suggesting that rehydration of the NP is probably related to the presence of more PGs in the tissue. However, after the intradiscal injection of OP-1, extradiscal bone formation has also been reported to occur, notably in a spontaneous canine early IVD degeneration model [131]. Beneficial results on in vitro ECM synthesis by rat AF cells [132,133] and improvement of MRI scores in an in vivo rabbit IVD degeneration model have also been observed upon bone morphogenetic protein 2 (BMP-2) treatment [104]. Interestingly, the biomechanical properties also sometimes improved after these pro-anabolic GF injections, with significant increases in the viscous, stiffness, and elastic properties of the treated IVDs [104,127]. GDF-5, which belongs to the same BMP family, has also undergone extensive assessment for use in disc treatments. Indeed, it has been shown that GDF-5 is essential for disc development, and it occurs naturally in IVD tissue [134], which makes it a highly suitable potential candidate for boosting a regenerative effect. In vitro treatment of IVD cells from various mammals with GDF-5 has been reported to increase the protein and gene expression levels of aggrecan and type II collagen as well as cell proliferation and the DNA content [135–138]. In vivo studies in rabbit, mice, or rat IVD degeneration models using GDF-5 injections have shown a partial restoration of IVD height with significant improvement of MRI and histological grading scores as early as 16 weeks post-injection [138–140]. Therefore, four clinical trials have taken place with patients who had at least one symptomatic lumbar level (L3/L4 to L5/S1) confirmed and who were suffering from persistent LBP with at least three months of non-surgical therapy. These clinical trials lasted 12 months, with follow-up at 36 months to evaluate the safety, tolerability, and preliminary effectiveness of a single injection of GDF-5 (0.25 mg to 2.0 mg) (NCT01158924, NCT00813813, NCT01182337, and NCT01124006 on <https://clinicaltrials.gov>). In three of these four trials, no major adverse events directly related to GDF-5 injection were observed. The patients reported moderate improvement of their pain and disability. To our knowledge, the results of these clinical trials have not yet been published. TGF- $\beta$  is another essential factor for IVD development and physiology that has been assessed as a potential therapeutic factor for restoring disc biological functions. In vitro and ex vivo studies have demonstrated a similar impact of TGF- $\beta$  treatment compared to GDF-5, with an increase in PGs and collagen synthesis [141–144]. In particular, TGF- $\beta$  has been shown to increase CTGF expression along with an enhancement of cellular activity via SMAD-3 and AP1 (activator protein) pathways [145]. Growth factors such as insulin-like growth factor (IGF-1) [146–149], platelet-derived growth factor (PDGF) [149,150], fibroblast growth factor (FGF) [149], and the transcription factor Sox9 [151,152] have also been investigated, and anabolic effects on ECM synthesis have been noted, along with cell proliferation and reduced apoptotic activity. In particular, Sox 9 and IGF-1 led to an increase in proteoglycan and collagen synthesis in the NP [146,151–153].

Partially beneficial outcomes on IVD matrix biosynthesis after injection of a single growth factor has led to the notion of using a concentrated form of these growth factors, such as platelet-rich plasma (PRP). PRP activates the proliferation of human and porcine NP cells and it upregulates the synthesis of aggrecan and type II collagen [154–156]. Injection of autologous PRP in an induced-IVD degeneration model in rabbit delayed the IVD degeneration and partially restored the disc height by stimulation of the synthesis of PGs, type II collagen, as well as cell proliferation [157,158]. Following these encouraging results in rabbits, clinical trials have been carried out with patients affected by moderate to severe discogenic LBP refractory to conventional treatments. Intradiscal injection of autologous PRP, with or without stromal vascular fraction (SVF), resulted in an improvement in pain relief and mobility as well as a reduction of disability [159,160].

Link-N peptide, which is an alternative bioactive entity that is less expensive as it is produced synthetically, has been shown to exert growth factor-like effects. Link-N naturally stabilizes PG aggregates in cartilaginous tissues, such as IVD, and it is expressed in vivo during tissue turnover [161,162]. Human and rabbit IVD cells treated with Link-N

**Table 2**  
Pro-anabolic strategies for the regeneration of IVD.

|   | Factor   | Model  | Study design  | Effects  | Ref           |
|---|--|--|---|--|---------------|
| <b>Growth Factors from TGF <math>\beta</math> superfamily</b> | BMP-2  | Rat AF cells   | In vitro studies  | Increase in aggrecan [132,133], collagen type II [132,133], mRNA levels [132,133], cell number [132], Sox9 [132], osteocalcin [132], TGF- $\beta$ 1 [133], OP-1 [133] and sGAG production [132]  | [132,133]     |
|   | BMP-2  | Induced IVD degeneration rabbit model  | In vivo study of 2 months - delivered by AAV vector   | Improvement of histological grades, MRI indices, serum biochemical analysis and biomechanical properties   | [104]         |
|   | OP-1   | Rabbit [120–122] or human [123,124] IVD cells  | In vitro studies – cultured in alginate beads with IL-1 [120], chondroitinase ABC [121] or TNF $\alpha$ [124]   | Increase in PGs and collagen production [120–124] and accumulation [123]<br>Increase in cell number, aggrecan and collagen type II mRNA levels [121]   | [120–124]     |
|   | OP-1   | Healthy [125] and induced IVD degeneration rabbit model [126–128,130]  | In vivo studies of 2 [127,128], 3 [125,130] or 6 [126] months on 10, 20 [125,127,128] or 90 [126] rabbits - by intradiscal injection  | Blocking of the TNF $\alpha$ effects on activation of NF $\kappa$ B, ADAMTS-4 and -5 and ECM degradation [124]<br>Improvement of disc height [125,126,128,130]<br>Increase in PGs [125–128] and collagen [127] production in NP<br>Increase in DNA content in AF [128]<br>Suppression of IL-6, 1 $\beta$ and TNF- $\alpha$ expression in AF and NP [130] | [125–128,130] |
|   | OP-1   | Induced IVD degeneration rat model   | In vivo study on 34 rats - intradiscal injection  | Reduction of aggrecanases, MMP-13 and substance P  | [129]         |
|   | OP-1   | Spontaneous IVD degeneration canine model  | In vivo study of 6 months- by intradiscal injection   | No regenerative effect and extensive extradiscal bone formation  | [131]         |
|   | GDF-5  | GDF-5 deficient mice IVD cells [135] rabbit [136], human [136], mouse [137] and bovine [138] IVD cells             | In vitro studies – directly delivered in medium [135,137,138] or by cells transfection via AAV vector [136,137]   | Up-regulation of aggrecan and collagen type II protein [136,138] and gene [135,137] expression<br>Stimulation of IVD cells growth [136–138]<br>Decrease in MMP-3 gene expression [137]   | [135–138]     |
|   | GDF-5  | Spontaneous [140] or induced [138,139] IVD degeneration rabbit [138,140] or mice [139] models                      | In vivo studies of 2 [139], 3 [140] and 4 [138] months - by directly [138,140] or AAV vector [139] intradiscal injection  | Restoration of disc height [138–140], histologic grading [138–140] and MRI [138–140]   | [138–140]     |
|   | GDF-5  | Patients with early lumbar disc degeneration   | Clinical trials of 36 months on 30 [319–321] or 40 patients [322] - by single intradiscal injection   | Safety, tolerability and efficacy studies  | [319–322]     |
|   | TGF- $\beta$ 1 [141,145] or 3 [142]  | Rat [145], bovine [141] or porcine [142] IVD cells   | In vitro studies – cultured with cells on microfibrillar PLLA scaffold [141] or porous alginate scaffold [142]  | Increase in CTGF expression and cell activity via SMAD and AP1 pathways signaling [145]<br>Sustained stimulation of ECM synthesis GAG- and collagen rich [141,142]   | [141,142,145] |
| TGF $\beta$ 1   | IVD degeneration canine [143] or rabbit [144] models   | Ex vivo study of 4 days<br>In vivo study of 1 week on 22 rabbits - by AAV/TGF- $\beta$ 1 intradiscal injection     | Increase in PGs synthesis by NP cells [143,144]<br>Production of TGF- $\beta$ 1 in IVD in vivo [144]  | [143,144]  |               |
| IGF-1   | Bovine coccygeal [146,147,149] or degenerated human [147] IVD cells<br>Degenerated caudal IVD bovine culture organ model [148] | In vitro studies [146,147,149]<br>Ex vivo study of 14 days - by AAV transfection of BMSCs deposited onto IVD [148] | Increase in PGs synthesis by NP cells [146,148] and DNA synthesis in quiescent IVD cells [149]<br>Reduction of cell apoptosis [147]<br>Stimulation of the IVD cell proliferation via the ERK and Akt signaling pathways [149] | [146–149]  |               |
| PDGF-BB   | Human degenerated IVD cells  | In vitro study - cultured with cells in monolayer and 3D pellet  | Inhibition of cell apoptosis and increase in cell proliferation and matrix production   | [150]  |               |
| CTGF  | Human degenerated NP cells   | In vitro study - cultured with IL-1 $\beta$ or TNF $\alpha$  | Maintenance of ECM genes mRNA expression<br>Suppression of the inductive effect of IL-1 $\beta$ on catabolic genes (MMP-3, ADAMTS-5)  | [323]  |               |
| <b>Transcription</b>  | Sox 9  | Human [151] or bovine [152] degenerated IVD cells IVD degeneration rabbit model [151]                              | In vitro studies [151,152]<br>In vivo study [151] of 5 weeks on 4 rabbits - by AAV cell transfection  | Increase in PGs [152] and collagen type II [151,152] synthesis and accumulation<br>Increase in cell proliferation and DNA content [152]<br>Histological preservation of NP morphology and NP cell phenotypic appearance [151]  | [151,152]     |
| <b>Natural molecule</b>                                       | Andrographolide  | Human degenerated NP cells   | In vitro study – cultured with LPS  | Reversion of the inflammatory and catabolic effects, inhibition of the NF- $\kappa$ B pathway and increase in GAG secretion  | [324]         |
| <b>Synthetic biological agent</b>                             | Link N peptide   | Human [164] or rabbit [163] IVD cells  | In vitro studies – cultured with cells on peptide nanofiber [163] or alginate scaffold with IL-1 [164]  | Increase in PGs [164], aggrecan [163] and collagen type II [163] synthesis and accumulation<br>Decrease in MMPs and ADAMTs levels [164]  | [163,164]     |
|   | Link N peptide   | Induced IVD degeneration rabbit model  | In vivo study of 12 weeks on 28 rabbits - by intradiscal injection  | Stimulation of aggrecan gene expression and downregulation of MMPs expression  | [161]         |
| <b>Combination of GFs</b>                                     | NTG-101 (TGF- $\beta$ 1 + CTGF)  | Induced IVD degeneration rat and canine models   | In vivo study of 6 or 10 weeks – by intradiscal injection   | Reduction of IL-1 $\beta$ , -6, -8, MMP-13, Cox-2 and PGE2 expression  | [325]         |
|   | TGF- $\beta$ 3 + Kartogenin  | Human ASCs   | In vitro study - loaded with hASCs in chitosan/HA hydrogel  | Increase in aggrecan and collagen type II expression<br>Stimulation of hASCs proliferation and differentiation into NP-like cells in hydrogel  | [272]         |
|   | TGF- $\beta$ 1   | Rabbit [167], porcine [168]  | In vitro studies – cultured with IVD  | No synergic effect observed<br>Synergistic effects [166–168]   | [166–168]     |

**Table 2** (continued)

| Factor   | Model  | Study design  | Effects  | Ref       |
|--|--|---|--|-----------|
| [166–168] or 3 <sup>63</sup> + BMP-2 [166–168] + IGF-1 [166]     | or human degenerated [166] IVD cells                           | cells on atelocollagen type II scaffold [167] with IL-1 $\beta$ and TNF $\alpha$ [168] or on alginate beads [166] | Increase in DNA <sup>53</sup> , synthesized PGs [166–168], aggrecan, collagen type I and II genes expression [167]   |           |
| TGF- $\beta$ 3 + FGF 2   | Human degenerated AF cells                                     | In vitro study – cultured with cells in HA hydrogel   | Decrease in IL-1 $\beta$ -mediated MMP-1 synthesis [168]   | [169]     |
| TGF- $\beta$ 1 + GDF-5   | Human ASCs [59] or induced IVD degeneration murine model [172] | In vitro study [59] – cultured on 3D<br>In vivo study [172] – by intradiscal injection                            | Formation of cartilaginous matrix and enhancement of MMP-13 expression<br>Synergistic effects [59,172]<br>Drive a robust and highly specific NP differentiation [59]<br>Increase in protein and genic expression of NP markers and synthesis of NP-like ECM [59,172]<br>Temporary increase in cell proliferation and DHI [172] | [59,172]  |
| GDF-5 + CTGF   | Human degenerated NP cells                                     | In vitro study  | Increase in aggrecan and collagen type II gene expression and GAGs production  | [326]     |
| OP-1 + SOX9  | IVD degeneration rabbit model                                  | In vivo study of 9 weeks - by AAV double gene co-transfection intradiscally injected                              | Improvement of DHI and T2-signal intensity<br>Increase in aggrecan and collagen type II gene and protein expression  | [171]     |
| PRP  | Human [154,156] and porcine [155] NP cells                     | In vitro study – cultured with cells in alginate beads [155] or with IL-1 $\beta$ and TNF $\alpha$ [154,156]      | Proliferation and aggregation of IVD cells [154,155]<br>Upregulation of PGs and collagen synthesis [155] and GAG accumulation [154]<br>Up-regulation of aggrecan [154,156], collagen type II [154,156] and Sox9 [154] mRNA expression levels<br>Decrease of MMP-1 and COX-2 gene expression levels [156]                       | [154–156] |
| PRP  | Induced IVD degeneration rabbit model                          | In vivo studies of 6 [158] or 8 [157] weeks - by intradiscal injection  | Increase in disc height and chondrocytes-like cells number [157]<br>Delay of degeneration process and decrease in ECM lesions [158]<br>Increase in collagen type II expression in NP and inner AF [158]  | [157,158] |
| PRP [160] + SVF [159]  | Patients with chronic DD                                       | Clinical trials of 12 months on 15 [159] or 47 patients [159] - by intradiscal injection                          | Improvement of pain, disability, quality of life and mobility of IVD<br>No adverse effects and incidences of infection   | [159,160] |
| <b>Combination with cells</b><br>Link N peptide + exogenous MSCs | Induced IVD degeneration bovine model                          | Ex vivo study of 2 weeks - by intradiscal injection   | Increase in sGAG, PGs, and collagen type II production<br>Survival, integration and distribution throughout the NP of MSCs   | [165]     |
| PRP + BM-MSCs  | Induced IVD degeneration rabbit model                          | In vivo study of 8 weeks - by intradiscal injection   | Rapid and stable improvement of MRI scores and T2 signal intensity<br>Increase in cell density and ECM production with synthesis of collagen type II   | [243]     |

**BMP-2:** Bone morphogenetic protein 2, **OP-1:** Osteogenic protein 1, **GDF5:** Growth differentiation factor 5, **TGF- $\beta$ :** Transforming growth factor  $\beta$ , **IGF-1:** Insulin-like growth factor 1, **PDGF-BB:** Platelet-derived growth factor BB, **CTGF:** Connective tissue growth factor, **FGF-2:** Fibroblast growth factor 2, **PRP:** Platelet-rich plasma, **SVF:** Stromal vascular fraction, **MSCs:** Mesenchymal stem cells, **BM-MSCs:** Bone marrow mesenchymal stem cells, **AAV:** Adeno-associated viral vector, **PLLA:** poly(L-lactide).

produced more PGs and type II collagen, and showed down-regulated MMP and ADAMTS expression compared to non-treated cells [163–165]. These encouraging results appear to confirm that combined therapies are superior to single-target approaches to achieve a higher level of restoration of disc homeostasis. Some studies have already combined different biological factors in order to simultaneously operate on different biological targets (Table 2). Thus, the aim is to enhance the therapeutic effects of these distinct biological factors by delivering them concomitantly. Of the cocktails assessed to date, BMP-2 and TGF- $\beta$ 1 have undergone testing in several in vitro studies. Their synergistic effects have been shown to stimulate the synthesis of PGs by human, rabbit, and pig degenerated IVD cells, enhance gene expression of aggrecan and collagen, and increase DNA synthesis [166–168]. Moreover, association with a third growth factor, IGF-1, further enhanced the anabolic effect on PG synthesis [166]. Interestingly, BMP-2 coupled with TGF- $\beta$ 1 exhibited an additional anti-catabolic effect on porcine AF cells cultured with pro-inflammatory cytokines, which was probably due to a decrease in IL-1 $\beta$  and MMP-1 expression [168]. Other growth factor cocktails comprising TGF- $\beta$ 1 and FGF2 [169] or GDF-5 and CTGF [170], have been shown to result in a similar in vitro enhancement of ECM synthesis by degenerated human IVD cells. An in vivo gene therapy study performed in a rabbit IVD degeneration model indicated that intradiscal injection of AAV-mediated OP1 and SOX9 double gene co-transfection

had a positive therapeutic effect, with the partial restoration of IVD height and a greater T2-signal intensity due to increased aggrecan and type II collagen gene and protein expression [171]. Interestingly, a synergistic action of TGF- $\beta$ 1 and GDF-5, which have been shown to drive robust differentiation of human adipose stromal cells into NPCy cells [59], has been reported to have beneficial effects, with improved cell proliferation, specific gene expression, and partial restoration of IVD height following their intradiscal injection in degenerated murine caudal discs [172].

To achieve an ad integrum biological repair of IVD, the presence of cells able to respond to pro-anabolic factors is an essential requirement. Indeed, since most approaches are based on the stimulation of cellular biological functions, the presence of healthy cells in the diseased microenvironment appears to be paramount to ensure that these pro-anabolic strategies have a sufficient degree of efficacy. However, as previously described, during IVD degeneration there is a decline in the cell density in the NP, which becomes more pronounced as the degeneration increases in severity. Therefore, the few cells that remain are in an unfavorable environment and subject to constant biological stresses, with the consequent impairment of their synthetic capacities. These pro-anabolic approaches to restoration of IVDs are hence greatly limited by the lack of healthy cells in the NP during IVD degeneration. In light of these shortcomings, NP

supplementation with functional cells has been widely recognized by the scientific community as a particularly relevant approach for the restoration of disc homeostasis.

#### 4.2.2. Cell supplementation

**4.2.2.1. Endogenous cell recruitment followed by mobilization.** Stem/progenitor cells have recently been described in healthy and degenerated IVD tissues in different mammals, including humans, rabbits, minipigs, and rats [173–177]. There is still no consensus on the phenotypic profiles of these progenitor cells, although Tie-2 and NOTCH-1 have been reported by several groups [174,178,179]. Resident stem cells are localized in several anatomical regions of the IVD (the CEP, AF, and NP). They express mesenchymal stem cell (MSC) markers, such as CD44, CD90, CD105, CD73 (reviewed in [102]), and have been shown to resemble bone marrow MSC (BM-MSCs) [173,175–177,180–182]. Stem cells from the CEP, AF, and NP have been isolated and their phenotypic profiles, capacities for differentiation into the mesenchymal lineage, and abilities to migrate have been compared [183–185]. The chondrogenic differentiation properties of CEP-MSCs were better than those of NP- or AF-derived MSCs, and they were even superior to BM-MSCs [184,186]. CEP-MSCs also exhibited greater migration and invasive properties [183]. Thus, CEP-MSCs are likely to represent a potential source of endogenous reparative cells. Endogenous repair, as an alternative to cell-based therapies, has already been reported for the regeneration of other tissues, such as cartilage, tendon, and heart [183,187–189], while it has only recently been considered for degenerated discs [190]. With the proximity of stem cell niches around the peripheral IVD (the perichondrium region and the AF border to the ligament zone) and the decreasing gradient of stem/progenitor cells from the CEP to the NP, potential migration patterns toward the degenerated NP have been suggested [173,191,192]. In order to recruit the stem/progenitor cells toward the NP tissue, the specific chemokines regulated and normal T cell expressed and secreted (RANTES), also called C-C motif ligand 5 (CCL5), and stromal cell-derived factor-1 (SDF-1), also called C-X-C motif chemokine ligand 12 (CXCL12), have been investigated. CCL5 is overexpressed by degenerative bovine [193] and human IVD cells [194], and it enhances the migration of BM-MSCs. In parallel, MSCs have been reported to express chemokine receptors and, more especially, human discal stem cells have been shown to express these chemokines receptors, with an increase of CXCR4 expression, which is the CXCL12 receptor, in MSCs isolated from endplates [183]. In light of the results demonstrating a superior response in terms of CEP-MSCs migration compared to AF-MSCs and NP-MSCs, recruitment followed by the mobilization of MSCs from the CEP towards the NP has been evaluated, as well as the regenerative and pro-anabolic impact. *Ex vivo* studies performed in a bovine nucleotomized IVD degeneration model have shown that it is possible to stimulate the migration of MSCs from the CEP toward the NP, thereby boosting ECM neosynthesis [195,196]. In summary, these resident disc stem/progenitor cells constitute a reservoir of potential reparative cells that could be an alternative to the injection of exogenous cells. They could be recruited from the vicinity of the disc toward the center of the degenerated IVD by the injection of chemokines into the NP tissue. However, their number and regenerative potency have been shown to decrease with age and DDD [178], thus limiting the use of these endogenous cells to repopulate the NP in severe cases of DDD and in elderly patients. Hence, in these cases of late IVD degeneration, recourse to exogenous cell injections appears to be a better option.

**4.2.2.2. Injection of exogenous cells.** A variety of potential sources for the replacement of NP cells have been explored in the past two decades, although no consensus has been reached regarding the ideal cell population for regeneration of IVDs [197]. Cell candidates that can replace the degenerated disc cells and act as metabolically active disc cells include IVD-derived cells (healthy NPCy and AF cells),

cells with an NP-like phenotype that are able to synthesize cartilaginous ECM (e.g., chondrocytes from articular cartilage), and stem/progenitor cells with the ability to differentiate into NP cells (e.g., MSCs or induced pluripotent stem cells) [99,102,197,198]. The most rational approach involves the use of native disc cells to repopulate the degenerated IVD. Autologous NP cell transplantation has been assessed in several *in vivo* studies that were performed in a number of different types of animal models. Doing so delayed the degenerative progress, sometimes promoting regeneration after injection, and the production of type II collagen (reviewed in [199]). Clinical trials have since been performed in patients undergoing spinal fusion in adjacent IVDs, and the safety and the effectiveness in terms of the decrease in the patient's pain after autologous cell injection have been described with a two-year follow-up [200–202]. Despite encouraging results, this strategy is nonetheless greatly limited by the low availability of such IVD-derived cells and the associated risk of donor site morbidity [200,202,203]. Human IVD cells have so far only been harvested from adjacent discs or from herniated discs, which were certainly degenerated and consequently compromised by a low metabolic activity [204]. To boost the biological activity of such cells, *in vitro* processing and/or co-culture with mesenchymal stem cells (MSCs) or AF cells prior to their injection have been suggested [205–207]. However, the low proliferative capacity of these cells and their tendency to undergo dedifferentiation during their *in vitro* expansion are major limitations of this strategy [204,208]. Others studies have sought to overcome the donor site morbidity by using xenogeneic IVD-derived cells, as they have been shown to survive for 6 months post-injection; however, these cells were ultimately not efficient enough to regenerate NP tissue [206,209,210]. As an alternative to IVD-derived cells, the transplantation of chondrocytes has been investigated as a means to regenerate IVDs in rabbit and porcine models [211,212]. Even though their phenotypic similarities with NPCy make them potential candidates to replace degenerated NP cells, limited chondrocyte availability, a low capacity to proliferate, the risk of dedifferentiation after *in vitro* expansion, and donor site morbidity have thus far precluded their use in disc cell therapies. Finally, MSCs, which constitute the third source of cells, have been studied the most and have been shown to have key properties for discal regeneration while allowing some of the previously mentioned limitations to be overcome. Indeed, MSCs are readily available, as they can be obtained from bone marrow, adipose tissue, skeletal muscles, synovial membranes, and umbilical cord blood with less donor site morbidity. BM-MSCs have been the most studied MSCs for disc regeneration, closely followed by adipose stromal cells [213]. Their ability to differentiate along the mesenchymal pathway, notably into chondrocyte-like cells, as well as their capacity for *in vitro* expansion without the alteration of their differentiation potential, make them promising candidates for IVD cell therapy. Consequently, several studies have investigated the differentiation of MSCs toward NPCy-like cells, with the aim of repopulating the degenerated NP following their intradiscal injection [59,214,215]. *In vitro* studies have assessed the use of a specific cocktail of growth factors to drive *in vitro* NP differentiation [216]. Growth factors of the TGF- $\beta$  superfamily are very attractive candidates for initiating MSCs differentiation toward NPCy-like cells, particularly TGF- $\beta$  and GDF-5 or GDF-6, which should act synergistically to stimulate the typical NP ECM synthesis and the gene expression of distinctive markers of NPCy [59,170,217–221]. Other strategies are focused on the cell-cell and paracrine interactions between NPCy and MSCs, which could alter the differentiation of MSCs toward the NPCy phenotype. Co-culturing MSCs derived from bone marrow, adipose tissue, and skeletal muscle with NP cells has been investigated extensively in order to study the relationship between these two cells types. This has revealed synergistic effects, with an increase in PGs and type II collagen gene expression and synthesis as well as up-regulation of specific miRNAs [222–226]. In light of the crucial

role of the microenvironment on the fate of MSCs, co-culture of degenerated NPCy has also been assessed [227,228]. Interestingly, the enhancement of NP cell viability and proliferation has been observed, thus indicating that collaboration between these two cell types can occur [206,229]. In keeping with these encouraging achievements, undifferentiated MSCs have been injected into degenerated IVDs to evaluate their regenerative potential as a result of communication with NPCy and their known immunomodulatory and anti-inflammatory properties [230,231]. A considerable number of such pre-clinical studies have been performed, in both small and large animal models (i.e., mice, rats, rabbits, dogs, pigs, goats, and sheep). In most cases, the restoration of IVD height, an increase in T2 signal intensity, the up-regulation of ECM component synthesis, and specific gene expression by resident IVD cells and/or transplanted MSCs have been reported (reviewed in [199]). While some authors have reported a superior regenerative effect with MSCs following disc injection, or with disc-like cells [212], most studies indicate that MSCs and chondrocyte-like cells have similar efficiencies [232,233]. Moreover, the use of more readily available allogenic or xenogenic cells has also been assessed, with comparable results and no immune reaction in light of the hypovascularity and immune privilege of the IVD [209,234–236]. Finally, a small number of clinical trials conducted in discogenic patients have confirmed the feasibility and the safety of intradiscal injection, as well as a significant decrease in pain [237] and improvements in IVD hydration and height have been observed [238–242].

While it could be more beneficial to associate simultaneous supplementation with cells and biological factors to allow for a greater degree of anabolic restoration of ECM synthesis, only a small number of studies along these lines have been reported to date (Table 2). Among these, combined intradiscal injection of Link-N peptide and MSCs in an ex vivo bovine induced IVD degeneration model resulted in anabolic effects on ECM synthesis and on MSC survival in the IVD microenvironment [165]. More recently, intradiscal injection of a PRP/BM-MSCs suspension in a rabbit IVD degeneration model has yielded similar results at 8 weeks post-injection, with an increase in T2 signal intensity observed after 1 week, and a continuous regenerative effect for the following 7 weeks [243].

Finally, the precise therapeutic mechanism of MSCs has not yet been elucidated. It may be mediated by direct cell-cell contact, the transfer of secreted molecules, or the transfer of extracellular vesicles (EVs) between cells. Indeed, EVs act as major mediators of intercellular communication [244] by transferring biologically active molecules such as proteins, lipids, mRNA, and miRNA from parental cells to target cells [245]. The term EVs encompasses exosomes, microvesicles, and apoptotic bodies, which are 40–500 nm-sized particles that are released by cells in a constitutive or inducible manner. As a cell-free strategy, EVs may provide an alternative to cell therapy, with the advantage of having an extended shelf life [246]. However, while the therapeutic benefits of EVs have been clearly shown with skin injuries [247] and inflammation-associated degenerative diseases [248,249] (e.g., osteoarthritis), their use in IVD regeneration is still in its infancy. Only two recent in vitro studies have shown that human NPCy-derived exosomes induce MSCs migration and differentiation toward an NP cell-like phenotype; that human MSCs-derived exosomes boost proliferation and healthy ECM synthesis by degenerated NPCy [250]; and that porcine MSC-derived EVs exert anabolic effects on canine and human NP cells [251].

## 5. Sequential delivery systems for IVD regeneration


A common denominator to all of these innovative strategies aimed to the restoration of the catabolic/anabolic balance is that they rely on the injection of biological factors and/or cells into a degenerated and harsh NP microenvironment. Since anti-catabolic and pro-anabolic factors, which are known to have very short half-lives, are particularly prone to in vivo degradation, and cells are known to have very low in vivo post-

injection survival, their protection within a biomaterial is highly relevant and could promote their tissue regenerative effects [252,253].

For over a decade, drug delivery systems (DDS) have been designed as macro-, micro-, and nano- platforms for specific applications and delivery routes (systemic and local). In the case of an avascular organ such as the IVD, systemic administration is not a viable option, and the recommended delivery route is minimally invasive injection directly into the damaged tissue. In light of this, IVD biomaterials should be injectable and allow the local and controlled release of biological factors and/or cells. Macro-hydrogels, microparticles, or nanoparticles appear to be the most appropriate biomaterials (reviewed in [99]). Synthetic or natural polymers have been extensively studied in the context of tissue engineering approaches, with the aim of structurally replacing the IVD and restoring its functionality. Various scaffolds able to withstand physiological loads have been reviewed in terms of their specific advantages and drawbacks for IVD regeneration [254]. Due to the high number of reviews published on the topic, we have focused this paper on the delivery of biological factors and cells. In terms of natural polymers, hyaluronic acid (HA) and collagen are particularly relevant due to their natural presence in healthy IVD tissue, their potential bioactivity, and their biodegradability in vivo. Alginate and chitosan, although not naturally present in the human body, are also of interest, given their biodegradability properties and the anti-bacterial capacities of chitosan [255,256]. In parallel, synthetic and inert polymers, such as polyethylene glycol (PEG), polyurethane (PU), polylactic/glycolic acid (PLA and PGA) and derivatives (e.g., PLGA), and poly-caprolactone (PCL) offer chemical versatility.

As detailed above, IVD degeneration involves multiple dysregulations at different levels, with co-involvement of various processes such as catabolic and inflammatory events that occur in parallel with the impairment of ECM component synthesis as well as cell senescence and apoptosis. Thus, a combination of strategies may be needed for the complete restoration of IVD tissue. Going one step further, we envision sequential delivery by a single intradiscal injection that would target i) the inflammatory, pro-catabolic, and hostile microenvironment by the release of anti-catabolic or anti-inflammatory cytokines; followed by ii) the cell density, by increasing the number of cells in this healed microenvironment either by endogenous cell mobilization or by exogenous cell injections; and finally iii) the cellular functions, mostly the synthesis of adequate ECM, by the release of pro-anabolic factors. Overall, the regenerative process (as illustrated in Fig. 3A) would be based on the release of anti-catabolic factors, to induce a more favorable microenvironment by both reduction of inflammation and down-regulation of degradative enzymes, followed by supplementation with cells and anabolic factors to encourage the neosynthesis of ECM that is essential for tissue restoration. It is worth noting that the sequence of effects needs to be given careful consideration since most of the anabolic cues undeniably require the presence of healthy cells to exert their therapeutic effects, and cell survival depends on the nature of the IVD microenvironment. The presence of cells in the damaged IVD tissue differs, along with their biological activities, according to the severity of the disease. Hence, when cells are non-functional or when the IVD cell number decreases, cell supplementation by the recruitment of endogenous cells or by exogenous cell injection is a fundamental pre-requisite for the subsequent efficacy of the released pro-anabolic factors. Thus, a hierarchical approach with sequential steps of the therapeutic agent delivery would be most beneficial to counteract the various IVD degenerative processes.

Although multistage drug delivery systems that are triggered by specific tumor microenvironment stimuli have been used for cancer therapy and imaging purposes, their design is based on parameters that do not apply to IVD regeneration, such as stability during transport in the bloodstream, deep penetration into tumor tissues, and multidrug resistance issues (reviewed in [257]). In this context, a complex design is needed to be able to deliver the biological factors in a consecutive and optimal manner as a single injection. Controlled release strategies



**Fig. 3.** Possible sequential biological agent release strategies for a maximal IVD regeneration. We hypothesize that a sequential delivery that would i) target the inflammatory, pro-catabolic, and hostile microenvironment by the release of anti-inflammatory or anti-catabolic cytokines, then ii) increase the cell density in this microenvironment, and finally iii) enhance the cellular synthesis of extracellular matrix by the release of pro-anabolic factors, constitutes an innovative yet challenging approach to treat IVD degeneration. It is worth noting that the sequence of events needs to be given careful consideration, as most of the anabolic cues undeniably require the presence of healthy cells to exert their therapeutic effects. **A.** Anti-catabolic factors can be incorporated into macro-scaled hydrogels, micro-scaled (matrix, porous, or capsules) particles, and nano-scaled particles (micelles, nanotubes, or matrix), with the aim of obtaining a sustained initial release in the hostile microenvironment. Due to the size of cells, the use of nanoparticles is not suitable for cell supplementation, and they are hence not presented in the diagrams (although nanoparticles could be used to deliver chemoattractant molecules to recruit endogenous cells). Moreover, macro-scaled hydrogels, which usually have quite fast delivery profiles for soluble molecules, are not suitable for the delivery of anabolic factors, which should occur in the final stage of regeneration, and they are hence not represented in this figure. **B.** The disease progression has to be taken into account when selecting a sequential delivery treatment. Indeed, to reverse the complex degenerative IVD process, treatment strategies that have an appropriate timing based on the degenerative cascade should be applied. According to the severity of the disease, different sequential release patterns can be envisioned, involving the use of macro-, micro-, and nano-scaled biomaterials. For discs at an early stage of degeneration, when local disc cells are still healthy and available, anti-catabolic entities followed by pro-anabolic strategies are likely to be suitable. For discs at an intermediate stage of degeneration, an additional step of endogenous cell recruitment is necessary to provide healthy targets for the pro-anabolic factors. Finally, tissue at the late stage of degeneration, whereby endogenous cells may no longer be available, would require supplementation with either autologous or allogenic exogenous cells. **TNF- $\alpha$** : Tumor necrosis factor  $\alpha$ ; **IL-1 $\beta$** : Interleukin 1 $\beta$ ; **IL-6**: Interleukin 6; **NP**: Nucleus pulposus; **TGF- $\beta$** : Transforming growth factor  $\beta$ ; **PRP**: Platelet-rich plasma; **NPCy**: Nucleopulpcytes.

are usually based on diffusion throughout a polymeric network (reviewed in [258]), polymer cleavage (reviewed in [259]), or affinity binding [260].

### 5.1. Sequential delivery of biological factors

In terms of skeletal tissue regeneration, sequential delivery systems specifically designed for bone and cartilage have been extensively reviewed [261–264]. These systems are multiphasic platforms composed of various polymers and biomaterials, often associating nano- or micro-particles (e.g., spheres, capsules) with an injectable macro-scale hydrogel (Fig. 3A). Hydrogels designed at different scales can be

combined to form a system for the delivery of multiple therapeutic agents (for a review on hydrogel features, see [265,266]). For example, IGF-1 has been loaded into gelatin microspheres that were then dispersed in a chitosan gel containing BMP-2. The *in vitro* release profiles showed that there was a slowdown of IGF-1 delivery when the loaded microspheres were embedded in a chitosan gel, compared to microspheres in suspension; and this temporally-controlled release of the two molecules was shown to enhance osteoblast differentiation *in vitro* [267]. Recently, the combination of three different biomaterials has also been tested as a dual delivery scaffold [268]. A calcium phosphate porous cement containing alginate microspheres loaded with BMP-2 was coated with an alginate hydrogel loaded with PDGF.

Following the rapid release of the PDGF over a 5-day period, there was a burst of BMP-2, followed by sustained release of both PDGF and BMP-2 for 10 days. A recent attempt at generating a flare-responsive hydrogel, considered as a smart biomaterial, that could undergo disassembly and thereby release the encapsulated drug in response to the concentration of matrix metalloproteinase MMP-2, MMP-3, or MMP-9, has been reported [269]. This system for “on demand” drug release upon exposure to high levels of inflammation, which was designed for inflammatory arthritis treatment when arthritis-related enzyme concentration increases during flares, could be considered for stage 1 of IVD regeneration by the incorporation anti-catabolic factors.

Sequential release of IVD therapeutic factors, whether anti-catabolic and pro-anabolic entities, should be carefully designed and could be based on sustained delivery systems (Table 3). PLA pellets (i.e., micro-scaled particles) provided sustained release of the anti-catabolic factor clonidine over a three-month period in a porcine model of IVD [270]. Moreover, poly- $\gamma$ -glutamic acid (PGA) and chitosan nanoparticles loaded with diclofenac exhibited anti-catabolic effects for at least 14 days in an ex vivo bovine model of degenerated IVD [118]. Two chondrogenic factors, kartogenin (KGN) and pentosane polysulphate (PPS), combined with chitosan or PEG, respectively, have been studied in association with an HA-based hydrogel [271,272]. The results revealed sustained in vitro release and a prolonged impact of these chondrogenic factors on BM-MSCs in terms of GAG and collagen synthesis. Pro-anabolic TGF- $\beta$ 3 was released in vitro from photocrosslinked carboxymethylcellulose (CMC) hydrogels and was shown to have prolonged biological effects on GAG and collagen synthesis for 8 weeks [273]. However, in this study, macro-scale hydrogels might not be effective when it comes to releasing chondrocyte-inducing factors or TGF- $\beta$ 3 during the last stage of the regeneration process, that is to say, long after the anti-catabolic factors and cells have been released (Fig. 3A). Lee et al. devised a combined system of PCL microspheres embedded in a pluronic F127/sodium hyaluronate hydrogel, and they confirmed that there was sustained release of this model drug in an ex vivo IVD model [274]. Similarly, PLGA microspheres have been shown to allow the sustained release of IL-1Ra for up to 35 days of culture of NP/agar constructs [111]. On the other hand, the sustained in vitro IGF-1 release from chitosan or PLGA microparticles was improved when PLGA microspheres were embedded in a silk fibroin porous scaffold [275,276]. Likewise, pullulan microparticles or nanofibrous silica can release TGF- $\beta$ 1 and GDF5 for at least 28 days in vitro, and their release was even slower when they were embedded in a hydroxypropyl methylcellulose silanized (HPMC-Si) hydrogel [277,278]. PRP, a concentrate of GFs, could also be released in a sustained fashion from gelatin microspheres for up to 8 weeks in a rabbit induced IVD degeneration model [279,280].

An IVD-specific platform based on injectable MMP-responsive hydrogel containing MMP-responsive polyplex-micelles loaded with a specific miRNA known to suppress fibrosis was recently developed by Feng and collaborators [281]. miR-29a was complexed with 70-nm MMP-responsive polyplex micelles and then encapsulated in an MMP-responsive PEG hydrogel. Two-stage delivery of miR-29a was demonstrated in vitro, in the presence of MMP-2, and significantly attenuated fibrosis progression in IVD was obtained in two needle puncture models (rat tails and rabbit lumbar spines). However, this could not be considered to be a sequential delivery system since the same factor was released in each stage. Of note, the efficacy of any miRNA strategy undeniably requires the presence of either exogenous or endogenous healthy cells. To our knowledge, no study to date has reported an IVD-specific sequential delivery system.

## 5.2. Cell and biological factors combined strategies

In terms of the cell supplementation stage, biocompatible natural or synthetic biomaterials that provide mechanical properties and that enable specific ECM synthesis have been extensively reviewed for cell

delivery aiming to restore the cell density in degenerated IVDs [198,254,282]. Among these, hyaluronic acid, which is a natural component of the NP matrix, has been widely considered for cartilage and spine applications [283,284], and as an IVD cell supporting hydrogel in particular [285]. In vitro studies have shown the maintenance of the phenotype of human, bovine, and rabbit NP and AF cells for one week when cultured in an HA hydrogel [286–289], as well as mechanical properties close to those of the of native tissue, which is a significant advantage for maintaining the NPC phenotype [287,289]. In some cases, an increase in the production of specific ECM components, as well as the expression of specific IVD markers have been reported [287,288]. Interestingly, alginate and chitosan hydrogels have yielded similar results in terms of the maintenance of the cellular phenotype and ECM synthesis by IVD cells from rabbits [290], pigs [291], sheep [292], cows [252,293,294], and humans [295,296]. Multiple pre-clinical studies have assessed the regenerative effects of cell supplementation strategies, combined with a macro-scaled hydrogel, after intradiscal injections in various animal models of IVD degeneration (reviewed in [199,297]).

The injection of combined exogenous cells and biological factors has also recently been investigated with the development of biphasic or even triphasic delivery systems that can be administered as a single injection. For example, PLGA nanoparticles were used to encapsulate TGF- $\beta$ 3 and these nanoparticles were then loaded into a dextran/gelatin hydrogel with MSCs. The in vitro results confirmed sustained release of TGF- $\beta$ 3 and induction of NP-like cell differentiation of the MSCs in this biphasic system, notably by the synthesis of suitable ECM [298]. In another study, basic fibroblast growth factor (bFGF) [299] or TGF- $\beta$ 3 [300] were encapsulated in heparin/poly-L-lysine nanoparticles that were loaded into dexamethasone/PLGA microspheres, and the resulting carrier was used to intradiscally deliver allogenic BM-MSCs or allogenic adipose-derived MSCs, respectively. This led to a significantly higher expression of matrix-specific genes and enhanced ECM synthesis in vitro, an improvement in the DHI score, and an accumulation of PGs in a rat IVD degeneration model. This strategy fits the requirements for a sequential delivery system, as illustrated in Fig. 3A. Indeed, anti-catabolic dexamethasone (stage 1, microparticles), exogenous cells (stage 2, micro-scaled carriers), and pro-anabolic TGF- $\beta$ 3 (stage 3, nanoparticles) are generated to ultimately allow the maximal restoration of IVD tissue. However, the sequence of events may not be optimal, as the cells are released first from the microcarriers into a harsh environment in which they may not survive. Hence, when finally released from the nanoparticles, the TGF- $\beta$ 3 target, i.e., healthy cells, will not be present and there will be no beneficial anabolic effect. Incorporation of this combined micro- and nano-particle systems within a macro-scale hydrogel (Fig. 3A) may provide a degree of protection to the cells, and delay their release into what by then may have become a less inflammatory microenvironment.

Recent cell therapy strategies have relied on the recruitment of endogenous reparative cells, such as resident stem/progenitor cells, by injection of specific chemokines embedded in either micro-scaled particles or macro-scaled hydrogels (Fig. 3A). CXCL-12, also called SDF-1, can be released over a 120 h period from chitosan/  $\gamma$ -PGA polyelectrolyte complexes and thus enhance migration of BM-MSCs in vitro after its release [301]. CXCL-12 released by a hyaluronic acid-based hydrogel in an ex vivo bovine IVD model after intradiscal injection has been shown to result in an increase in cell migration from the CEP to the NP in terms of both cell number and migration distance [195]. A recent in vivo study performed in a rat IVD degeneration model has shown enhanced IVD regeneration 8 weeks after intradiscal injection of CXCL12 loaded on albumin/heparin nanoparticles [302]. The authors reported an increase in Sox9, aggrecan, and type II collagen mRNA and protein levels, which could be due to either stimulation of the resident NP cells or the recruitment of stem/progenitor cells from the vicinity of the IVD toward the NP. These recruited cells could then

**Table 3**  
Nano-, micro-, macro-scaled delivery platforms for IVD regeneration.

|                          | Biomaterial  | Biological factors  | Study design   | Effects  | Ref                |
|--------------------------|--|---|--|--|--------------------|
| <b>Nano-scaled</b>       | Chitosan/ $\gamma$ -PGA nanoparticles  | Diclofenac  | Ex vivo study of 14 days –induced IVD degeneration bovine model – by intradiscal injection   | Down-regulation of IL-6, IL-8, MMP-1, -3 and PGE2 production<br>Up-regulation of aggrecan and collagen type II   | [118]              |
|                          | Silica nanofibrous   | TGF- $\beta$ 1<br>GDF-5   | In vitro study – loaded on HPMC-Si hydrogel  | Sustained release of bioactive TGF- $\beta$ 1 and GDF-5  | [278]              |
|                          | Albumin/heparin nanoparticles  | CXCL12  | In vivo study of 8 weeks – IVD degeneration rat model – by intradiscal injection   | Improvement of the regeneration of AF and NP with increase of histological grade score<br>Increase in sox9, aggrecan and collagen type II mRNA and protein expression levels   | [302]              |
| <b>Micro-scaled</b>      | PLA pellets  | Clonidine   | In vivo study of 3 months – IVD degeneration pig model – by postero–transforaminal placement   | Detection of Clonidine up to 6 cm away from implantation zone<br>Sustained local release   | [270]              |
|                          | PLGA microspheres  | IL-1Ra [111]<br>IGF-1 [275]<br>GDF-5 [327]  | In vitro studies – in bovine NP constructs (agarose) with IL-1 $\beta$ [111] or in silk fibroin porous scaffold [275]<br>In vivo study of 8 weeks – induced IVD degeneration rat model [327]                           | Release from PLGA microspheres for up 35 days [111] or 42 days [327]<br>Increase in sustained release as compared to without silk-fibroin scaffolds [275]<br>Restoration of disc height with increase of sGAG, DNA content and collagen type II mRNA level [327]     | [111,275,327]      |
|                          | Pullulan microbeads  | TGF- $\beta$ 1 [277]<br>GDF-5 [277]<br>CCL5 [328]                                     | In vitro study [277] – loaded on HPMC-Si hydrogel<br>In vivo study [328] – injection in mouse ischemic hindlimb model  | Sustained release of bioactive TGF- $\beta$ 1 [277], GDF-5 [277] and CCL5 [328]  | [277,328]          |
|                          | Gelatin microspheres   | PRP   | In vivo studies of 8 weeks[279,280] – intradiscal injection in induced IVD degeneration rabbit model   | Stopping of the progression of DD [279] and decrease in cell apoptosis [280]<br>Increase in disc height [280], PGs protein and mRNA expression [280] levels  | [279,280]          |
| <b>Macro-scaled</b>      | Elastin-like polypeptide hydrogel  | Curcumin  | In vivo study of 4 days – mice model – by intramuscular injection  | Rapid delivery of active curcumin, with in situ depot formation of released curcumin and anti-neuro-inflammatory effects   | [329]              |
|                          | Chitosan/gelatin/glycerol phosphate hydrogel   | Ferulic acid  | In vitro study – with NP cells cultured with H <sub>2</sub> O <sub>2</sub>   | Sustained release for 48 hours<br>Reduction of the cellular stress, GAGs accumulation, up-regulation of aggrecan and type II collagen and down-regulation of MMP-3 mRNA expression levels  | [330]              |
|                          | CMC hydrogel   | TGF- $\beta$ 3  | In vitro study - cultured with hMSCs   | Increase in GAG and collagens type I and II accumulation with homogenous deposition<br>Improvement of mechanical properties of scaffold overtime   | [273]              |
|                          | Chitosan/HA hydrogel   | Kartogenin  | In vitro study – with hASCs  | In vitro sustained release for up 16 days<br>Stimulation of hASCs proliferation and differentiation into NP-like cells in hydrogel   | [272]              |
|                          | PEG/HA hydrogel  | PPS   | In vitro study – with MSCs encapsulated in hydrogel  | Increase in the synthesis and deposition of sGAG, collagen<br>No effect of the mechanical properties of hydrogel and cell viability  | [271]              |
|                          | HA hydrogel  | CXCL12  | Ex vivo study - induced IVD degeneration bovine model with MSCs seed on one endplate – by intradiscal injection  | Increase in MSCs migration number and distance from cartilage endplate to NP<br>Enhancement of collagen type II expression   | [195,331]          |
| <b>'Combined-scaled'</b> | PCL microspheres in Pluronic F127/Sodium Hyaluronate hydrogel  | Bupivacaine   | In vitro and ex vivo studies – bovine lumbar IVD – by intradiscal injection  | In vitro sustained release for 142 days<br>Verification of delivery factors after injection in ex vivo IVD   | [274]              |
|                          | PGPC polyplex micelles in PEG hydrogel   | miR-29a   | In vivo studies of 30 days and 4 weeks – induced IVD degeneration rat and rabbit models – by intradiscal injection   | Release of miR-29a/PGPC polyplex micelles from PEG hydrogel<br>Attenuation of fibrosis progression<br>Sustained inhibition of MMP-2  | [281]              |
|                          | Chitosan microparticles [276] Chitosan/ $\gamma$ -PGA complexes [301]  | IGF-1 [276]<br>CXCL12 [301]   | In vitro studies – with BM-MSCs [301]  | Sustained release of bioactive IGF-1 [276]<br>Continuous release of CXCL12 during 120h [301]<br>Increase in cell migration up to 6 fold compared to without CXCL12 [301]   | [276,301]          |
|                          | PLGA nanoparticles in Dextran/Gelatin hydrogel<br>Heparin/poly(L-lysine) nanoparticles loaded in PLGA microspheres | TGF- $\beta$ 3 + mouse BM-MSCs<br>TGF- $\beta$ 3 [300] or FGF [299] + rat ASCs + Dexa | In vitro study – loaded in PLGA nanoparticles seeded in Dextran/Gelatin hydrogel<br>In vitro study [299]<br>In vivo study of 24 weeks on 96 rats - induced IVD degeneration rat model [300] – by intradiscal injection | Release of TGF and induction of NP-like cell differentiation of MSCs with specific ECM synthesis<br>Increase in GAG/DNA ratio, aggrecan, collagen type II and versican genes expression levels [299]<br>Improvement of DHI and PGs production and accumulation [300] | [298]<br>[299,300] |

$\gamma$ -PGA: Poly- $\gamma$ -glutamic acid, TGF- $\beta$ : Transforming growth factor  $\beta$ , GDF-5: Growth differentiation factor 5, PLA: Polylactic acid, PLGA: Poly(lactic-co-glycolic acid), IL-1Ra: Interleukin-1 receptor antagonist, IGF-1: Insulin-like growth factor 1, PRP: Platelet-rich plasma, CMC: Carboxymethylcellulose, HA: Hyaluronic acid, PEG: Poly(ethylene glycol), PCL: Polycaprolactone, PGPC: poly(ethylene glycol)-GPLGVRG-poly[N-[N-(2-aminoethyl)-2-aminoethyl]aspartamide]-cholesteryl (PEG-GPLGVRG-PAsp(DET)-Chole), BM-MSCs: Bone marrow mesenchymal stem cells, FGF: Fibroblast growth factor, ASCs: Adipose stromal cells, Dexa: Dexamethasone.

synthesize these specific ECM components in the NP microenvironment or stimulate resident NP cells [302].

### 5.3. On-demand release strategies

Although a sequential release system can be a powerful tool for the restoration of degenerated IVDs, its rational design is much more complex than that of a single-compound delivery system. Such a strategy requires the separate control of different drug releases, in space, time, and dose. This is particularly difficult to achieve in the harsh environment of a degenerated tissue, and even more so when combined with the high pressure and osmolarity of IVDs. Furthermore, while examples of DDS with simultaneous multi-release rates (i.e., fast vs. slow) have been reported [303], the feasibility of an actual sequential release in vivo, where one compound is released after another, remains to be shown. To date, most stimuli-responsive strategies for on-demand release are based on sudden changes in pH, temperature, redox potential, chemical environment, or light exposure [304]. These are mostly not compatible with single injection approaches, and they are often not practical for treatment, especially for IVDs, which are not readily accessible. Thus, being able to independently set intervals between release phases is a major roadblock that cannot be overcome with the currently available technologies; and the development of innovative in situ triggers will be required to succeed. In addition, it is worth noting that protein therapeutics are often prone to rapid unfolding and degradation, with their efficacy limited to days or weeks, thus calling for advanced stabilization techniques in protein design for further development of sequential release methods. Finally, when considering the co-delivery or in situ activation of cells, the secretion of biologically active factors must occur as a second stage mechanism, thus implying transient ways of maintaining cells in a dormant state or of blocking secretion for a certain amount of time, which adds to the complexity. Notwithstanding these challenges, tremendous progress in drug delivery and conceptual release strategies has nonetheless been made over the past 20 years, hence giving rise to innovative and promising approaches. Polymer-drug conjugates and tunable nanocarriers are becoming common tools for the controlled release of small-molecule drugs [305–307]; libraries of cleavable linkers and conjugation kits have become commercially available; and materials with programmable degradation, including self-immolating, stimuli-responsive, and supramolecular approaches, are being developed [308,309], thus paving the way for more achievable sequential release strategies. All things considered, it seems likely that new generations of DDS that are based on composite materials whereby bio-physico-chemical phenomena are controlled from the nano- to the macroscopic scale will eventually become available. This will presumably involve the convergence of innovations in drug design, biological targets, macromolecular design, and biomaterial engineering, with the cutting-edge technologies of today becoming the building blocks of tomorrow.

### 5.4. Sequential release strategies as a function of disease progression

Finally, in terms of the severity of disc disease, different release sequences can be considered, in association with the use of macro-, micro- and nanoplateforms (Fig. 3B). For discs at an early stage of degeneration, when not all of the local disc cells have already died, anti-catabolic factors followed by pro-anabolic strategies may be a suitable approach. For discs at an intermediate stage of degeneration, an additional step involving endogenous cell recruitment is necessary to provide healthy cell targets for the pro-anabolic factors. Finally, tissues at a late stage of degeneration, and thus when the endogenous cells may no longer be available, would require either autologous or allogenic exogenous cells being added to the anti-catabolic and pro-anabolic factors. The difficulties in implementing these strategies are, however, multiple. Clinically, the assessment of early DDD, which is mostly asymptomatic, and the consequent establishment of preventive treatments to reverse

the IVD degeneration processes before the appearance of pain and disability, constitute a real challenge. An imaging technique such as T1 $\rho$ -weighted MRI, which correlates with the PG concentration [310], appears to be a promising way to detect early asymptomatic DDD that is superior to the T2-weighted MRI in athletes [311] and in an ex vivo model of lumbar caprine IVD [312]. Indeed, the quantitative T1 $\rho$  values of weightlifters were significantly lower than those of sedentary matched control patients [311] and they displayed a strong positive correlation with the disc mechanical behavior, IVD histology, and water and GAG content of an ex vivo early IVD degeneration caprine model [312], with higher differences than with T2-weighted images compared to IVDs that have not undergone degeneration. Loss of diffusion routes is another parameter that needs to be considered when implementing these strategies based on the severity of the disease. Indeed, calcification of CEPs during IVD degeneration decreases oxygen, nutrient, and waste metabolite diffusion, which places stress on the IVD microenvironment. The restoration of transport thus appears to be paramount for the effectiveness of biological approaches. This is particularly the case for the restoration of nutrient supply, which is an essential prerequisite for the therapeutic effect of endogenous or exogenous cells [76].

## 6. Conclusion

The process of IVD degeneration is complex and multifactorial, with dysregulation of multiple processes, including the overexpression of degradative enzymes, the up-regulation of pro-inflammatory cytokines, the loss of healthy cells, and decreased matrix synthesis. While approaches based on biological factors or cell therapy, sometimes in association with biomaterials, have yielded promising results, it seems reasonable to speculate that effective strategies for the full biological and mechanical healing of the tissue will likely require advanced strategies based on multiscale delivery systems of biological factors. We hypothesize that sequential delivery systems, aiming to target the three main stages of IVD degeneration, can restore the IVD machinery and regenerate all of the tissue components, both structurally and functionally. It should be stressed, however, that the sequence of biological factor release needs to be given careful consideration. To our knowledge, no IVD-specific sequential delivery system has been reported to date. Although a sequential delivery system could constitute a powerful tool for restoring degenerated IVDs, its rational design is much more difficult than that of a single-component system. Among the limitations that could stymie such development, the precise control of temporal release, both in terms of the timing and the degree of the release, is difficult to engineer, in light of the harsh environment of a degenerated IVD, combined with the high local pressure and osmolarity. There is nonetheless ample reason to believe that the recent developments of more complex delivery systems, based on macro, micro-, and nano-objects will pave the way to innovative and effective regenerative strategies.

## Acknowledgments

The authors acknowledge having received financial support from the Inserm, the Région Pays de la Loire (Paris Scientifique BIO2 #2015-10762), the Agence Nationale pour la Recherche (REMEDIV #ANR-14-CE16-0017, JC/JC STIMUDISC #ANR-16-CE18-0008), and the Fondation de l'Avenir pour la Recherche Médicale Appliquée (AP-RMA-2015-018 and BO-RMA-15-001). L. Frapin was supported by a fellowship from Ministère de l'Enseignement supérieur et de la Recherche (France). We thank Dr. A. Camus for critical suggestions and discussions regarding the manuscript, and S. Domingues for English language editing services.

## References

- [1] D. Borenstein, Mechanical low back pain - a rheumatologist's view, *Nat. Rev. Rheumatol.* (2013) <https://doi.org/10.1038/nrrheum.2013.133>.

- [2] A.A. Abajobir, K.H. Abate, C. Abbafati, K.M. Abbas, F. Abd-Allah, R.S. Abdulkader, A.M. Abdulle, T.A. Abebo, S.F. Abera, V. Aboyans, L.J. Abu-Raddad, I.N. Ackerman, I.A. Adedeji, O. Adetokunbo, A. Afshin, R. Aggarwal, S. Agrawal, A. Agrawal, M.B. Ahmed, M.T.E. Aichour, A.N. Aichour, A. F. Aiyar, S. Aiyar, T.F. Akinwemiju, N. Akseer, F.H. Al Lami, F. Alahdab, Z. Al-Aly, K. Alam, N. Alam, T. Alam, D. Alasfoor, K.A. Alene, R. Ali, R. Alizadeh-Navaei, J.M. Alkaabi, A. Alkerwi, F. Alla, P. Allebeck, C. Allen, F. Al-Maskari, M.A.A. AlMazroa, R. Al-Raddadi, U. Alsharif, S. Alsowaidi, B.M. Althouse, K.A. Altirkawi, N. Alvis-Guzman, A.T. Amare, E. Amini, W. Ammar, Y.A. Amoako, M.G. Ansha, C.A.T. Antonio, P. Anwari, J. Ärnlöv, M. Arora, A. Artaman, K.K. Aryal, S.W. Asgedom, T.M. Atey, N.T. Atnaful, L. Avila-Burgos, E.F.G.A. Avokpaho, A. Awasthi, S. Awasthi, M.R. Azarpazhooh, P. Azzopardi, T.K. Babalola, U. Bacha, A. Badawi, K. Balakrishnan, M.S. Bannick, A. Barac, S.L. Barker-Collo, T. Barnighausen, S. Barquera, L.H. Barrero, S. Basu, R. Battista, K.E. Battle, B.T. Baune, S. Bazargan-Hejazi, J. Beardsley, N. Bedi, Y. Béjot, B.B. Bekele, M.L. Bell, D.A. Bennett, J.R. Bennett, I.M. Bensenor, J. Benson, A. Berhane, D.F. Berhe, E. Bernabé, B.D. Betsu, M. Beuran, A.S. Beyene, A. Bhansali, S. Bhatt, Z.A. Bhutta, S. Biadgilign, B.K. Bicer, K. Bienhoff, B. Bikbov, C. Birungi, S. Biryukov, D. Bisanzio, H.M. Bizuayehu, F.M. Blyth, D.J. Boneya, D. Bose, I.R. Bou-Orm, R.R.A. Bourne, M. Brainin, C. Brayne, A. Brazinova, N.J.K. Breitborde, P.S. Briant, G. Britton, T.S. Brugha, R. Buchbinder, L.N.B. Bulto, B.R. Bumgarner, Z.A. Butt, L. Cahuana-Hurtado, E. Cameron, I.R. Campos-Nonato, H. Carabin, R. Cárdenas, D.O. Carpenter, J.J. Carrero, A. Carter, F. Carvalho, D. Casey, C.A. Castañeda-Orjuela, C.D. Castle, F. Catalá-López, J.C. Chang, F.J. Charlson, P. Chaturvedi, H. Chen, M. Chibalabala, C.E. Chibueze, V.H. Chisumpa, A.A. Chitheer, R. Chowdhury, D.J. Christopher, L.G. Ciobanu, M. Cirillo, D. Colombara, L.T. Cooper, C. Cooper, P.A. Cortesi, M. Cortinovis, M.H. Criqui, E.A. Cromwell, M. Cross, J.A. Crump, A.F. Dadi, K. Dalal, A. Damasceno, L. Dandona, R. Dandona, J. das Neves, D.V. Davitov, G. Davletov, B. de Courten, D. De Leo, H. De Steur, B.K. Defo, L. Degenhardt, S. Deiparine, R.P. Dellavalle, K. Deribe, A. Deribew, D.C. Des Jarlais, S. Dey, S.D. Dharmaratne, P.K. Dhillon, D. Dicker, S. Djalalinia, H.P. Do, K. Dokova, D.T. Doku, E.R. Dorsey, K.P.B. dos Santos, T.R. Driscoll, M. Dubej, B.B. Duncan, B.E. Ebel, M. Echko, Z.Z. El-Khatib, A. Enayati, A.Y. Endries, S.P. Ermakov, H.E. Erskine, S. Eshetie, B. Eshrati, A. Esteghamati, K. Estep, F.B.B. Fanuel, T. Farag, C.S.e.S. Farinha, A. Faro, F. Farzadfar, M.S. Fazeli, V.L. Feigin, A.B. Feigl, S.M. Fereshtehnejad, J.C. Fernandes, A.J. Ferrari, T.R. Feyissa, I. Filip, F. Fischer, C. Fitzmaurice, A.D. Flaxman, N. Foigt, K.J. Foreman, R.C. Franklin, J.J. Frostad, N. Fullman, T. Fürst, J.M. Furtado, N.D. Futran, E. Gakidou, A.L. Garcia-Basteiro, T. Gebre, G.B. Gebregers, T.T. Gebrehiwot, J.M. Geleijnse, A. Geleto, B.L. Gemechu, H.A. Gesesew, P.W. Gething, A. Ghajar, K.B. Gibney, R.F. Gillum, I.A.M. Ginawi, M.D. Gishu, G. Giussani, W.W. Godwin, K. Goel, S. Goenka, E.M. Goldberg, P.N. Gona, A. Goodridge, S.V. Gopalani, R.Z. Gosselin, C.C. Gotay, A. Goto, A.C. Goulart, N. Graetz, H.C. Gughani, P.C. Gupta, R. Gupta, T. Gupta, V. Gupta, R. Gupta, R.A. Gutiérrez, V. Hachinski, N. Hafezi-Nejad, A.D. Hailu, G.B. Hailu, R.R. Hamadeh, S. Hamidi, M. Hammami, A.J. Handal, G.J. Hankey, Y. Hao, H.L. Harb, H.A. Hareri, J.M. Haro, K.M. Harun, J. Harvey, M.S. Hassanvand, R. Havmoeller, S.J. Hay, R.J. Hay, M.T. Hedayati, D. Hendrie, N.J. Henry, I.B. Heredia-Pi, P. Heydarpoor, H.W. Hoek, H.J. Hoffman, M. Horino, N. Horita, N.D. Hosgood, S. Hostiuc, P.J. Hotez, D.G. Hoy, A.S. Htet, G. Hu, J.J. Huang, C. Huynh, K.M. Iburg, E.U. Igumbor, C. Ikeda, C.M.S. Irvine, S.M.S. Islam, K.H. Jacobsen, N. Jahanmehr, M.B. Jakovljevic, P. James, S.K. Jassal, M. Javanbakht, S.P. Jayaraman, P. Jeemon, P.N. Jensen, V. Jha, G. Jiang, D. John, C.O. Johnson, S.C. Johnson, J.B. Jonas, M. Jürisson, Z. Kabir, R. Kadel, A. Kahsay, R. Kamal, C. Kar, N.E. Karam, A. Karch, C.K. Karema, S.M. Karimi, C. Karimkhani, A. Kasaeian, G.M. Kassa, N.A. Kassaw, N.J. Kassebaum, A. Kastor, S.V. Katikireddi, A. Kaul, N. Kawakami, P.N. Keiyoro, L. Kemmer, A.P. Kengne, A. Keren, C.N. Kesavachandran, Y.S. Khader, I.A. Khalil, E.A. Khan, Y.H. Khang, A.T. Khoja, A. Khosravi, J. Khubchandani, A.A. Kiadaliri, C. Kieling, Y.J. Kim, D. Kim, R.W. Kimokoti, Y. Kinifu, A. Kisa, K.A. Kissimova-Skarbek, N. Kissoon, M. Kivimaki, A.K. Knudsen, Y. Kokubo, D. Kolte, J.A. Kopec, S. Kosen, G.A. Kotsakis, P.A. Koul, A. Koyanagi, M. Kravchenko, K.J. Krohn, G.A. Kumar, P. Kumar, H.H. Kyu, A.C.J. Lager, D.K. Lal, R. Lalloo, T. Lallukka, N. Lambert, Q. Lan, V.C. Lansingh, A. Larsson, J.L. Leasher, P.H. Lee, J. Leigh, C.T. Leshargie, J. Leung, R. Leung, M. Levi, Y. Li, Y. Li, X. Liang, M.L. Liben, S.S. Lim, S. Linn, P.Y. Liu, A. Liu, S. Liu, Y. Liu, R. Lodha, G. Logroscino, G.J. Looker, A.D. Lopez, S. Lorkowski, P.A. Lotufo, R. Lozano, T.C.D. Lucas, R. Lunevicius, R.A. Lyons, E.R.K. Macarayan, E.R. Maddison, H.M.A. Magdy Abd El Razek, M. Magdy Abd El Razek, C. Magis-Rodriguez, M. Mahdavi, M. Majdan, R. Majdzadeh, A. Majeed, R. Malekzadeh, R. Malhotra, D.C. Malta, A.A. Mamun, H. Manguerra, T. Manhertz, L.G. Mantovani, C.C. Mapoma, L.M. March, L.B. Marczak, J. Martinez-Raga, P.H.V. Martins, F.R. Martins-Melo, I. Martopullo, W. März, M.R. Mathur, M. Mazidi, C. McAlinden, M. McGaughey, J.J. McGrath, M. McKee, S. Mehata, T. Meier, K.G. Meles, P. Memiah, Z.A. Memish, W. Mendoza, M.M. Mengesha, M.A. Mengistie, D.T. Mengistu, G.A. Mensah, T.J. Meretoja, A. Meretoja, H.B. Mezegebe, R. Micha, A. Millier, T.R. Miller, S. Minnig, M. Mirarefin, E.M. Mirrahimi, A. Misganaw, S.R. Mishra, P.B. Mitchell, K.A. Mohammadi, A. Mohammadi, M.S.K. Mohammed, K.E. Mohammed, S. Mohammed, M.B.V. Mohan, A.H. Mokdad, S.K. Mollenkopf, L. Monasta, J.C. Montañez Hernandez, M. Montico, M. Moradi-Lakeh, P. Moraga, L. Morawska, R. Mori, S.D. Morrison, M. Moses, C. Mountjoy-Venning, K.B. Mruts, U.O. Mueller, K. Muller, M.E. Murdoch, C.J.L. Murray, G.V.S. Murthy, S. Murthy, K.I. Musa, J.B. Nachega, G. Nagel, M. Naghavi, A. Naheed, K.S. Naidoo, V. Nangia, J.T. Nasher, G. Natarajan, D.E. Negasa, R.I. Negoi, I. Negoi, C.R. Newton, J.W. Ngunjiri, C.T. Nguyen, Q. Le Nguyen, T.H. Nguyen, G. Nguyen, M. Nguyen, E. Nichols, D.N.A. Ningrum, V.M. Nong, O.F. Norheim, B. Norrving, J.J.N. Noubiap, A. Nyandwi, C.M. Obermeyer, M.J. O'Donnell, F.A. Ogbo, I.H. Oh, A. Okoro, O. Oladimeji, A.T. Olagunju, T.O. Olagunju, H.E. Olsen, B.O. Olusanya, J.O. Olusanya, K. Ong, J.N. Opio, E. Oren, A. Ortiz, R.H. Osborne, A. Osgood-Zimmerman, M. Osman, E. Ota, M.O. Owolabi, M. PA, R.E. Pacella, B.K. Panda, J.D. Pandian, C. Papachristou, E.K. Park, C.D. Parry, M. Parsaiean, S.T. Patil, S.B. Patten, C.J. Patton, D. Paudel, K. Paulson, N. Pearce, D.M. Pereira, K.M. Perez, N. Perico, K. Pesudovs, C.B. Peterson, W.A. Petri, M. Petzold, M.R. Phillips, G. Phipps, D.M. Pigott, J.D. Pillay, C. Pinho, M.A. Piradov, D. Plass, M.A. Pletcher, S. Popova, R.G. Poulton, F. Pourmalek, D. Prabhakaran, N. Prasad, C. Purcell, M. Purwar, M. Qorbani, B.P.A. Quinlan, R.H.S. Rabiee, A. Radfar, A. Rafay, K. Rahimi, A. Rahimi-Movaghar, V. Rahimi-Movaghar, M.H.U. Rahman, M.A. Rahman, M. Rahman, R.K. Rai, S. Rajic, U. Ram, C.L. Ranabhat, T. Rangaswamy, Z. Rankin, P.V. Rao, P.C. Rao, S. Rawaf, S.E. Ray, R.C. Reiner, N. Reinig, M. Reitsma, G. Remuzzi, A.M.N. Renzaho, S. Resnikoff, S. Rezaei, A.L. Ribeiro, J.C. Rivas, H.S. Roba, S.R. Robinson, D. Rojas-Rueda, M.B. Rokni, L. Ronfani, G. Roshandel, G.A. Roth, D. Rothenbacher, A. Roy, E. Rubagotti, G.M. Ruhago, S. Saadat, M. Safdar, S. Safiri, R. Sagar, R. Sahathevan, M.A. Sahraian, J. Salama, M.M. Saleh, J.A. Salomon, S.S. Salvi, A.M. Samy, J.R. Sanabria, M.D. Sanchez-Niño, D. Santomauro, J.V. Santos, I.S. Santos, M.M. Santric Milicevic, B. Sartorius, M. Satpathy, M. Sawhney, S. Saxena, K. Schelch, N.L. Schmidt, I.J.C. Schneider, B. Schöttker, A.E. Schutte, D.C. Schwebel, F. Schwendicke, S. Seedat, S.G. Sepanlou, E.E. Servan-Mori, A. Shaheen, M.A. Shaikh, M. Shamsipour, R. Sharma, J. Sharma, J. She, P. Shi, K. Shibuya, C. Shields, G.T. Shifa, M.S. Shiferaw, M. Shigematsu, R. Shiri, R. Shirkoobi, S. Shirude, K. Shishani, H. Shoman, S. Siabani, A.M. Sibai, I.D. Sigfusdottir, D.H. Silberberg, D.A.S. Silva, J.P. Silva, D.G.A. Silveira, J.A. Singh, O.P. Singh, N.P. Singh, V. Singh, D.N. Sinha, E. Skiadaresi, E.L. Slepak, D.L. Smith, M. Smith, B.H.A. Sobaih, E. Sobngwi, M. Soljak, R.J.D. Sorensen, T.C.M. Sousa, L.A. Sposato, C.T. Sreeramareddy, V. Srinivasan, J.D. Stanaway, V. Stathopoulou, N. Steel, D.J. Stein, C. Steiner, S. Steinke, M.A. Stokes, J.L. Stovner, B. Strub, M. Subart, M.B. Sufiyani, B.F. Sunguya, P.J. Sur, S. Swaminathan, B.L. Sykes, D. Sylte, C.E.I. Zsoeke, R. Tabarés-Seisdedos, S.K. Tadakamadla, G.R. Taffere, J.S. Takala, N. Tandon, D. Tanne, Y.L. Tarekegn, M. Tavakkoli, N. Taveira, H.R. Taylor, T.K. Tegegne, A. Tehrani-Banihashemi, T. Tekelab, A.S. Terkawi, D.J. Tesfaye, B. Tessema, J.S. Thakur, O. Thamsuwan, A.M. Theadom, A.M. Theis, K.E. Thomas, N. Thomas, R. Thompson, A.G. Thrift, R. Tobe-A-Gai, M. Tobollik, M. Tonelli, R. Topor-Madry, M. Tortajada, M. Touvier, J. Traebert, B.X. Tran, C. Troeger, T. Truelsen, D. Tsoi, E.M. Tuzcu, H. Tymeson, S. Tyrovolas, K.N. Ukwaja, E.A. Undurraga, C.J. Uneke, R. Updike, O.A. Uthman, B.S.C. Uzoichukwu, J.F.M. van Boven, S. Varughese, T. Vasankari, L.J. Veerman, S. Venkatesh, N. Venketasubramanian, R. Vidavalur, L. Vijayakumar, F.S. Violante, A. Vishnu, S.K. Vladimirov, V.V. Vlassov, S.E. Vollset, T. Vos, F. Wadilo, T. Wakayo, M.T. Wallin, Y.P. Wang, S. Weichenthal, E. Weiderpass, R.G. Weintraub, D.J. Weiss, A. Werdecker, R. Westerman, H.A. Whiteford, T. Wijeratne, A.C. Williams, C.S. Wiysonge, B.G. Woldeyes, C.D.A. Wolfe, R. Woodbrook, A.D. Woolf, A. Workicho, D. Xavier, G. Xu, S. Yadgir, M. Yaghoobi, B. Yakob, L.L. Yan, Y. Yano, P. Ye, M.G. Yihdego, H.H. Yimam, P. Yip, N. Yonemoto, S.J. Yoon, M. Yotebieng, M.Z. Younis, C. Yu, Z. Zaidi, M.E.S. Zaki, E.A. Zegeye, Z.M. Zenebe, Z. Zhang, Y. Zheng, M. Zhou, B. Zipkin, S. Zodpey, L. Zoccker, L.J. Zuhlke, Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, *Lancet*. (2017) [https://doi.org/10.1016/S0140-6736\(17\)32130-X](https://doi.org/10.1016/S0140-6736(17)32130-X).
- [3] L. Manchikanti, V. Singh, S. Datta, S.P. Cohen, J.A. Hirsch, Comprehensive review of epidemiology, scope, and impact of spinal pain, *Pain Physician* 12 (4) (2009) <https://doi.org/10.1016/j.jmpt.2008.08.003> E35–70.
- [4] W.J. Wang, X.H. Yu, C. Wang, W. Yang, W.S. He, S.J. Zhang, Y.G. Yan, J. Zhang, MMPs and ADAMTSs in intervertebral disc degeneration, *Clin. Chim. Acta* 448 (2015) 238–246, <https://doi.org/10.1016/j.cca.2015.06.023>.
- [5] D. Hoy, P. Brooks, F. Blyth, R. Buchbinder, The Epidemiology of low back pain, *Best Pract. Res. Clin. Rheumatol.* 24 (2010) 769–781, <https://doi.org/10.1016/j.berh.2010.10.002>.
- [6] L. March, E.U.R. Smith, D.G. Hoy, M.J. Cross, L. Sanchez-Riera, F. Blyth, R. Buchbinder, T. Vos, A.D. Woolf, Burden of disability due to musculoskeletal (MSK) disorders, *Best Pract. Res. Clin. Rheumatol.* (2014) <https://doi.org/10.1016/j.berh.2014.08.002>.
- [7] K.M.C. Cheung, J. Karppinen, D. Chan, D.W.H. Ho, Y.-Q. Song, P. Sham, K.S.E. Cheah, J.C.Y. Leong, K.D.K. Luk, Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals, *Spine (Phila. Pa. 1976)* 34 (2009) 934–940, <https://doi.org/10.1097/BRS.0b013e3181a01b3f>.
- [8] G.B.J. Andersson, Epidemiological features of chronic low-back pain, *Lancet*. 354 (1999) 581–585, [https://doi.org/10.1016/S0140-6736\(99\)01312-4](https://doi.org/10.1016/S0140-6736(99)01312-4).
- [9] J.P.G. Urban, S. Roberts, Degeneration of the intervertebral disc, *Arthritis Res. Ther.* 5 (2003) 120–130, <https://doi.org/10.1186/ar629>.
- [10] S.K. Mirza, A.A. White, Anatomy of intervertebral disc and pathophysiology of herniated disc disease, *J. Clin. Laser Med. Surg.* 13 (1995) 131–142, <https://doi.org/10.1089/clm.1995.13.131>.
- [11] Z. Zhou, M. Gao, F. Wei, J. Liang, W. Deng, X. Dai, G. Zhou, X. Zou, Shock absorbing function study on denucleated intervertebral disc with or without hydrogel injection through static and dynamic biomechanical tests in vitro, *Biomed. Res. Int.* 2014 (2014) <https://doi.org/10.1155/2014/461724>.
- [12] B.R. Whatley, X. Wen, Intervertebral disc (IVD): Structure, degeneration, repair and regeneration, *Mater. Sci. Eng. C* 32 (2012) 61–77, <https://doi.org/10.1016/j.msec.2011.10.011>.
- [13] L.A. Setton, J. Chen, Cell mechanics and mechanobiology in the intervertebral disc, *Spine* 29 (2004) (1976) 2710–2723, <https://doi.org/10.1097/01.brs.0000146050.57722.2a>.
- [14] G. Fontana, E. See, A. Pandit, Current trends in biologics delivery to restore intervertebral disc anabolism, *Adv. Drug Deliv. Rev.* 84 (2015) 146–158, <https://doi.org/10.1016/j.addr.2014.08.008>.
- [15] A. Maroudas, R.A. Stockwell, A. Nachemson, J. Urban, Factors involved in the nutrition of the human lumbar intervertebral disc: cellularity and diffusion of glucose

- in vitro, *J. Anat.* 120 (1975) 113–130. <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=1184452&retmode=ref&cmd=prlinks>.
- [16] J.J. Trout, J.A. Buckwalter, K.C. Moore, et al., *Anat. Rec.* 204 (1982) 307–314, <https://doi.org/10.1002/ar.1092040403>.
- [17] J. Chen, W. Yan, L.A. Setton, et al., *Eur. Cells Mater.* (2005) <https://doi.org/10.1007/s00586-006-0088-x> p. 16.
- [18] P. Colombier, A. Camus, L. Lescaudron, J. Clouet, J. Guicheux, Intervertebral disc regeneration: A great challenge for tissue engineers, *Trends Biotechnol.* 32 (2014) 433–435, <https://doi.org/10.1016/j.tibtech.2014.05.006>.
- [19] X. Yang, X. Li, Nucleus pulposus tissue engineering: a brief review, *Eur. Spine J.* 18 (2009) 1564–1572, <https://doi.org/10.1007/s00586-009-1092-8>.
- [20] C.J. Hunter, J.R. Matyas, N.A. Duncan, The notochordal cell in the nucleus pulposus: a review in the context of tissue engineering, *Tissue Eng.* 9 (2003) 667–677, <https://doi.org/10.1089/107632703768247368>.
- [21] P. Colombier, J. Clouet, O. Hamel, L. Lescaudron, J. Guicheux, The lumbar intervertebral disc: from embryonic development to degeneration, *Jt. Bone Spine* 81 (2014) 125–129, <https://doi.org/10.1016/j.jbspin.2013.07.012>.
- [22] C.J. Hunter, J.R. Matyas, N.A. Duncan, The functional significance of cell clusters in the notochordal nucleus pulposus: survival and signaling in the canine intervertebral disc, *Spine (Phila Pa 1976)* 29 (2004) 1099–1104 (doi:00007632-200405150-00010 [pii]).
- [23] W.M. Erwin, K. Ashman, P. O'Donnel, R.D. Inman, Nucleus pulposus notochord cells secrete connective tissue growth factor and up-regulate proteoglycan expression by intervertebral disc chondrocytes, *Arthritis Rheum.* 54 (2006) 3859–3867, <https://doi.org/10.1002/art.22258>.
- [24] W.M. Erwin, The Notochord, Notochordal cell and CTGF/CCN-2: ongoing activity from development through maturation, *J. Cell Commun. Signal.* 2 (2008) 59–65, <https://doi.org/10.1007/s12079-008-0031-5>.
- [25] J.G. Abreu, N.I. Ketpura, B. Reversade, E.M. De Robertis, Connective-tissue growth factor (ctgf) modulates cell signalling by bmp and TGF- $\beta$ , *Nat. Cell Biol.* (2002) <https://doi.org/10.1038/ncb826>.
- [26] T. Winkler, E.J. Mahoney, D. Sinner, C.C. Wylie, C.L. Dahia, Wnt signaling activates Shh signaling in early postnatal intervertebral discs, and re-activates Shh signaling in old discs in the mouse, *PLoS One* (2014) <https://doi.org/10.1371/journal.pone.0098444>.
- [27] C.L. Dahia, E. Mahoney, C. Wylie, Shh signaling from the nucleus pulposus is required for the postnatal growth and differentiation of the mouse intervertebral disc, *PLoS One* (2012) <https://doi.org/10.1371/journal.pone.0035944>.
- [28] C.L. Dahia, E.J. Mahoney, A.A. Durrani, C. Wylie, Intercellular signaling pathways active during intervertebral disc growth, differentiation, and aging, *Spine (Phila Pa. 1976)* (2009) <https://doi.org/10.1097/BRS.0b013e3181913e98>.
- [29] A.J. Hayes, J.R. Ralphs, The response of foetal annulus fibrosus cells to growth factors: modulation of matrix synthesis by TGF- $\beta$ 1 and IGF-1, *Histochem. Cell Biol.* (2011) <https://doi.org/10.1007/s00418-011-0835-x>.
- [30] C.C. Guterl, E.Y. See, S.B.G. Blanquer, A. Pandit, S.J. Ferguson, L.M. Benneker, D.W. Grijpmma, D. Sakai, D. Eglin, M. Alini, J.C. Iatridis, S. Grad, Challenges and strategies in the repair of ruptured annulus fibrosus, *Eur. Cell. Mater.* 25 (2013) 1–21, <https://doi.org/10.1016/j.jbsmb.2011.07.002>. Identification.
- [31] F. Marchand, A.M. Ahmed, et al., *Spine (Phila Pa 1976)* 15 (1990) 402–410, <https://doi.org/10.1097/00007632-199005000-00011>.
- [32] J. Yu, Elastic tissues of the intervertebral disc, *Biochem. Soc. Trans.* 30 (2002) 848–852, <https://doi.org/10.1042/bst0300848>.
- [33] P.P. Raj, Intervertebral disc: anatomy-physiology-pathophysiology-treatment, *Pain Pract.* (2008) <https://doi.org/10.1111/j.1533-2500.2007.00171.x>.
- [34] J. Antoniou, T. Steffen, F. Nelson, N. Winterbottom, A.P. Hollander, R.A. Poole, M. Aebi, M. Alini, The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration, *J. Clin. Invest.* 98 (1996) 996–1003, <https://doi.org/10.1172/JCI118884>.
- [35] J.C. Lotz, A.J. Fields, E.C. Liebenberg, The role of the vertebral end plate in low back pain, *Glob. Spine J.* 3 (2013) 153–163, <https://doi.org/10.1055/s-0033-1347298>.
- [36] E.M. Bartels, J.C. Fairbank, C.P. Winlove, J.P. Urban, Oxygen and lactate concentrations measured in vivo in the intervertebral discs of patients with scoliosis and back pain, *Spine (Phila Pa 1976)* 23 (1998) 1–7, discussion 8 <https://doi.org/10.1097/00007632-199801010-00002>.
- [37] T. Grunhagen, A. Shirazi-Adl, J.C.T. Fairbank, J.P.G. Urban, Intervertebral disk nutrition: a review of factors influencing concentrations of nutrients and metabolites, *Orthop. Clin. North Am.* 42 (2011) 465–477, <https://doi.org/10.1016/j.jocl.2011.07.010>.
- [38] R. Rajpurohit, M.V. Risbud, P. Ducheyne, E.J. Vresilovic, I.M. Shapiro, Phenotypic characteristics of the nucleus pulposus: Expression of hypoxia inducing factor-1, glucose transporter-1 and MMP-2, *Cell Tissue Res.* 308 (2002) 401–407, <https://doi.org/10.1007/s00441-002-0563-6>.
- [39] M.V. Risbud, A. Guttapalli, D.G. Stokes, D. Hawkins, K.G. Danielson, T.P. Schaefer, T.J. Albert, I.M. Shapiro, Nucleus pulposus cells express HIF-1 alpha under normoxic culture conditions: a metabolic adaptation to the intervertebral disc microenvironment, *J. Cell. Biochem.* 98 (2006) 152–159, <https://doi.org/10.1002/jcb.20765>.
- [40] N. Kalsou, S. Richardson, J. Hoyland, Strategies for regeneration of the intervertebral disc, *Regen. Med.* 3 (2008) 717–729, <https://doi.org/10.2217/17460751.3.5.717>.
- [41] A. Struglics, M. Hansson, MMP proteolysis of the human extracellular matrix protein aggrecan is mainly a process of normal turnover, *Biochem. J.* 446 (2012) 213–223, <https://doi.org/10.1042/Bj20120274>.
- [42] A.J. Pockert, S.M. Richardson, C.L. Le Maitre, M. Lyon, J.A. Deakin, D.J. Buttle, A.J. Freemont, J.A. Hoyland, Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration, *Arthritis Rheum.* 60 (2009) 482–491, <https://doi.org/10.1002/art.24291>.
- [43] H.J. Wilke, P. Neef, M. Caimi, T. Hoogland, L.E. Claes, New in vivo measurements of pressures in the intervertebral disc in daily life, *Spine (Phila Pa 1976)* 24 (8) (1999) 755–762, <https://doi.org/10.1097/00007632-199904150-00005>.
- [44] B. Johnstone, J.P. Urban, S. Roberts, J. Menage, The fluid content of the human intervertebral disc. Comparison between fluid content and swelling pressure profiles of discs removed at surgery and those taken postmortem, *Spine* 17 (1992) (1976) 412–416, <https://doi.org/10.1097/00007632-199204000-00006>.
- [45] M.A. Adams, P.J. Roughley, What is intervertebral disc degeneration, and what causes it? *Spine* 31 (2006) (1976) 2151–2161, <https://doi.org/10.1097/01.brs.0000231761.73859.2c>.
- [46] P. Brinckmann, W. Frobin, E. Hierholzer, M. Horst, Deformation of the vertebral end-plate under axial loading of the spine, *Spine* 8 (1983) (1976) 851–856, <https://doi.org/10.1097/00007632-198311000-00007>.
- [47] N. Yoganandan, D.J. Maiman, F. Pintar, G. Ray, J.B. Myklebust, A. Sances, S.J. Larson, Microtrauma in the lumbar spine: a cause of low back pain, *Neurosurgery.* 23 (1988) 162–168, <https://doi.org/10.1227/00006123-198808000-00006>.
- [48] S. Roberts, Disc morphology in health and disease, *Biochem. Soc. Trans.* (2002) <https://doi.org/10.1042/bst0300864>.
- [49] M.C. Battie, T. Videman, E. Levalanti, K. Gill, J. Kaprio, Heritability of low back pain and the role of disc degeneration, *Pain* (2007) <https://doi.org/10.1016/j.pain.2007.01.010>.
- [50] L. Kalichman, D.J. Hunter, The genetics of intervertebral disc degeneration. Associated genes, *Joint. Bone Spine* 75 (2008) 388–396, <https://doi.org/10.1016/j.jbspin.2007.11.002>.
- [51] A.G. Hadjipavlou, M.N. Tzermiadianos, N. Bogduk, M.R. Zindrick, The pathophysiology of disc degeneration: a critical review, *J. Bone Jt. Surg. - Br. Vol. 90-B* (2008) 1261–1270, <https://doi.org/10.1302/0301-620X.90B10.20910>.
- [52] R. Shiri, J. Karppinen, P. Leino-Arjas, S. Solovieva, E. Viikari-Juntura, The association between obesity and low back pain: a meta-analysis, *Am. J. Epidemiol.* (2010) <https://doi.org/10.1093/aje/kwp356>.
- [53] L. Manchikanti, V. Singh, S. Datta, S.P. Cohen, J.A. Hirsch, Comprehensive review of epidemiology, scope, and impact of spinal pain, *Pain Phys.* 12 (2009) E35–E70, <https://doi.org/10.1016/j.jmpt.2008.08.003>.
- [54] S. Elmasry, S. Asfour, J.P. De Rivero Vaccari, F. Travascio, Effects of tobacco smoking on the degeneration of the intervertebral disc: a finite element study, *PLoS One* (2015) <https://doi.org/10.1371/journal.pone.0136137>.
- [55] A.J. Freemont, The cellular pathobiology of the degenerate intervertebral disc and discogenic back pain, *Rheumatology.* 48 (2009) 5–10, <https://doi.org/10.1093/rheumatology/ken396>.
- [56] L.J. Smith, N.L. Nerurkar, K.-S. Choi, B.D. Harfe, D.M. Elliott, Degeneration and regeneration of the intervertebral disc: lessons from development, *Dis. Model. Mech.* (2011) <https://doi.org/10.1242/dmm.006403>.
- [57] K. Luoma, H. Riihimäki, R. Luukkonen, R. Raininko, E. Viikari-Juntura, A. Lamminen, Low back pain in relation to lumbar disc degeneration, *Spine (Phila Pa 1976)* 25 (2000) 487–492, <https://doi.org/10.1097/00007632-200002150-00016>.
- [58] W. Erwin, D. Islam, R.D. Inman, M.G. Fehlings, F.W. Tsui, Notochordal cells protect nucleus pulposus cells from degradation and apoptosis: implications for the mechanisms of intervertebral disc degeneration, *Arthritis Res. Ther.* 13 (2011) R215, <https://doi.org/10.1186/ar3548>.
- [59] P. Colombier, J. Clouet, C. Boyer, M. Ruel, G. Bonin, J. Lesoeur, A. Moreau, B.H. Fellah, P. Weiss, L. Lescaudron, A. Camus, J. Guicheux, TGF- $\beta$ 1 and GDF5 act synergistically to drive the differentiation of human adipose stromal cells toward nucleus pulposus-like cells, *Stem Cells* 34 (2016) 653–667, <https://doi.org/10.1002/stem.2249>.
- [60] J.A. Maier, B.D. Harfe, Nuclei pulposi formation from the embryonic notochord occurs normally in GDF-5-deficient mice, *Spine* 36 (2011) (1976) E1555–E1561, <https://doi.org/10.1097/BRS.0b013e31821e0ec4>.
- [61] H.E. Gruber, G.L. Hoelscher, J.A. Ingram, S. Bethea, E.N.J. Hanley, Growth and differentiation factor-5 (GDF-5) in the human intervertebral annulus cells and its modulation by IL-1 $\alpha$  and TNF- $\alpha$  in vitro, *Exp. Mol. Pathol.* 96 (2014) 225–229, <https://doi.org/10.1016/j.yexmp.2014.02.005>.
- [62] C. Feng, H. Liu, Y. Yang, B. Huang, Y. Zhou, Growth and differentiation factor-5 contributes to the structural and functional maintenance of the intervertebral disc, *Cell. Physiol. Biochem.* 35 (2015) 1–16, <https://doi.org/10.1159/000369670>.
- [63] C. Weiler, A. Nerlich, J. Zipperer, B. Bachmeier, N. Boos, 2002 SSE award competition in basic science: expression of major matrix metalloproteinases is associated with intervertebral disc degradation and resorption, *Eur. Spine J.* 11 (2002) 308–320, <https://doi.org/10.1007/s00586-002-0472-0>.
- [64] B.E. Bachmeier, A. Nerlich, N. Mittermaier, C. Weiler, C. Lumenta, K. Wuertz, N. Boos, Matrix metalloproteinase expression levels suggest distinct enzyme roles during lumbar disc herniation and degeneration, *Eur. Spine J.* (2009) <https://doi.org/10.1007/s00586-009-1031-8>.
- [65] M.V. Risbud, I.M. Shapiro, Role of cytokines in intervertebral disc degeneration: pain and disc content, *Nat. Rev. Rheumatol.* 10 (2014) 44–56, <https://doi.org/10.1038/nrrheum.2013.160>.
- [66] T. Ohba, H. Haro, T. Ando, M. Wako, F. Suenaga, Y. Aso, K. Koyama, Y. Hamada, A. Nakao, TNF- $\alpha$ -induced NF- $\kappa$ B signaling reverses age-related declines in VEGF induction and angiogenic activity in intervertebral disc tissues, *J. Orthop. Res.* 27 (2009) 229–235, <https://doi.org/10.1002/jor.20727>.
- [67] J. Clouet, C. Vinatier, C. Merceron, M. Pot-Vauclot, O. Hamel, P. Weiss, G. Grimandi, J. Guicheux, The intervertebral disc: From pathophysiology to tissue engineering, *Jt. Bone Spine* 76 (2009) 614–618, <https://doi.org/10.1016/j.jbspin.2009.07.002>.
- [68] C.A. Séguin, R.M. Pilliar, P.J. Roughley, R.A. Kandel, Tumor necrosis factor- $\alpha$  modulates matrix production and catabolism in nucleus pulposus tissue, *Spine*

- (Phila Pa 1976) 30 (17) (2005) 1940–1948 (doi:00007632-200509010-00006 [pii]).
- [69] C.L. Le Maitre, A.J. Freemont, J.A. Hoyland, The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration, *Arthritis Res. Ther.* (2005) <https://doi.org/10.1186/ar1732>.
- [70] C.L. Le Maitre, J.A. Hoyland, A.J. Freemont, Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile, *Arthritis Res. Ther.* (2007) <https://doi.org/10.1186/ar2275>.
- [71] S. Roberts, H. Evans, J. Trivedi, J. Menage, Histology and pathology of the human intervertebral disc, *J. Bone Jt. Surg. - Ser. A* (2006) <https://doi.org/10.1021/bi060673f>.
- [72] N. Henry, P. Colombier, L. Lescaudron, O. Hamel, J. Le Bideau, J. Guicheux, J. Clouet, Regenerative medicine of the intervertebral disc: from pathophysiology to clinical application, *Med. Sci. (Paris)* 30 (2014) 1091–1100, <https://doi.org/10.1051/medsci/20143012012>.
- [73] T. Aigner, K.R. Gresk-otter, J.C. Fairbank, K. von der Mark, J.P. Urban, Variation with age in the pattern of type X collagen expression in normal and scoliotic human intervertebral discs., *Calcif. Tissue Int.* 63 (1998) 263–268. <http://www.ncbi.nlm.nih.gov/pubmed/9701632>.
- [74] H.T. Hee, Y.J. Chuah, B.H.M. Tan, T. Setiobudi, H.K. Wong, Vascularization and morphological changes of the endplate after axial compression and distraction of the intervertebral disc, *Spine* 36 (2011) (1976) 505–511, <https://doi.org/10.1097/BRS.0b013e3181d32410>.
- [75] R.C. Paietta, E.L. Burger, V.L. Ferguson, Mineralization and collagen orientation throughout aging at the vertebral endplate in the human lumbar spine, *J. Struct. Biol.* 184 (2013) 310–320, <https://doi.org/10.1016/j.jsb.2013.08.011>.
- [76] Y.C. Huang, J.P.G. Urban, K.D.K. Luk, Intervertebral disc regeneration: do nutrients lead the way? *Nat. Rev. Rheumatol.* 2014 <https://doi.org/10.1038/nrrheum.2014.91>.
- [77] H.A. Horner, J.P. Urban, 2001 volvo award winner in basic science studies: effect of nutrient supply on the viability of cells from the nucleus pulposus of the intervertebral disc, *Spine (Phila Pa 1976)* 26 (2001) 2543–2549, <https://doi.org/10.1097/00007632-200112010-00006>.
- [78] C.K. Kepler, D.G. Anderson, C. Tannoury, R.K. Ponnappan, Intervertebral disk degeneration and emerging biologic treatments, *J. Am. Acad. Orthop. Surg.* (2011) <https://doi.org/10.5435/00124635-201109000-00005>.
- [79] V.Y.L. Leung, W.C.W. Chan, S.-C. Hung, K.M.C. Cheung, D. Chan, Matrix remodeling during intervertebral disc growth and degeneration detected by multichromatic FAST Staining, *J. Histochem. Cytochem.* 57 (2009) 249–256, <https://doi.org/10.1369/jhc.2008.952184>.
- [80] F. Rannou, T.-S. Lee, R.-H. Zhou, J. Chin, J.C. Lotz, M.-A. Mayoux-Benhamou, J.P. Barbet, A. Chevrot, J.Y.-J. Shyy, Intervertebral disc degeneration: the role of the mitochondrial pathway in annulus fibrosus cell apoptosis induced by overload, *Am. J. Pathol.* 164 (2004) 915–924, [https://doi.org/10.1016/S0002-9440\(10\)63179-3](https://doi.org/10.1016/S0002-9440(10)63179-3).
- [81] F. Heuer, H. Schmidt, H.J. Wilke, The relation between intervertebral disc bulging and annular fiber associated strains for simple and complex loading, *J. Biomech.* (2008) <https://doi.org/10.1016/j.jbiomech.2007.11.019>.
- [82] M.A. Adams, P. Lama, U. Zehra, P. Dolan, Why do some intervertebral discs degenerate, when others (in the same spine) do not? *Clin. Anat.* (2015) <https://doi.org/10.1002/ca.22404>.
- [83] N. Schwarz, Retrospective and concurrent self-reports: the rationale for real-time data capture, *Sci. Real-Time Data Capture Self-Reports Heal. Res.* (2007) 11–26.
- [84] A. Kongsted, C. Leboeuf-Yde, The Nordic back pain subpopulation program - individual patterns of low back pain established by means of text messaging: a longitudinal pilot study, *Chiropr. Osteopat.* 27 (2009) 493–502, <https://doi.org/10.1016/j.jmpt.2004.08.001>.
- [85] C. Maher, M. Underwood, R. Buchbinder, Non-specific low back pain, *Lancet.* 389 (2017) 736–747, [https://doi.org/10.1016/S0140-6736\(16\)30970-9](https://doi.org/10.1016/S0140-6736(16)30970-9).
- [86] M.T. Modic, P.M. Steinberg, J.S. Ross, T.J. Masaryk, J.R. Carter, Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging, *Radiology.* 166 (1988) 193–199, <https://doi.org/10.1148/radiology.166.1.3336678>.
- [87] C.W.A. Pfirrmann, A. Metzendorf, M. Zanetti, J. Hodler, N. Boos, Magnetic resonance classification of lumbar intervertebral disc degeneration, *Spine* 26 (2001) (1976) 1873–1878, <https://doi.org/10.1097/00007632-200109010-00011>.
- [88] D.G. Anderson, C. Tannoury, Molecular pathogenic factors in symptomatic disc degeneration, *Spine J.* 5 (2005) <https://doi.org/10.1016/j.spinee.2005.02.010>.
- [89] A. Durocher, S. Laversin, Diagnostic, prise en charge et suivi des malades atteints de lombalgie chronique, *Www.Has-Sante.Fr.* 2000 [https://doi.org/10.1016/S1169-8330\(02\)00303-4](https://doi.org/10.1016/S1169-8330(02)00303-4).
- [90] R. Chou, A. Qaseem, V. Snow, D. Casey, T.J. Cross, P. Shekelle, D.K. Owens, Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society, *Ann. Intern. Med.* 147 (2007) 478–491, <https://doi.org/10.7326/0003-4819-147-7-200710020-00006>.
- [91] M.A. Stafford, P. Peng, D.A. Hill, Sciatica: a review of history, epidemiology, pathogenesis, and the role of epidural steroid injection in management, *Br. J. Anaesth.* 99 (2007) 461–473, <https://doi.org/10.1093/bja/aem238>.
- [92] L. Kuritzky, G.P. Samraj, Nonsteroidal anti-inflammatory drugs in the treatment of low back pain, *J. Pain Res.* 5 (2012) 579–590, <https://doi.org/10.2147/JPR.S6775>.
- [93] B.I. Martin, R.A. Deyo, S.K. Mirza, J.A. Turner, B.A. Comstock, W. Hollingworth, S.D. Sullivan, Expenditures and health status among adults with back and neck problems, *JAMA - J. Am. Med. Assoc.* 299 (2008) 656–664, <https://doi.org/10.1001/jama.299.6.656>.
- [94] C.M. Bono, S.R. Garfin, History and evolution of disc replacement, *Spine J.* 4 (2004) 1455–1505, <https://doi.org/10.1016/j.spinee.2004.07.005>.
- [95] K.D. Van Den Eerenbeemt, R.W. Ostelo, B.J. Van Royen, W.C. Peul, M.W. Van Tulder, Total disc replacement surgery for symptomatic degenerative lumbar disc disease: a systematic review of the literature, *Eur. Spine J.* 19 (2010) 1262–1280, <https://doi.org/10.1007/s00586-010-1445-3>.
- [96] R.A. Deyo, S.K. Mirza, Trends and variations in the use of spine surgery, *Clin. Orthop. Relat. Res.* (2006) 139–146, <https://doi.org/10.1097/01.blo.0000198726.62514.75>.
- [97] P.P.A. Vergroesen, I. Kingma, K.S. Emanuel, R.J.W. Hoogendoorn, T.J. Welting, B.J. van Royen, J.H. van Dieën, T.H. Smit, Mechanics and biology in intervertebral disc degeneration: a vicious circle, *Osteoarthr. Cartil.* 23 (2015) 1057–1070, <https://doi.org/10.1016/j.joca.2015.03.028>.
- [98] D.J. Buttle, Factors controlling matrix turnover in health and disease, *Biochem. Soc. Trans.* 35 (2007) 643–646, <https://doi.org/10.1042/BST0350643>.
- [99] N. Henry, J. Clouet, J. Le Bideau, C. Le Visage, J. Guicheux, Innovative strategies for intervertebral disc regenerative medicine: from cell therapies to multiscale delivery systems, *Biotechnol. Adv.* 36 (2018) 281–294, <https://doi.org/10.1016/j.biotechadv.2017.11.009>.
- [100] G. Vadalà, F. Russo, G. Pattappa, D. Schiuma, M. Peroglio, L.M. Benneker, S. Grad, M. Alini, V. Denaro, The transpedicular approach as an alternative route for intervertebral disc regeneration, *Spine* 2013 (1976) <https://doi.org/10.1097/BRS.0b013e318285bc4a>.
- [101] L. Le Fournier, M. Fusellier, B. Halgand, J. Lesoeur, O. Gauthier, P. Menei, C. Montero-Menei, J. Guicheux, J. Clouet, The transpedicular surgical approach for the development of intervertebral disc targeting regenerative strategies in an ovine model, *Eur. Spine J.* 26 (8) (2017) 2072–2083, <https://doi.org/10.1007/s00586-017-5199-z>.
- [102] J. Clouet, M. Fusellier, A. Camus, C. Le Visage, J. Guicheux, Intervertebral disc regeneration: from cell therapy to the development of novel bioinspired endogenous repair strategies, *Adv. Drug Deliv. Rev.* (2018) <https://doi.org/10.1016/j.addr.2018.04.017>.
- [103] S. Seki, Y. Asanuma-Abe, K. Masuda, Y. Kawaguchi, K. Asanuma, C. Muehleman, A. Iwai, T. Kimura, Effect of small interference RNA (siRNA) for ADAMT55 on intervertebral disc degeneration in the rabbit anular needle-puncture model, *Arthritis Res. Ther.* (2009) <https://doi.org/10.1186/ar2851>.
- [104] S.K. Leckie, B.P. Bechara, R.A. Hartman, G.A. Sowa, B.I. Woods, J.P. Coelho, W.T. Witt, Q.D. Dong, B.W. Bowman, K.M. Bell, N.V. Vo, B. Wang, J.D. Kang, Injection of AAV2-BMP2 and AAV2-TIMP1 into the nucleus pulposus slows the course of intervertebral disc degeneration in an in vivo rabbit model, *Spine J.* (2012) <https://doi.org/10.1016/j.spinee.2011.09.011>.
- [105] S. Genevay, S. Stingelin, C. Gabay, Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study, *Ann. Rheum. Dis.* (2004) <https://doi.org/10.1136/ard.2003.016451>.
- [106] S. Genevay, A. Finckh, P. Zufferey, S. Viatte, F. Balagué, C. Gabay, Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial, *Ann. Rheum. Dis.* (2012) <https://doi.org/10.1136/annrheumdis-2011-200373>.
- [107] S. Genevay, S. Viatte, A. Finckh, P. Zufferey, F. Balagué, C. Gabay, Adalimumab in severe and acute sciatica: A multicenter, randomized, double-blind, placebo-controlled trial, *Arthritis Rheum.* (2010) <https://doi.org/10.1002/art.27499>.
- [108] S.P. Cohen, N. Bogduk, A. Dragovich, C.C. Buckenmaier, S. Griffith, C. Kurihara, J.L. Raymond, P.J. Richter, N. Williams, T.L. Yaksh, Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica, *Anesthesiology.* (2009) <https://doi.org/10.1097/ALN.0b013e3181a05aa0>.
- [109] E. Tobinick, S. Davoodifar, Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients, *Curr. Med. Res. Opin.* (2004) <https://doi.org/10.1185/030079903125004286>.
- [110] T. Korhonen, J. Karppinen, L. Paimela, A. Malmivaara, K.-A. Lindgren, C. Bowman, A. Hammond, B. Kirkham, S. Järvinen, J. Niinimäki, N. Veeger, M. Haapea, M. Torkki, O. Tervonen, S. Seitsalo, H. Hurri, The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial, *Spine (Phila. Pa. 1976)* (2006) <https://doi.org/10.1097/01.brs.0000245873.23876.1e>.
- [111] D.J. Gorth, R.L. Mauck, J.A. Chiaro, B. Mohanraj, N.M. Hebel, G.R. Dodge, D.M. Elliott, L.J. Smith, IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1β-mediated degradation of nucleus pulposus in vitro, *Arthritis Res. Ther.* (2012) <https://doi.org/10.1186/ar3932>.
- [112] C.L. Le Maitre, J.A. Hoyland, A.J. Freemont, Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study, *Arthritis Res. Ther.* (2007) <https://doi.org/10.1186/ar2282>.
- [113] S.M. Sinclair, M.F. Shamji, J. Chen, L. Jing, W.J. Richardson, C.R. Brown, R.D. Fitch, L.A. Setton, Attenuation of inflammatory events in human intervertebral disc cells with a tumor necrosis factor antagonist, *Spine* 2011 (1976) <https://doi.org/10.1097/BRS.0b013e3181ebdb43>.
- [114] B.A. Walter, D. Purmessur, M. Likhthpanichkul, A. Weinberg, S.K. Cho, S.A. Qureshi, A.C. Hecht, J.C. Iatridis, Inflammatory kinetics and efficacy of anti-inflammatory treatments on human nucleus pulposus cells, *Spine* 2015 (1976) <https://doi.org/10.1097/BRS.0000000000000932>.
- [115] R.K. Studer, L.G. Gilbertson, H. Georgescu, G. Sowa, N. Vo, J.D. Kang, p38 MAPK inhibition modulates rabbit nucleus pulposus cell response to IL-1, *J. Orthop. Res.* 26 (2008) 991–998, <https://doi.org/10.1002/jor.20604>.
- [116] M. Klawitter, L. Quero, J. Klasein, T. Liebscher, A. Nerlich, N. Boos, K. Wuertz, Triptolide exhibits anti-inflammatory, anti-catabolic as well as anabolic effects and suppresses TLR expression and MAPK activity in IL-1β treated human

- intervertebral disc cells, *Eur. Spine J.* (2012) <https://doi.org/10.1007/s00586-011-1919-y>.
- [117] M.H. Hu, K.C. Yang, Y.J. Chen, Y.H. Sun, S.H. Yang, Lovastatin prevents discography-associated degeneration and maintains the functional morphology of intervertebral discs, *Spine J.* (2014) <https://doi.org/10.1016/j.spinee.2014.03.050>.
- [118] G.Q. Teixeira, C. Leite Pereira, F. Castro, J.R. Ferreira, M. Gomez-Lazaro, P. Aguiar, M.A. Barbosa, C. Neidlinger-Wilke, R.M. Goncalves, Anti-inflammatory Chitosan/Poly- $\gamma$ -glutamic acid nanoparticles control inflammation while remodeling extracellular matrix in degenerated intervertebral disc, *Acta Biomater.* (2016) <https://doi.org/10.1016/j.actbio.2016.06.013>.
- [119] L.A. Nasto, H.Y. Seo, A.R. Robinson, J.S. Tilstra, C.L. Clauson, G.A. Sowa, K. Ngo, Q. Dong, E. Pola, J.Y. Lee, L.J. Niedernhofer, J.D. Kang, P.D. Robbins, N.V. Vo, ISSLS prize winner: Inhibition of NF- $\kappa$ B activity ameliorates age-associated disc degeneration in a mouse model of accelerated aging, *Spine* 2012 (1976) <https://doi.org/10.1097/BRS.0b013e31824ee87f>.
- [120] K. Takegami, E.J.M.A. Thonar, H.S. An, H. Kamada, K. Masuda, Osteogenic protein-1 enhances matrix replenishment by intervertebral disc cells previously exposed to interleukin-1, *Spine (Phila Pa 1976)* (2002) <https://doi.org/10.1097/00007632-200206150-00014>.
- [121] K. Masuda, K. Takegami, H. An, F. Kumano, K. Chiba, G.B.J. Andersson, T. Schmid, E. Thonar, Recombinant osteogenic protein-1 upregulates extracellular matrix metabolism by rabbit annulus fibrosus and nucleus pulposus cells cultured in alginate beads, *J. Orthop. Res.* (2003) [https://doi.org/10.1016/S0736-0266\(03\)00037-8](https://doi.org/10.1016/S0736-0266(03)00037-8).
- [122] K. Takegami, H.S. An, F. Kumano, K. Chiba, E.J. Thonar, K. Singh, K. Masuda, Osteogenic protein-1 is most effective in stimulating nucleus pulposus and annulus fibrosus cells to repair their matrix after chondroitinase ABC-induced in vitro chemonucleolysis, *Spine J.* (2005) <https://doi.org/10.1016/j.spinee.2004.11.001>.
- [123] Y. Imai, K. Miyamoto, H.S. An, E.J.M.A. Thonar, G.B.J. Andersson, K. Masuda, Recombinant human osteogenic protein-1 upregulates proteoglycan metabolism of human annulus fibrosus and nucleus pulposus cells, *Spine* 2007 (1976) <https://doi.org/10.1097/BRS.0b013e3180593238>.
- [124] Z. Wang, W.C. Hutton, S.T. Yoon, Bone morphogenetic protein-7 antagonizes tumor necrosis factor- $\alpha$ -induced activation of nuclear factor  $\kappa$ b and up-regulation of the ADAMTS, leading to decreased degradation of disc matrix macromolecules aggrecan and collagen II, *Spine J.* (2014) <https://doi.org/10.1016/j.spinee.2013.08.016>.
- [125] Y. Imai, H. An, C. Nguyen, C. Muehleman, E. Thonar, G. Anderson, K. Masuda, Chondroitinase ABC-induced intervertebral disc degeneration is minimized when the enzyme is co-injected with osteogenic protein-1, *Spine J.* (2002) [https://doi.org/10.1016/S1529-9430\(02\)00231-0](https://doi.org/10.1016/S1529-9430(02)00231-0).
- [126] K. Masuda, Y. Imai, M. Okuma, C. Muehleman, K. Nakagawa, K. Akeeda, E. Thonar, G. Andersson, H.S. An, Osteogenic protein-1 injection into a degenerated disc induces the restoration of disc height and structural changes in the rabbit anular puncture model, *Spine* 2006 (1976) <https://doi.org/10.1097/01.brs.0000206358.66412.7b>.
- [127] K. Miyamoto, K. Masuda, J.G. Kim, N. Inoue, K. Akeeda, G.B.J. Andersson, H.S. An, Intradiscal injections of osteogenic protein-1 restore the viscoelastic properties of degenerated intervertebral discs, *Spine J.* (2006) <https://doi.org/10.1016/j.spinee.2006.04.014>.
- [128] H.S. An, K. Takegami, H. Kamada, C.M. Nguyen, E.J.M.A. Thonar, K. Singh, G.B. Andersson, K. Masuda, Intradiscal administration of osteogenic protein-1 increases intervertebral disc height and proteoglycan content in the nucleus pulposus in normal a, *Spine* 2005 (1976) <https://doi.org/10.1097/01.brs.0000148002.68656.4d>.
- [129] S. Chubinskaya, M. Kawakami, L. Rappoport, T. Matsumoto, N. Migita, D.C. Rueger, Anti-catabolic effect of OP-1 in chronically compressed intervertebral discs, *J. Orthop. Res.* (2007) <https://doi.org/10.1002/jor.20339>.
- [130] M.K. Pichika, H. An, K. Asanuma, H. Tonomura, M. Lenz, Intradiscal injection of recombinant human bone morphogenetic protein-7 significantly suppressed the expression of cytokines and catabolic enzymes in the rabbit anular puncture model, *Ortho. Res. Soc. Trans.* 33 (2008) 1289, <https://doi.org/10.1097/BRS.0b013e318158dea6>.
- [131] N. Willems, F.C. Bach, S.G.M. Plomp, M.H.P. van Rijen, J. Wolfswinkel, G.C.M. Grinwis, C. Bos, G.J. Strijkers, W.J.A. Dhert, B.P. Meij, L.B. Creemers, M.A. Tryfonidou, Intradiscal application of rhBMP-7 does not induce regeneration in a canine model of spontaneous intervertebral disc degeneration, *Arthritis Res. Ther.* (2015) <https://doi.org/10.1186/s13075-015-0625-2>.
- [132] S.T. Yoon, K.S. Kim, J. Li, J.S. Park, T. Akamaru, W.A. Elmer, W.C. Hutton, The effect of bone morphogenetic protein-2 on rat intervertebral disc cells in vitro, *Spine* 2003 (1976) <https://doi.org/10.1097/01.BRS.0000083204.44190.34>.
- [133] J. Li, S.T. Yoon, W.C. Hutton, Effect of bone morphogenetic protein-2 (BMP-2) on matrix production, other BMPs, and BMP receptors in rat intervertebral disc cells, *J. Spinal Disord. Tech.* (2004) <https://doi.org/10.1097/01.bsd.0000112084.85112.5d>.
- [134] C. Feng, H. Liu, Y. Yang, B. Huang, Y. Zhou, Growth and differentiation factor-5 contributes to the structural and functional maintenance of the intervertebral disc, *Cell. Physiol. Biochem.* 35 (2015) 1–16, <https://doi.org/10.1159/000369670>.
- [135] X. Li, B.M. Leo, G. Beck, G. Balian, D.G. Anderson, Collagen and proteoglycan abnormalities in the GDF-5-deficient mice and molecular changes when treating disk cells with recombinant growth factor, *Spine* 2004 (1976) <https://doi.org/10.1097/01.brs.0000142427.82605.fb>.
- [136] H. Wang, M. Kroeber, M. Hanke, R. Ries, C. Schmid, W. Poller, W. Richter, Release of active and depot GDF-5 after adenovirus-mediated overexpression stimulates rabbit and human intervertebral disc cells, *J. Mol. Med.* (2004) <https://doi.org/10.1007/s00109-003-0507-y>.
- [137] M. Cui, Y. Wan, D.G. Anderson, F.H. Shen, B.M. Leo, C.T. Laurencin, G. Balian, X. Li, Mouse growth and differentiation factor-5 protein and DNA therapy potentiates intervertebral disc cell aggregation and chondrogenic gene expression, *Spine J.* (2008) <https://doi.org/10.1016/j.spinee.2007.05.012>.
- [138] T. Chujo, H.S. An, K. Akeeda, K. Miyamoto, C. Muehleman, M. Attawia, G. Andersson, K. Masuda, Effects of growth differentiation factor-5 on the intervertebral disc - In vitro bovine study and in vivo rabbit disc degeneration model study, *Spine* 31 (2006) (1976) 2909–2917, <https://doi.org/10.1097/01.brs.0000248428.22823.86>.
- [139] H. Liang, S.Y. Ma, G. Feng, F.H. Shen, X. Joshua Li, Therapeutic effects of adenovirus-mediated growth and differentiation factor-5 in a mice disc degeneration model induced by annulus needle puncture, *Spine J.* (2010) <https://doi.org/10.1016/j.spinee.2009.10.006>.
- [140] T. Chujo, H.S. An, R. Takatori, N. Inoue, M. Attawia, C.-K. Lee, C. Muehleman, K. Masuda, Single injection of recombinant human GDF-5 effectively restores mature rabbit of intervertebral discs degenerated by anular puncture, *Trans Orthop Res Soc.* 267 (2007).
- [141] G. Vadalà, P. Mozetic, A. Rainer, M. Centola, M. Loppini, M. Trombetta, V. Denaro, Bioactive electrospun scaffold for annulus fibrosus repair and regeneration, *Eur. Spine J.* (2012) <https://doi.org/10.1007/s00586-012-2235-x>.
- [142] O. Guillaume, A. Daly, K. Lennox, J. Gansau, S.F. Buckley, C.T. Buckley, Shape-memory porous alginate scaffolds for regeneration of the annulus fibrosus: effect of TGF- $\beta$ 3 supplementation and oxygen culture conditions, *Acta Biomater.* (2014) <https://doi.org/10.1016/j.actbio.2013.12.037>.
- [143] J.P. THOMPSON, T.R. OEGEMA, D. BRADFORD, Stimulation of mature canine intervertebral disc by growth factors, *Spine* 1991 (1976) <https://doi.org/10.1097/00007632-199103000-00001>.
- [144] K. Nishida, J.D. Kang, J.K. Suh, P.D. Robbins, C.H. Evans, L.G. Gilbertson, Adenovirus-mediated gene transfer to nucleus pulposus cells. Implications for the treatment of intervertebral disc degeneration, *Spine (Phila Pa 1976)* 23 (1998) 2437–2442, <https://doi.org/10.1097/00007632-199811150-00016>.
- [145] C.M. Tran, D. Markova, H.E. Smith, B. Susarla, R.K. Ponnappan, D.G. Anderson, A. Symes, I.M. Shapiro, M.V. Risbud, Regulation of CCN2/connective tissue growth factor expression in the nucleus pulposus of the intervertebral disc: Role of smad and activator protein 1 signaling, *Arthritis Rheum.* (2010) <https://doi.org/10.1002/art.27445>.
- [146] R. Osada, H. Ohshima, H. Ishihara, K. Yudoh, K. Sakai, H. Matsui, H. Tsuji, Autocrine/paracrine mechanism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs, *J. Orthop. Res.* (1996) <https://doi.org/10.1002/jor.1100140503>.
- [147] H.E. Gruber, H.J. Norton, E.N. Hanley, Anti-apoptotic effects of IGF-1 and PDGF on human intervertebral disc cells in vitro, *Spine (Phila Pa 1976)* 25 (2000) 2153–2157, <https://doi.org/10.1097/00007632-200009010-00002>.
- [148] S. Illien-Jünger, G. Pattappa, M. Peroglio, L.M. Benneker, M.J. Stoddart, D. Sakai, J. Mochida, S. Grad, M. Alini, Homing of mesenchymal stem cells in induced degenerative intervertebral discs in a whole organ culture system, *Spine (Phila Pa 1976)* (2012) <https://doi.org/10.1097/BRS.0b013e3182544a8a>.
- [149] H. Pratsinis, D. Kletsas, PDGF, bFGF and IGF-1 stimulate the proliferation of intervertebral disc cells in vitro via the activation of the ERK and Akt signaling pathways, *Eur. Spine J.* (2007) <https://doi.org/10.1007/s00586-007-0408-9>.
- [150] S.M. Presciutti, D.N. Paglia, T. Karukonda, D.Y. Soung, R. Guzzo, H. Drissi, I.L. Moss, PDGF-BB inhibits intervertebral disc cell apoptosis in vitro, *J. Orthop. Res.* (2014) <https://doi.org/10.1002/jor.22638>.
- [151] R. Paul, R.C. Haydon, H. Cheng, A. Ishikawa, N. Nenadovich, W. Jiang, L. Zhou, B. Breyer, T. Feng, P. Gupta, T.C. He, F.M. Phillips, Potential use of Sox9 gene therapy for intervertebral degenerative disc disease, *Spine* 2003 (1976) <https://doi.org/10.1097/01.BRS.00000558946.64222.92>.
- [152] Y. Zhang, H.S. An, E.J.M.A. Thonar, S. Chubinskaya, T.C. He, F.M. Phillips, Comparative effects of bone morphogenetic proteins and Sox9 overexpression on extracellular matrix metabolism of bovine nucleus pulposus cells, *Spine* 2006 (1976) <https://doi.org/10.1097/01.brs.0000232792.66632.d8>.
- [153] S. Illien-Jünger, G. Pattappa, M. Peroglio, L.M. Benneker, M.J. Stoddart, D. Sakai, J. Mochida, S. Grad, M. Alini, Homing of mesenchymal stem cells in induced degenerative intervertebral discs in a whole organ culture system, *Spine (Phila Pa 1976)* 37 (2012) 1865–1873, <https://doi.org/10.1097/BRS.0b013e3182544a8a>.
- [154] W.-H. Chen, W.-C. Lo, J.-J. Lee, C.-H. Su, C.-T. Lin, H.-Y. Liu, T.-W. Lin, W.-C. Lin, T.-Y. Huang, W.-P. Deng, Tissue-engineered intervertebral disc and chondrogenesis using human nucleus pulposus regulated through TGF-beta1 in platelet-rich plasma, *J. Cell. Physiol.* (2006) <https://doi.org/10.1002/jcp.20765>.
- [155] K. Akeeda, H.S. An, R. Pichika, M. Attawia, E.J.M.A. Thonar, M.E. Lenz, A. Uchida, K. Masuda, Platelet-rich plasma (PRP) stimulates the extracellular matrix metabolism of porcine nucleus pulposus and annulus fibrosus cells cultured in alginate beads, *Spine (Phila Pa 1976)* (2006) <https://doi.org/10.1097/01.brs.00000214942.78119.24>.
- [156] H.-J. Kim, J.S. Yeom, Y.-G. Koh, J.-E. Yeo, K.-T. Kang, Y.-M. Kang, B.-S. Chang, C.-K. Lee, Anti-inflammatory effect of platelet-rich plasma on nucleus pulposus cells with response of TNF- $\alpha$  and IL-1, *J. Orthop. Res.* (2014) <https://doi.org/10.1002/jor.22532>.
- [157] S. Obata, K. Akeeda, T. Imanishi, K. Masuda, W. Bae, R. Morimoto, Y. Asanuma, Y. Kasai, A. Uchida, A. Sudo, Effect of autologous platelet-rich plasma-releasate on intervertebral disc degeneration in the rabbit anular puncture model: a preclinical study, *Arthritis Res. Ther.* (2012) <https://doi.org/10.1186/ar4084>.
- [158] I.D. Gelalis, G. Christoforou, A. Charchanti, I. Gkiatas, E. Pakos, D. Papadopoulos, A. Ploumis, A. Korompilias, Autologous platelet-rich plasma (PRP) effect on intervertebral disc restoration: an experimental rabbit model, *Eur. J. Orthop. Surg. Traumatol.* (2018) <https://doi.org/10.1007/s00590-018-2337-1>.
- [159] K. Comella, S. Robert, P. Michelle, Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease, *J. Transl. Med.* (2017) <https://doi.org/10.1186/s12967-016-1109-0>.

- [160] Y.A. Tuakli-Wosornu, A. Terry, K. Boachie-Adjei, J.R. Harrison, C.K. Gribbin, E.E. LaSalle, J.T. Nguyen, J.L. Solomon, G.E. Lutz, Lumbar intradiscal platelet-rich plasma (PRP) injections: a prospective, double-blind, randomized controlled study, *PM&R* (2016) <https://doi.org/10.1016/j.pmrj.2015.08.010>.
- [161] F. Mwale, K. Masuda, R. Pichika, L.M. Epure, T. Yoshikawa, A. Hemmad, P.J. Roughley, J. Antoniou, The efficacy of Link N as a mediator of repair in a rabbit model of intervertebral disc degeneration, *Arthritis Res. Ther.* (2011) <https://doi.org/10.1186/ar3423>.
- [162] E.S. Vasiliadis, S.G. Pneumaticos, D.S. Evangelopoulos, A.G. Papavassiliou, Biologic treatment of mild and moderate intervertebral disc degeneration, *Mol. Med.* 18 (20) (2014) 400–409, <https://doi.org/10.2119/molmed.2014.00145>.
- [163] K. Ma, Y. Wu, B. Wang, S. Yang, Y. Wei, Z. Shao, Effect of a synthetic link N peptide nanofiber scaffold on the matrix deposition of aggrecan and type II collagen in rabbit notochordal cells, *J. Mater. Sci. Mater. Med.* (2013) <https://doi.org/10.1007/s10856-012-4811-3>.
- [164] R. Gawri, J. Antoniou, J. Ouellet, W. Awwad, T. Steffen, P. Roughley, L. Haglund, F. Mwale, Best paper NASS 2013: link-N can stimulate proteoglycan synthesis in the degenerated human intervertebral discs, *Eur. Cells Mater.* (2013) <https://doi.org/10.22203/eCM.v026a08>.
- [165] F. Mwale, H.T. Wang, P. Roughley, J. Antoniou, L. Haglund, Link N and mesenchymal stem cells can induce regeneration of the early degenerate intervertebral disc, *Tissue Eng. Part A*. (2014) <https://doi.org/10.1089/ten.TEA.2013.0749>.
- [166] S.-H. Moon, K. Nishida, L.G. Gilbertson, H.-M. Lee, H. Kim, R.A. Hall, P.D. Robbins, J.D. Kang, Biologic response of human intervertebral disc cells to gene therapy cocktail, *Spine (Phila Pa 1976)* 2008 (1976) <https://doi.org/10.1097/BRS.0b013e31817e1cd7>.
- [167] K. Il Lee, S.H. Moon, H. Kim, U.H. Kwon, H.J. Kim, S.N. Park, H. Suh, H.M. Lee, H.S. Kim, H.J. Chun, I.K. Kwon, J.W. Jang, Tissue engineering of the intervertebral disc with cultured nucleus pulposus cells using atelocollagen scaffold and growth factors, *Spine (Phila Pa 1976)* (2012) <https://doi.org/10.1097/BRS.0b013e31823c8603>.
- [168] H. Cho, S. Lee, S.-H. Park, J. Huang, K.A. Hasty, S.-J. Kim, Synergistic effect of combined growth factors in porcine intervertebral disc degeneration, *Connect. Tissue Res.* (2013) <https://doi.org/10.3109/03008207.2013.775258>.
- [169] A.A. Hegewald, S. Zouhair, M. Andres, M. Cabrera, C. Woiciechowsky, C. Thomé, C. Kaps, Towards biological annulus repair: TGF- $\beta$ 3, FGF-2 and human serum support matrix formation by human annulus fibrosus cells, *Tissue Cell* (2013) <https://doi.org/10.1016/j.tice.2012.09.011>.
- [170] C.L. Le Maitre, A.J. Freemont, J.A. Hoyland, Expression of cartilage-derived morphogenetic protein in human intervertebral discs and its effect on matrix synthesis in degenerate human nucleus pulposus cells, *Arthritis Res. Ther.* 11 (2009) R137, <https://doi.org/10.1186/ar2808>.
- [171] S. Ren, Y.J. Liu, J. Ma, Z. Diao, D. Yang, X. Zhang, Y. Xi, Y. Hu, Treatment of rabbit intervertebral disc degeneration with co-transfection by adeno-associated virus-mediated SOX9 and osteogenic protein-1 double genes in vivo, *Int. J. Mol. Med.* (2013) <https://doi.org/10.3892/ijmm.2013.1497>.
- [172] A.J.L. Walsh, D.S. Bradford, J.C. Lotz, In Vivo growth factor treatment of degenerated intervertebral discs, *Spine (Phila Pa 1976)* (2004) <https://doi.org/10.1097/01.BRS.0000107231.67854.9F>.
- [173] H. Henriksson, M. Thormemo, C. Karlsson, O. Hägg, K. Junevik, A. Lindahl, H. Brisby, Identification of cell proliferation zones, progenitor cells and a potential stem cell niche in the intervertebral disc region: a study in four species, *Spine (Phila Pa 1976)* 34 (2009) 2278–2287, <https://doi.org/10.1097/BRS.0b013e3181a95ad2>.
- [174] H. Brisby, N. Papadimitriou, C. Brantsing, P. Bergh, A. Lindahl, H. Barreto Henriksson, The Presence of Local Mesenchymal Progenitor Cells in Human Degenerated Intervertebral Discs and Possibilities to Influence These In Vitro: A Descriptive Study in Humans, *Stem Cells Dev.* 22 (2013) 804–814, <https://doi.org/10.1089/scd.2012.0179>.
- [175] J.F. Blanco, I.F. Graciani, F.M. Sanchez-Guijo, S. Muntión, P. Hernandez-Campo, C. Santamaria, S. Carrancio, M.-V. Barbadó, G. Cruz, S. Gutierrez-Cosío, C. Herrero, J.F. San Miguel, J.G. Briño, M.-C. del Cañizo, Isolation and characterization of mesenchymal stromal cells from human degenerated nucleus pulposus: comparison with bone marrow mesenchymal stromal cells from the same subjects, *Spine (Phila Pa 1976)* 35 (2010) 2259–2265, <https://doi.org/10.1097/BRS.0b013e3181cb8828>.
- [176] M.V. Risbud, A. Guttapalli, T.-T. Tsai, J.Y. Lee, K.G. Danielson, A.R. Vaccaro, T.J. Albert, Z. Gazit, D. Gazit, I.M. Shapiro, Evidence for skeletal progenitor cells in the degenerate human intervertebral disc, *Spine (Phila Pa 1976)* 32 (2007) 2537–2544, <https://doi.org/10.1097/BRS.0b013e318158dea6>.
- [177] C. Liu, Q. Guo, J. Li, S. Wang, Y. Wang, B. Li, H. Yang, Identification of rabbit annulus fibrosus-derived stem cells, *PLoS One* 9 (2014) <https://doi.org/10.1371/journal.pone.0108239>.
- [178] D. Sakai, Y. Nakamura, T. Nakai, T. Mishima, S. Kato, S. Grad, M. Alini, M.V. Risbud, D. Chan, K.S.E. Cheah, K. Yamamura, K. Masuda, H. Okano, K. Ando, J. Mochida, Exhaustion of nucleus pulposus progenitor cells with ageing and degeneration of the intervertebral disc, *Nat. Commun.* 3 (2012) 1264, <https://doi.org/10.1038/ncomms2226>.
- [179] S. Turner, B. Balain, B. Caterson, C. Morgan, S. Roberts, Viability, growth kinetics and stem cell markers of single and clustered cells in human intervertebral discs: implications for regenerative therapies, *Eur. Spine J.* 23 (2014) 2462–2472, <https://doi.org/10.1007/s00586-014-3500-y>.
- [180] X.-C. Li, Y. Tang, J.-H. Wu, P.-S. Yang, D.-L. Wang, D.-K. Ruan, Characteristics and potentials of stem cells derived from human degenerated nucleus pulposus: potential for regeneration of the intervertebral disc, *BMC Musculoskelet. Disord.* 18 (2017) 242, <https://doi.org/10.1186/s12891-017-1567-4>.
- [181] G. Feng, X. Yang, H. Shang, I.W. Marks, F.H. Shen, A. Katz, V. Arlet, C.T. Laurencin, X. Li, Multipotential differentiation of human annulus fibrosus cells, *J. Bone Jt. Surg.-Am. Vol.* 92 (2010) 675–685, <https://doi.org/10.2106/JBJS.H.01672>.
- [182] H.E. Gruber, F.E. Riley, G.L. Hoelscher, J.A. Ingram, L. Bullock, E.N. Hanley, Human annulus progenitor cells: analyses of this viable endogenous cell population, *J. Orthop. Res.* 34 (2016) 1351–1360, <https://doi.org/10.1002/jor.23319>.
- [183] S. Liu, H. Liang, S.M. Lee, Z. Li, J. Zhang, Q. Fei, Isolation and identification of stem cells from degenerated human intervertebral discs and their migration characteristics, *Acta Biochim. Biophys. Sin. Shanghai* (2017) <https://doi.org/10.1093/abbs/gmw121>.
- [184] H. Wang, Y. Zhou, T.W. Chu, C.Q. Li, J. Wang, Z.F. Zhang, B. Huang, Distinguishing characteristics of stem cells derived from different anatomical regions of human degenerated intervertebral discs, *Eur. Spine J.* 25 (2016) 2691–2704, <https://doi.org/10.1007/s00586-016-4522-4>.
- [185] H. Wang, Y. Zhou, B. Huang, L.-T. Liu, M.-H. Liu, J. Wang, C.-Q. Li, Z.-F. Zhang, T.-W. Chu, C.-J. Xiong, Utilization of stem cells in alginate for nucleus pulposus tissue engineering, *Tissue Eng. Part A*. 20 (2014) 908–920, <https://doi.org/10.1089/ten.tea.2012.0703>.
- [186] L.T. Liu, B. Huang, C.Q. Li, Y. Zhuang, J. Wang, Y. Zhou, Characteristics of stem cells derived from the degenerated human intervertebral disc cartilage endplate, *PLoS One* 6 (2011) <https://doi.org/10.1371/journal.pone.0026285>.
- [187] J. Lu, X. Shen, X. Sun, H. Yin, S. Yang, C. Lu, Y. Wang, Y. Liu, Y. Huang, Z. Yang, X. Dong, C. Wang, Q. Gui, L. Zhao, X. Sun, S. Lu, A. Mikos, J. Peng, X. Wang, Increased recruitment of endogenous stem cells and chondrogenic differentiation by a composite scaffold containing bone marrow homing peptide for cartilage regeneration, *Theranostics*. 8 (2018) 5039–5058.
- [188] S. Bollini, A. Smits, C. Balbi, E. Lazzarini, P. Ameri, Triggering endogenous cardiac repair and regeneration via extracellular vesicle-mediated communication, *Front. Physiol.* 9 (2018) 1497.
- [189] C.H. Lee, F.Y. Lee, S. Tarafder, K. Kao, Y. Jun, G. Yang, J.J. Mao, Harnessing endogenous stem/progenitor cells for tendon regeneration, *J. Clin. Invest.* (2015) <https://doi.org/10.1172/JCI81589>.
- [190] K. Ma, S. Chen, Z. Li, X. Deng, D. Huang, L. Xiong, Z. Shao, Mechanisms of endogenous repair failure during intervertebral disc degeneration, *Osteoarthritis Cartil.* (2018) <https://doi.org/10.1016/j.joca.2018.08.021>.
- [191] H.B. Henriksson, E. Svala, E. Skioldebrand, A. Lindahl, H. Brisby, Support of concept that migrating progenitor cells from stem cell niches contribute to normal regeneration of the adult mammal intervertebral disc, *Spine (Phila Pa 1976)* 37 (2012) 722–732, <https://doi.org/10.1097/BRS.0b013e318231c2f7>.
- [192] H.B. Henriksson, N. Papadimitriou, S. Tschernitz, E. Svala, E. Skioldebrand, S. Windahl, K. Junevik, H. Brisby, Indications of that migration of stem cells is influenced by the extra cellular matrix architecture in the mammalian intervertebral disk region, *Tissue Cell* 47 (2015) 439–455, <https://doi.org/10.1016/j.tice.2015.08.001>.
- [193] G. Pattappa, M. Peroglio, D. Sakai, J. Mochida, L.M. Benneker, M. Alini, S. Grad, CCL5/rantes is a key chemoattractant released by degenerative intervertebral discs in organ culture, *Eur. Cells Mater.* (2014) <https://doi.org/10.22203/eCM.v027a10>.
- [194] C.K. Kepler, D.Z. Markova, F. Dibra, S. Yadla, A.R. Vaccaro, M.V. Risbud, T.J. Albert, D.G. Anderson, Expression and relationship of proinflammatory chemokine RANTES/CCL5 and cytokine IL-1  $\beta$  in painful human intervertebral discs, *Spine (Phila Pa 1976)* 2013 (1976) <https://doi.org/10.1097/BRS.0b013e318285ae08>.
- [195] C.L. Pereira, R.M. Gonçalves, M. Peroglio, G. Pattappa, M. D'Este, D. Eglin, M.A. Barbosa, M. Alini, S. Grad, The effect of hyaluronan-based delivery of stromal cell-derived factor-1 on the recruitment of MSCs in degenerating intervertebral discs, *Biomaterials*. 35 (2014) 8144–8153, <https://doi.org/10.1016/j.biomaterials.2014.06.017>.
- [196] C.L. Pereira, G.Q. Teixeira, C. Ribeiro-Machado, J. Caldeira, M. Costa, F. Figueiredo, R. Fernandes, P. Aguiar, S. Grad, M.A. Barbosa, R.M. Gonçalves, Mesenchymal stem/stromal cells seeded on cartilaginous endplates promote intervertebral disc regeneration through extracellular matrix remodeling, *Sci. Rep.* 6 (2016) 33836, <https://doi.org/10.1038/srep33836>.
- [197] G. Vadalà, F. Russo, L. Ambrosio, M. Loppini, V. Denaro, Stem cells sources for intervertebral disc regeneration, *World J. Stem Cells.* (2016) <https://doi.org/10.4252/wjsc.v8.i5.185>.
- [198] S.B.G. Blanquer, D.W. Grijpma, A.A. Poot, Delivery systems for the treatment of degenerated intervertebral discs, *Adv. Drug Deliv. Rev.* 84 (2015) 172–187, <https://doi.org/10.1016/j.addr.2014.10.024>.
- [199] D. Sakai, G.B.J. Andersson, Stem cell therapy for intervertebral disc regeneration: obstacles and solutions, *Nat. Rev. Rheumatol.* (2015) <https://doi.org/10.1038/nrrheum.2015.13>.
- [200] C. Hohaus, T.M. Ganey, Y. Minkus, H.J. Meisel, Cell transplantation in lumbar spine disc degeneration disease, *Eur. Spine J.* (2008) <https://doi.org/10.1007/s00586-008-0750-6>.
- [201] H.J. Meisel, V. Siodla, T. Ganey, Y. Minkus, W.C. Hutton, O.J. Alasevic, Clinical experience in cell-based therapeutics: disc chondrocyte transplantation. A treatment for degenerated or damaged intervertebral disc, *Biomol. Eng.* 24 (2007) 5–21, <https://doi.org/10.1016/j.bioeng.2006.07.002>.
- [202] H.J. Meisel, T. Ganey, W.C. Hutton, J. Libera, Y. Minkus, O. Alasevic, Clinical experience in cell-based therapeutics: intervention and outcome, *Eur. Spine J.* (2006) <https://doi.org/10.1007/s00586-006-0169-x>.
- [203] G. Paesold, A.G. Nerlich, N. Boos, Biological treatment strategies for disc degeneration: potentials and shortcomings, *Eur. Spine J.* (2007) <https://doi.org/10.1007/s00586-006-0220-y>.

- [204] A.A. Hegewald, M. Endres, A. Abbushi, M. Cabraja, C. Woiciechowsky, K. Schmieder, C. Kaps, C. Thomé, Adequacy of herniated disc tissue as a cell source for nucleus pulposus regeneration, *J. Neurosurg. Spine*. (2011) <https://doi.org/10.3171/2010.10.SPINE10223>.
- [205] T. Watanabe, D. Sakai, Y. Yamamoto, T. Iwashina, K. Serigano, F. Tamura, J. Mochida, Human nucleus pulposus cells significantly enhanced biological properties in a co-culture system with direct cell-to-cell contact with autologous mesenchymal stem cells, *J. Orthop. Res.* (2010) <https://doi.org/10.1002/jor.21036>.
- [206] Y. Yamamoto, J. Mochida, D. Sakai, T. Nakai, K. Nishimura, H. Kawada, T. Hotta, Up-regulation of the viability of nucleus pulposus cells by bone marrow-derived stromal cells: significance of direct cell-to-cell contact in coculture system, *Spine (Phila Pa 1976)* 2004 (1976) <https://doi.org/10.1097/01.BRS.0000131416.90906.20>.
- [207] M. Okuma, J. Mochida, K. Nishimura, K. Sakabe, K. Seiki, Reinsertion of stimulated nucleus pulposus cells retards intervertebral disc degeneration: an in vitro and in vivo experimental study, *J. Orthop. Res.* (2000) <https://doi.org/10.1002/jor.1100180620>.
- [208] S.M. Richardson, N. Hughes, J.A. Hunt, A.J. Freemont, J.A. Hoyland, Human mesenchymal stem cell differentiation to NP-like cells in chitosan-glycerophosphate hydrogels, *Biomaterials* 29 (2008) 85–93, <https://doi.org/10.1016/j.biomaterials.2007.09.018>.
- [209] H.B. Henriksson, T. Svanvik, M. Jonsson, M. Hagman, M. Horn, A. Lindahl, H. Brisby, Transplantation of human mesenchymal stem cells into intervertebral discs in a xenogeneic porcine model, *Spine (Phila Pa 1976)* 34 (2009) (1976) 141–148, <https://doi.org/10.1097/BRS.0b013e31818188c20>.
- [210] K. Serigano, D. Sakai, A. Hiyama, F. Tamura, M. Tanaka, J. Mochida, Effect of cell number on mesenchymal stem cell transplantation in a canine disc degeneration model, *J. Orthop. Res.* (2010) <https://doi.org/10.1002/jor.21147>.
- [211] M. Gorensek, C. Jaksimović, N. Kregar-Velikonja, M. Gorensek, M. Knezevic, M. Jeras, V. Pavlovic, A. Cör, Nucleus pulposus repair with cultured autologous elastic cartilage derived chondrocytes, *Cell. Mol. Biol. Lett.* 9 (2004) 363–378 (doi: papers3://publication/uuid/877D2C6B-3DBF-45C0-9572-01EA0CA8A1220).
- [212] F.L. Acosta, L. Metz, H.D. Adkisson, J. Liu, E. Carruthers-Liebenberg, C. Millman, M. Maloney, J.C. Lotz, Porcine intervertebral disc repair using allogeneic juvenile articular chondrocytes or mesenchymal stem cells, *Tissue Eng. Part A*. (2011) <https://doi.org/10.1089/ten.tea.2011.0229>.
- [213] M.B. Murphy, K. Moncivais, A.I. Caplan, Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine, *Exp. Mol. Med.* (2013) <https://doi.org/10.1038/emmm.2013.94>.
- [214] J.V. Stoyanov, B. Gantenbein-Ritter, A. Bertolo, N. Aebli, M. Baur, M. Alini, S. Grad, Role of hypoxia and growth and differentiation factor-5 on differentiation of human mesenchymal stem cells towards intervertebral nucleus pulposus-like cells, *Eur. Cells Mater.* 21 (2011) 533–547, <https://doi.org/10.22203/eCM.v021a40>.
- [215] K. Xia, J. Zhu, J. Hua, Z. Gong, C. Yu, X. Zhou, J. Wang, X. Huang, W. Yu, L. Li, J. Gao, Q. Chen, F. Li, C. Liang, Intradiscal injection of induced pluripotent stem cell-derived nucleus pulposus-like cell-seeded polymeric microspheres promotes rat disc regeneration, *Stem Cells Int.* (2019) <https://doi.org/10.1155/2019/6806540>.
- [216] M.V. Risbud, T.J. Albert, A. Guttapalli, E.J. Vresilovic, A.S. Hillibrand, A.R. Vaccaro, I.M. Shapiro, Differentiation of mesenchymal stem cells towards a nucleus pulposus-like phenotype in vitro: implications for cell-based transplantation therapy, *Spine (Phila Pa 1976)* 29 (2004) 2627–2632, <https://doi.org/10.1097/01.brs.0000146462.92171.7f>.
- [217] C. Merceron, S. Portron, C. Vignes-Colombeix, E. Rederstorff, M. Masson, J. Lesoeur, S. Sourice, C. Sinquin, S. Collic-Jouault, P. Weiss, C. Vinatier, J. Guicheux, Pharmacological modulation of human mesenchymal stem cell chondrogenesis by a chemically oversulfated polysaccharide of marine origin: potential application to cartilage regenerative medicine, *Stem Cells* (2012) <https://doi.org/10.1002/stem.1686>.
- [218] S. Portron, C. Merceron, O. Gauthier, J. Lesoeur, S. Sourice, M. Masson, B.H. Fella, O. Geffroy, E. Lallemand, P. Weiss, J. Guicheux, C. Vinatier, Effects of in vitro low oxygen tension preconditioning of adipose stromal cells on their in vivo chondrogenic potential: application in cartilage tissue repair, *PLoS One* (2013) <https://doi.org/10.1371/journal.pone.0062368>.
- [219] B. Gantenbein-Ritter, L.M. Benneker, M. Alini, S. Grad, Differential response of human bone marrow stromal cells to either TGF- $\beta$ (1) or rhGDF-5, *Eur. Spine J.* 20 (2011) 962–971, <https://doi.org/10.1007/s00586-010-1619-z>.
- [220] J.V. Stoyanov, B. Gantenbein-Ritter, A. Bertolo, N. Aebli, M. Baur, M. Alini, S. Grad, Role of hypoxia and growth and differentiation factor-5 on differentiation of human mesenchymal stem cells towards intervertebral nucleus pulposus-like cells, *Eur. Cells Mater.* (2011) <https://doi.org/10.22203/eCM.v021a40>.
- [221] L.E. Clarke, J.C. McConnell, M.J. Sherratt, B. Derby, S.M. Richardson, J.A. Hoyland, Growth differentiation factor 6 and transforming growth factor-beta differentially mediate mesenchymal stem cell differentiation, composition, and biomechanical properties of nucleus pulposus constructs, *Arthritis Res. Ther.* 16 (2014) R67, <https://doi.org/10.1186/ar4505>.
- [222] S. Sobajima, G. Vadala, A. Shimer, J.S. Kim, L.G. Gilbertson, J.D. Kang, Feasibility of a stem cell therapy for intervertebral disc degeneration, *Spine J.* (2008) <https://doi.org/10.1016/j.spinee.2007.09.011>.
- [223] G. Vadala, S. Sobajima, J.Y. Lee, J. Huard, V. Denaro, J.D. Kang, L.G. Gilbertson, In vitro interaction between muscle-derived stem cells and nucleus pulposus cells, *Spine J.* (2008) <https://doi.org/10.1016/j.spinee.2007.07.394>.
- [224] S.M. Richardson, R.V. Walker, S. Parker, N.P. Rhodes, J.A. Hunt, A.J. Freemont, J.A. Hoyland, Intervertebral disc cell-mediated mesenchymal stem cell differentiation, *Stem Cells* 24 (2006) 707–716, <https://doi.org/10.1634/stemcells.2005-0205>.
- [225] C. Le Visage, S.W. Kim, K. Tatenno, A.N. Sieber, J.P. Kostuiak, K.W. Leong, Interaction of human mesenchymal stem cells with disc cells: Changes in extracellular matrix biosynthesis, *Spine (Phila Pa 1976)* (2006) <https://doi.org/10.1097/01.brs.0000231442.05245.87>.
- [226] Z. Han, J. Wang, L. Gao, Q. Wang, J. Wu, Aberrantly expressed messenger RNAs and long noncoding RNAs in degenerative nucleus pulposus cells co-cultured with adipose-derived mesenchymal stem cells, *Arthritis Res. Ther.* (2018) <https://doi.org/10.1186/s13075-018-1677-x>.
- [227] M.F. Pittenger, Multilineage potential of adult human mesenchymal stem cells, *Science* (80-) (1999) <https://doi.org/10.1126/science.284.5411.143>.
- [228] G. Vadala, R.K. Studer, G. Sowa, F. Spiezia, C. Iucii, V. Denaro, L.G. Gilbertson, J.D. Kang, Coculture of bone marrow mesenchymal stem cells and nucleus pulposus cells modulate gene expression profile without cell fusion, *Spine (Phila Pa 1976)* (2008) <https://doi.org/10.1097/BRS.0b013e31818188c20>.
- [229] Z.F. Lu, B. Zandieh Doulabi, P.I. Wuisman, R.A. Bank, M.N. Helder, Differentiation of adipose stem cells by nucleus pulposus cells: Configuration effect, *Biochem. Biophys. Res. Commun.* (2007) <https://doi.org/10.1016/j.bbrc.2007.06.002>.
- [230] A. Uccelli, L. Moretta, V. Pistoia, Immunoregulatory function of mesenchymal stem cells, *Eur. J. Immunol.* (2006) <https://doi.org/10.1002/eji.200636416>.
- [231] F. Gao, S.M. Chiu, D.A.L. Motan, Z. Zhang, L. Chen, H.-L. Ji, H.-F. Tse, Q.-L. Fu, Q. Lian, Mesenchymal stem cells and immunomodulation: current status and future prospects, *Cell Death Dis.* (2016) <https://doi.org/10.1038/cddis.2015.327>.
- [232] G. Feng, X. Zhao, H. Liu, H. Zhang, X. Chen, R. Shi, X. Liu, X. Zhao, W. Zhang, B. Wang, Transplantation of mesenchymal stem cells and nucleus pulposus cells in a degenerative disc model in rabbits: a comparison of 2 cell types as potential candidates for disc regeneration, *J. Neurosurg. Spine.* (2011) <https://doi.org/10.3171/2010.11.SPINE10285>.
- [233] H.B. Henriksson, M. Hagman, M. Horn, A. Lindahl, H. Brisby, Investigation of different cell types and gel carriers for cell-based intervertebral disc therapy, in vitro and in vivo studies, *J. Tissue Eng. Regen. Med.* (2012) <https://doi.org/10.1002/term.480>.
- [234] J.D. Prologo, A. Pirasteh, N. Tenley, L. Yuan, D. Corn, D. Hart, Z. Love, H.M. Lazarus, Z. Lee, Percutaneous image-guided delivery for the transplantation of mesenchymal stem cells in the setting of degenerated intervertebral discs, *J. Vasc. Interv. Radiol.* (2012) <https://doi.org/10.1016/j.jvir.2012.04.032>.
- [235] Y.-G. Zhang, X. Guo, P. Xu, L.-L. Kang, J. Li, Bone mesenchymal stem cells transplanted into rabbit intervertebral discs can increase proteoglycans, *Clin. Orthop. Relat. Res.* (2005) <https://doi.org/10.1097/01.blo.0000146534.31120.cf>.
- [236] C.-J. Ma, X. Liu, L. Che, Z.-H. Liu, D. Samartzis, H.-Q. Wang, Stem cell therapies for intervertebral disc degeneration: immune privilege reinforcement by Fas/FasL regulating machinery, *Curr. Stem Cell Res. Ther.* (2015) <https://doi.org/10.2174/157488X10666150416114027>.
- [237] C. Elabd, C.J. Centeno, J.R. Schultz, G. Lutz, T. Ichim, F.J. Silva, Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: A long-term safety and feasibility study, *J. Transl. Med.* (2016) <https://doi.org/10.1186/s12967-016-1015-5>.
- [238] T. Yoshikawa, Y. Ueda, K. Miyazaki, M. Koizumi, Y. Takakura, Disc regeneration therapy using marrow mesenchymal cell transplantation: A report of two case studies, *Spine (Phila Pa 1976)* (2010) <https://doi.org/10.1097/BRS.0b013e31818181c2cf4>.
- [239] L. Orozco, R. Soler, C. Morera, M. Alberca, A. Sánchez, J. García-Sancho, Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study, *Transplantation*. 92 (2011) 822–828, <https://doi.org/10.1097/TP.0b013e3182298a15>.
- [240] Y. Sun, V. Leung, K. Cheung, Clinical trials of intervertebral disc regeneration: current status and future developments, *Int. Orthop.* 43 (4) (2018) 1003–1010.
- [241] K. Pettine, R. Suzuki, T. Sand, M. Murphy, Treatment of discogenic back pain with autologous bone marrow concentrate injection with minimum two year follow-up, *Int. Orthop.* (2016) <https://doi.org/10.1007/s00264-015-2886-4>.
- [242] K.A. Pettine, R.K. Suzuki, T.T. Sand, M.B. Murphy, Autologous bone marrow concentrate intradiscal injection for the treatment of degenerative disc disease with three-year follow-up, *Int. Orthop.* (2017) <https://doi.org/10.1007/s00264-017-3560-9>.
- [243] S.Z. Wang, J.Y. Jin, Y.D. Guo, L.Y. Ma, Q. Chang, X.G. Peng, F.F. Guo, H.X. Zhang, X.F. Hu, C. Wang, Intervertebral disc regeneration using platelet-rich plasma-containing bone marrow-derived mesenchymal stem cells: a preliminary investigation, *Mol. Med. Rep.* (2016) <https://doi.org/10.3892/mmr.2016.4983>.
- [244] M. Tkach, C. Théry, Communication by extracellular vesicles: where we are and where we need to go, *Cell* (2016) <https://doi.org/10.1016/j.cell.2016.01.043>.
- [245] J. Malda, J. Boere, C.H.A. Van De Lest, P.R. Van Weeren, M.H.M. Wauben, Extracellular vesicles - new tool for joint repair and regeneration, *Nat. Rev. Rheumatol.* (2016) <https://doi.org/10.1038/nrrheum.2015.170>.
- [246] A.M. Silva, J.H. Teixeira, M.I. Almeida, R.M. Gonçalves, M.A. Barbosa, S.G. Santos, Extracellular Vesicles: immunomodulatory messengers in the context of tissue repair/regeneration, *Eur. J. Pharm. Sci.* (2017) <https://doi.org/10.1016/j.ejps.2016.09.017>.
- [247] B. Zhang, M. Wang, A. Gong, X. Zhang, X. Wu, Y. Zhu, H. Shi, L. Wu, W. Zhu, H. Qian, W. Xu, HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing, *Stem Cells* (2015) <https://doi.org/10.1002/stem.1771>.
- [248] M. Tofiño-Vian, M.I. Guillén, M.D. Pérez Del Caz, A. Silvestre, M.J. Alcaraz, Microvesicles from human adipose tissue-derived mesenchymal stem cells as a new protective strategy in osteoarthritic chondrocytes, *Cell. Physiol. Biochem.* (2018) <https://doi.org/10.1159/000489739>.
- [249] W.S. Toh, R.C. Lai, J.H.P. Hui, S.K. Lim, MSC exosome as a cell-free MSC therapy for cartilage regeneration: implications for osteoarthritis treatment, *Semin. Cell Dev. Biol.* (2017) <https://doi.org/10.1016/j.semcdb.2016.11.008>.
- [250] K. Lu, H. Yin Li, K. Yang, J. Long Wu, X. Wei Cai, Y. Zhou, C. Qing Li, Exosomes as potential alternatives to stem cell therapy for intervertebral disc degeneration: in vitro study on exosomes in interaction of nucleus pulposus cells and bone marrow

- mesenchymal stem cells, *Stem Cell Res Ther* (2017) <https://doi.org/10.1186/s13287-017-0563-9>.
- [251] F. Bach, S. Libregts, L. Creemers, B. Meij, K. Ito, M. Wauben, M. Tryfonidou, Notochordal-cell derived extracellular vesicles exert regenerative effects on canine and human nucleus pulposus cells, *Oncotarget*. (2017) <https://doi.org/10.18632/oncotarget.21483>.
- [252] A.I. Chou, S.O. Akintoye, S.B. Nicoll, Photo-crosslinked alginate hydrogels support enhanced matrix accumulation by nucleus pulposus cells in vivo, *Osteoarthr. Cartil.* 17 (10) (2009) 1377–1384, <https://doi.org/10.1016/j.joca.2009.04.012>.
- [253] M.S. Gupta, E.S. Cooper, S.B. Nicoll, Transforming growth factor-beta 3 stimulates cartilage matrix elaboration by human marrow-derived stromal cells encapsulated in photocrosslinked carboxymethylcellulose hydrogels: potential for nucleus pulposus replacement, *Tissue Eng. Part A* 17 (23–24) (2011) 2903–2910, <https://doi.org/10.1089/ten.tea.2011.0152>.
- [254] E.M. Schutgens, M.A. Tryfonidou, T.H. Smit, F. Cumhur Öner, A. Krouwels, K. Ito, L.B. Creemers, Biomaterials for intervertebral disc regeneration: past performance and possible future strategies, *Eur. Cells Mater.* (2015) <https://doi.org/10.22203/eCM.v030a15>.
- [255] A. Di Martino, M. Sittering, M.V. Risbud, Chitosan: a versatile biopolymer for orthopaedic tissue-engineering, *Biomaterials.* (2005) <https://doi.org/10.1016/j.biomaterials.2005.03.016>.
- [256] T. Dai, M. Tanaka, Y.Y. Huang, M.R. Hamblin, Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects, *Expert Rev. Anti-Infect. Ther.* (2011) <https://doi.org/10.1586/eri.11.59>.
- [257] B. Chen, W. Dai, B. He, H. Zhang, X. Wang, Y. Wang, Q. Zhang, Current multistage drug delivery systems based on the tumor microenvironment, *Theranostics.* (2017) <https://doi.org/10.7150/tno.16684>.
- [258] N. Kamaly, B. Yameen, J. Wu, O.C. Farokhzad, Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release, *Chem. Rev.* (2016) <https://doi.org/10.1021/acs.chemrev.5b00346>.
- [259] E. Mauri, S. Papa, M. Masi, P. Veglianesi, F. Rossi, Novel functionalization strategies to improve drug delivery from polymers, *Expert Opin. Drug Deliv.* (2017) <https://doi.org/10.1080/17425247.2017.1285280>.
- [260] V. Delplace, J. Obermeyer, M.S. Shoichet, Local affinity release, *ACS Nano* (2016) <https://doi.org/10.1021/acsnano.6b04308>.
- [261] V.E. Santo, M.E. Gomes, J.F. Mano, R.L. Reis, Controlled release strategies for bone, cartilage, and osteochondral engineering—part II: challenges on the evolution from single to multiple bioactive factor delivery, *Tissue Eng. Part B Rev.* (2013) [https://doi.org/10.1016/0167-6911\(87\)90067-3](https://doi.org/10.1016/0167-6911(87)90067-3).
- [262] V.E. Santo, M. Gomes, J. Mano, R.L. Reis, Controlled release strategies for bone, cartilage and osteochondral engineering - Part I: recapitulation of native tissue healing and variables for the design of delivery systems, *Tissue Eng. Part B* (2012) <https://doi.org/10.1089/ten.TEB.2012.0138>.
- [263] J. Lam, S. Lu, F.K. Kasper, A.G. Mikos, Strategies for controlled delivery of biologics for cartilage repair, *Adv. Drug Deliv. Rev.* (2015) <https://doi.org/10.1016/j.addr.2014.06.006>.
- [264] M. Mehta, K. Schmidt-Bleek, G.N. Duda, D.J. Mooney, Biomaterial delivery of morphogens to mimic the natural healing cascade in bone, *Adv. Drug Deliv. Rev.* (2012) <https://doi.org/10.1016/j.addr.2012.05.006>.
- [265] J. Li, D.J. Mooney, Designing hydrogels for controlled drug delivery, *Nat. Rev. Mater.* (2016) <https://doi.org/10.1038/natrevmats.2016.71>.
- [266] K. Flégeau, R. Pace, H. Gautier, G. Rethore, J. Guicheux, C. Le Visage, P. Weiss, Toward the development of biomimetic injectable and macroporous biohydrogels for regenerative medicine, *Adv. Colloid Interf. Sci.* 247 (2017) 589–609, <https://doi.org/10.1016/j.cis.2017.07.012>.
- [267] S. Kim, Y. Kang, C.A. Krueger, M. Sen, J.B. Holcomb, D. Chen, J.C. Wenke, Y. Yang, Sequential delivery of BMP-2 and IGF-1 using a chitosan gel with gelatin microspheres enhances early osteoblastic differentiation, *Acta Biomater.* (2012) <https://doi.org/10.1016/j.actbio.2012.01.009>.
- [268] E.A. Bayer, J. Jordan, A. Roy, R. Gottardi, M.V. Fedorchak, P.N. Kumta, S.R. Little, Programmed platelet-derived growth factor-BB and bone morphogenetic protein-2 delivery from a hybrid calcium phosphate/alginate scaffold, *Tissue Eng. Part A.* (2017) <https://doi.org/10.1089/ten.tea.2017.0027>.
- [269] N. Joshi, J. Yan, S. Levy, S. Bhagchandani, K.V. Slaughter, N.E. Sherman, J. Amirault, Y. Wang, L. Riegel, X. He, T.S. Rui, M. Valic, P.K. Vemula, O.R. Miranda, O. Levy, E.M. Gravallesse, A.O. Aliprantis, J. Ermann, J.M. Karp, Towards an arthritis flare-responsive drug delivery system, *Nat. Commun.* (2018) <https://doi.org/10.1038/s41467-018-03691-1>.
- [270] D. Beall, T.R. Deer, J. Wilsey, A. Walsh, J.H. Block, W. McKay, J.M. Zanella, B.P. Parsons, C.C. Carson, Tissue distribution of clonidine following intraforaminal implantation of biodegradable pellets: potential alternative to epidural steroid for radiculopathy, *J. Vasc. Interv. Radiol.* (2013) <https://doi.org/10.1016/j.jvir.2013.01.271>.
- [271] J.E. Frith, D.J. Menzies, A.R. Cameron, P. Ghosh, D.L. Whitehead, S. Gronthos, A.C.W. Zannettino, J.J. Cooper-White, Effects of bound versus soluble pentosan polysulphate in PEG/HA-based hydrogels tailored for intervertebral disc regeneration, *Biomaterials.* (2014) <https://doi.org/10.1016/j.biomaterials.2013.10.056>.
- [272] Y. Zhu, J. Tan, H. Zhu, G. Lin, F. Yin, L. Wang, K. Song, Y. Wang, G. Zhou, W. Yi, Development of kartogenin-conjugated chitosan-hyaluronic acid hydrogel for nucleus pulposus regeneration, *Biomater. Sci.* (2017) <https://doi.org/10.1039/c7bm00001d>.
- [273] M.S. Gupta, S.B. Nicoll, Duration of TGF- $\beta$ 3 exposure impacts the chondrogenic maturation of human MSCs in photocrosslinked carboxymethylcellulose hydrogels, *Ann. Biomed. Eng.* (2015) <https://doi.org/10.1007/s10439-014-1179-1>.
- [274] J.W. Lee, T.H. Lim, J.B. Park, Intradiscal drug delivery system for the treatment of low back pain, *J. Biomed. Mater. Res. - Part A* (2010) <https://doi.org/10.1002/jbm.a.32377>.
- [275] E. Wenk, A.J. Meinel, S. Wildy, H.P. Merkle, L. Meinel, Microporous silk fibroin scaffolds embedding PLGA microparticles for controlled growth factor delivery in tissue engineering, *Biomaterials.* (2009) <https://doi.org/10.1016/j.biomaterials.2008.12.073>.
- [276] V.P. Mantripragada, A.C. Jayasuriya, IGF-1 release kinetics from chitosan microparticles fabricated using environmentally benign conditions, *Mater. Sci. Eng. C* (2014) <https://doi.org/10.1016/j.msec.2014.05.068>.
- [277] N. Henry, J. Clouet, A. Fragale, L. Griveau, C. Chédeville, J. Véziers, P. Weiss, J. Le Bideau, J. Guicheux, C. Le Visage, Pullulan microbeads/Si-HPMC hydrogel injectable system for the sustained delivery of GDF-5 and TGF- $\beta$ 1: new insight into intervertebral disc regenerative medicine, *Drug Deliv.* 24 (2017) 999–1010, <https://doi.org/10.1080/10717544.2017.1340362>.
- [278] N. Henry, J. Clouet, C. Le Visage, P. Weiss, E. Gautron, D. Renard, T. Cordonnier, F. Boury, B. Humbert, H. Terrisse, J. Guicheux, Silica nanofibers as a new drug delivery system: a study of the protein-silica interactions, *J. Mater. Chem. B* (2017) <https://doi.org/10.1039/c7tb00332c>.
- [279] M. Nagae, T. Ikeda, Y. Mikami, H. Hase, H. Ozawa, K.-I. Matsuda, H. Sakamoto, Y. Tabata, M. Kawata, T. Kubo, Intervertebral disc regeneration using platelet-rich plasma and biodegradable gelatin hydrogel microspheres, *Tissue Eng.* (2007) <https://doi.org/10.1089/ten.2006.0042>.
- [280] K. Sawamura, T. Ikeda, M. Nagae, S. Okamoto, Y. Mikami, H. Hase, K. Ikoma, T. Yamada, H. Sakamoto, K. Matsuda, Y. Tabata, M. Kawata, T. Kubo, Characterization of *in vivo* effects of platelet-rich plasma and biodegradable gelatin hydrogel microspheres on degenerated intervertebral discs, *Tissue Eng. Part A.* (2009) <https://doi.org/10.1089/ten.tea.2008.0697>.
- [281] G. Feng, Z. Zha, Y. Huang, J. Li, Y. Wang, W. Ke, H. Chen, L. Liu, Y. Song, Z. Ge, Sustained and bioresponsive two-stage delivery of therapeutic miRNA via polyplex micelle-loaded injectable hydrogels for inhibition of intervertebral disc fibrosis, *Adv. Healthc. Mater.* (2018) 1–14.
- [282] J. Schol, D. Sakai, Cell therapy for intervertebral disc herniation and degenerative disc disease: clinical trials, *Int. Orthop.* 43 (4) (2018) 1011–1025.
- [283] M.N. Collins, C. Birkinshaw, Hyaluronic acid based scaffolds for tissue engineering - a review, *Carbohydr. Polym.* (2013) <https://doi.org/10.1016/j.carbpol.2012.10.028>.
- [284] I.L. Kim, R.L. Mauck, J.A. Burdick, Hydrogel design for cartilage tissue engineering: a case study with hyaluronic acid, *Biomaterials.* (2011) <https://doi.org/10.1016/j.biomaterials.2011.08.073>.
- [285] H. Kumar, D.H. Ha, E.J. Lee, J.H. Park, J.H. Shim, T.K. Ahn, K.T. Kim, A.E. Ropper, S. Sohn, C.H. Kim, D.K. Thakor, S.H. Lee, I.B. Han, Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study, *Stem Cell Res Ther* (2017) <https://doi.org/10.1186/s13287-017-0710-3>.
- [286] E.C. Collin, S. Grad, D.J. Zeugolis, C.S. Vinatier, J.R. Clouet, J.J. Guicheux, P. Weiss, M. Alini, A.S. Pandit, An injectable vehicle for nucleus pulposus cell-based therapy, *Biomaterials.* 32 (2011) 2862–2870, <https://doi.org/10.1016/j.biomaterials.2011.01.018>.
- [287] Y.C. Chen, W.Y. Su, S.H. Yang, A. Gefen, F.H. Lin, In situ forming hydrogels composed of oxidized high molecular weight hyaluronic acid and gelatin for nucleus pulposus regeneration, *Acta Biomater.* (2013) <https://doi.org/10.1016/j.actbio.2012.09.039>.
- [288] M. Peroglio, D. Eglin, L.M. Benneker, M. Alini, S. Grad, Thermoreversible hyaluronan-based hydrogel supports in vitro and ex vivo disc-like differentiation of human mesenchymal stem cells, *Spine J.* 13 (2013) 1627–1639, <https://doi.org/10.1016/j.spinee.2013.05.029>.
- [289] I.L. Moss, L. Gordon, K.A. Woodhouse, C.M. Whyne, A.J.M. Yee, A novel thiol-modified hyaluronan and elastin-like polypeptide composite material for tissue engineering of the nucleus pulposus of the intervertebral disc, *Spine (Phila Pa 1976)* 2011 (1976) <https://doi.org/10.1097/BRS.0b013e3181e7b705>.
- [290] K. Chiba, G.B.J. Andersson, K. Masuda, E.J.M.A. Thonar, Metabolism of the extracellular matrix formed by intervertebral disc cells cultured in alginate, *Spine (Phila Pa 1976)* 1997 (1976) <https://doi.org/10.1097/00007632-199712150-00011>.
- [291] A.E. Baer, J.Y. Wang, V.B. Kraus, L.A. Setton, Collagen gene expression and mechanical properties of intervertebral disc cell-collagen cultures, *J. Orthop. Res.* (2001) [https://doi.org/10.1016/S0736-0266\(00\)00003-6](https://doi.org/10.1016/S0736-0266(00)00003-6).
- [292] H. Mizuno, A.K. Roy, C.A. Vacanti, K. Kojima, M. Ueda, L.J. Bonassar, Tissue-engineered composites of anulus fibrosus and nucleus pulposus for intervertebral disc replacement, *Spine (Phila Pa 1976)* (2004) <https://doi.org/10.1097/01.BRS.0000128264.46510.27>.
- [293] D. Bosnakovski, M. Mizuno, G. Kim, S. Takagi, M. Okumura, T. Fujinaga, Chondrogenic differentiation of bovine bone marrow mesenchymal stem cells (MSCs) in different hydrogels: influence of collagen type II extracellular matrix on MSC chondrogenesis, *Biotechnol. Bioeng.* (2006) <https://doi.org/10.1002/bit.20828>.
- [294] P. Roughley, C. Hoemann, E. DesRosiers, F. Mwale, J. Antoniou, M. Alini, The potential of chitosan-based gels containing intervertebral disc cells for nucleus pulposus supplementation, *Biomaterials.* (2006) <https://doi.org/10.1016/j.biomaterials.2005.06.037>.
- [295] F. Mwale, M. Iordanova, C.N. Demers, T. Steffen, P. Roughley, J. Antoniou, Biological evaluation of chitosan salts cross-linked to genipin as a cell scaffold for disk tissue engineering, *Tissue Eng.* (2005) <https://doi.org/10.1089/ten.2005.11.130>.
- [296] S.M. Richardson, N. Hughes, J.A. Hunt, A.J. Freemont, J.A. Hoyland, Human mesenchymal stem cell differentiation to NP-like cells in chitosan-glycerophosphate

- hydrogels, *Biomaterials*. (2008) <https://doi.org/10.1016/j.biomaterials.2007.09.018>.
- [297] W. Tong, Z. Lu, L. Qin, R.L. Mauck, H.E. Smith, L.J. Smith, N.R. Malhotra, M.F. Heyworth, F. Caldera, M. Enomoto-Iwamoto, Y. Zhang, Cell therapy for the degenerating intervertebral disc, *Transl. Res.* (2017) <https://doi.org/10.1016/j.trsl.2016.11.008>.
- [298] Y. Gan, S. Li, P. Li, Y. Xu, L. Wang, C. Zhao, B. Ouyang, B. Tu, C. Zhang, L. Luo, X. Luo, X. Mo, Q. Zhou, A. Controlled Release, Codelivery system of MSCs encapsulated in dextran/gelatin hydrogel with TGF- $\beta$  3-loaded nanoparticles for nucleus pulposus regeneration, *Stem Cells Int.* (2016) <https://doi.org/10.1155/2016/9042019>.
- [299] C.Z. Liang, H. Li, Y.Q. Tao, X.P. Zhou, Z.R. Yang, Y.X. Xiao, F.C. Li, B. Han, Q.X. Chen, Dual delivery for stem cell differentiation using dexamethasone and bFGF in/on polymeric microspheres as a cell carrier for nucleus pulposus regeneration, *J. Mater. Sci. Mater. Med.* (2012) <https://doi.org/10.1007/s10856-012-4563-0>.
- [300] C.Z. Liang, H. Li, Y.Q. Tao, L.H. Peng, J.Q. Gao, J. Wu, F.C. Li, J.M. Hua, Q.X. Chen, Dual release of dexamethasone and TGF- $\beta$ 3 from polymeric microspheres for stem cell matrix accumulation in a rat disc degeneration model, *Acta Biomater.* (2013) <https://doi.org/10.1016/j.actbio.2013.08.019>.
- [301] R.M. Gonçalves, J.C. Antunes, M.A. Barbosa, Mesenchymal stem cell recruitment by stromal derived factor-1-delivery systems based on chitosan/poly( $\gamma$ -glutamic acid) polyelectrolyte complexes, *Eur. Cells. Mater.* (2012) <https://doi.org/10.22203/eCM.v023a19>.
- [302] H. Zhang, S. Yu, X. Zhao, Z. Mao, C. Gao, Stromal cell-derived factor-1 $\alpha$ -encapsulated albumin/heparin nanoparticles for induced stem cell migration and intervertebral disc regeneration in vivo, *Acta Biomater.* (2018) <https://doi.org/10.1016/j.actbio.2018.03.032>.
- [303] I. Freeman, S. Cohen, The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization, *Biomaterials*. (2009) <https://doi.org/10.1016/j.biomaterials.2008.12.057>.
- [304] M. Wei, Y. Gao, X. Li, M.J. Serpe, Stimuli-responsive polymers and their applications, *Polym. Chem.* (2017) <https://doi.org/10.1039/c6py01585a>.
- [305] F. Seidi, R. Renjoh, D. Crespy, Designing smart polymer conjugates for controlled release of payloads, *Chem. Rev.* (2018) <https://doi.org/10.1021/acs.chemrev.8b00006>.
- [306] W. Xu, P.A. Ledin, Z. Iatridi, C. Tsitsilianis, V. Tsukruk, Multicompartmental microcapsules with orthogonal programmable two-way sequencing of hydrophobic and hydrophilic cargo release, *Angew. Chem. Int. Ed.* (2016) <https://doi.org/10.1002/anie.201600383>.
- [307] S. Mura, J. Nicolas, P. Couvreur, Stimuli-responsive nanocarriers for drug delivery, *Nat. Mater.* (2013) <https://doi.org/10.1038/nmat3776>.
- [308] S.J. Bryant, F.J. Vernerey, Programmable hydrogels for cell encapsulation and neo-tissue growth to enable personalized tissue engineering, *Adv. Healthc. Mater.* (2018) <https://doi.org/10.1002/adhm.201700605>.
- [309] J. Hoque, N. Sangaj, S. Varghese, Stimuli-responsive supramolecular hydrogels and their applications in regenerative medicine, *Macromol. Biosci.* 19 (1) (2019) e1800259.
- [310] K.R. Mulligan, C.E. Ferland, R. Gawri, A. Borthakur, L. Haglund, J.A. Ouellet, Axial T1 $\rho$  MRI as a diagnostic imaging modality to quantify proteoglycan concentration in degenerative disc disease, *Eur. Spine J.* (2014) <https://doi.org/10.1007/s00586-014-3582-6>.
- [311] G. Vadalà, F. Russo, S. Battisti, L. Stellato, F. Martina, R. Del Vescovo, A. Gialalone, A. Borthakur, B.B. Zobel, V. Denaro, Early intervertebral disc degeneration changes in asymptomatic weightlifters assessed by T1 $\rho$ -magnetic resonance imaging, *Spine (Phila Pa 1976)* (2014) <https://doi.org/10.1097/BRS.0000000000000554>.
- [312] C.P.L. Paul, T.H. Smit, M. de Graaf, R.M. Holewijn, A. Bisschop, P.M. van de Ven, M.G. Mullender, M.N. Helder, G.J. Strijkers, Quantitative MRI in early intervertebral disc degeneration: T1 $\rho$  correlates better than T2 and ADC with biomechanics, histology and matrix content, *PLoS One* (2018) <https://doi.org/10.1371/journal.pone.0191442>.
- [313] T.W. Evashwick-Rogler, A. Lai, H. Watanabe, J.M. Salandra, B.A. Winkelstein, S.K. Cho, A.C. Hecht, J.C. Iatridis, Inhibiting tumor necrosis factor-alpha at time of induced intervertebral disc injury limits long-term pain and degeneration in a rat model, *JOR Spine*. 1 (2018).
- [314] S. Ohtori, M. Miyagi, Y. Eguchi, G. Inoue, S. Orita, N. Ochiai, S. Kishida, K. Kuniyoshi, J. Nakamura, Y. Aoki, T. Ishikawa, G. Arai, H. Kamoda, M. Suzuki, M. Takaso, T. Furuya, G. Kubota, Y. Sakuma, Y. Oikawa, T. Toyone, K. Takahashi, Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica, *Eur. Spine J.* (2012) <https://doi.org/10.1007/s00586-012-2183-5>.
- [315] T. Sainoh, S. Orita, M. Miyagi, G. Inoue, K. Yamauchi, M. Suzuki, Y. Sakuma, G. Kubota, Y. Oikawa, K. Inage, J. Sato, Y. Nakata, Y. Aoki, K. Takahashi, S. Ohtori, Single intradiscal injection of the interleukin-6 receptor antibody tocilizumab provides short-term relief of discogenic low back pain; prospective comparative cohort study, *J. Orthop. Sci.* (2016) <https://doi.org/10.1016/j.jos.2015.10.005>.
- [316] R.K. Studer, A.M. Aboka, L.G. Gilbertson, H. Georgescu, G. Sowa, N. Vo, J.D. Kang, p38 MAPK inhibition in nucleus pulposus cells: A potential target for treating intervertebral disc degeneration, *Spine (Phila Pa 1976)* 2007 (1976) <https://doi.org/10.1097/BRS.0b013e31815b757a>.
- [317] J.S. Kim, M.B. Ellman, D. Yan, H.S. An, R. Kc, X. Li, D. Chen, G. Xiao, G. Cs-Szabo, D.W. Hoskin, D.D. Buechter, A.J. Van Wijnen, H.J. Im, Lactoferricin mediates anti-inflammatory and anti-catabolic effects via inhibition of IL-1 and LPS activity in the intervertebral disc, *J. Cell. Physiol.* (2013) <https://doi.org/10.1002/jcp.24350>.
- [318] W. Fang, X. Zhou, J. Wang, L. Xu, L. Zhou, W. Yu, Y. Tao, J. Zhu, B. Hu, C. Liang, F. Li, J. Hua, Q. Chen, Wogonin mitigates intervertebral disc degeneration through the Nrf2/ARE and MAPK signaling pathways, *Int. Immunopharmacol.* (2018) <https://doi.org/10.1016/j.intimp.2018.10.024>.
- [319] *ClinicalTrials.gov*, NCT00813813, (2016).
- [320] *ClinicalTrials.gov*, NCT01182337, (2016).
- [321] *ClinicalTrials.gov*, NCT01124006, (2016).
- [322] *ClinicalTrials.gov*, NCT01158924, (2016).
- [323] C.M. Tran, Z.R. Schoepflin, D.Z. Markova, C.K. Kepler, D.G. Anderson, I.M. Shapiro, M.V. Risbud, CCN2 suppresses catabolic effects of interleukin-1beta through alpha5beta1 and alphaVbeta3 integrins in nucleus pulposus cells: implications in intervertebral disc degeneration, *J. Biol. Chem.* 289 (2014) 7374–7387, <https://doi.org/10.1074/jbc.M113.526111>.
- [324] Liu Jianwei, Jiang Tongmeng, He Mingwei, Fang Depeng, Shen Chong, He Molin Le Yiguan, Zhao Jinmin, Zheng Li, Andrographolide prevents human nucleus pulposus cells against degeneration by inhibiting the NF- $\kappa$ B pathway, *J. Cell. Physiol.* 234 (6) (2018) 9631–9639.
- [325] A. Matta, M.Z. Karim, D.E. Isenman, W.M. Erwin, Molecular therapy for degenerative disc disease: clues from secretome analysis of the notochordal cell-rich nucleus pulposus, *Sci. Rep.* (2017) <https://doi.org/10.1038/srep45623>.
- [326] C.L. Le Maitre, P. Baird, A.J. Freemont, J.A. Hoyland, An in vitro study investigating the survival and phenotype of mesenchymal stem cells following injection into nucleus pulposus tissue, *Arthritis Res. Ther.* 11 (2009) R20, <https://doi.org/10.1186/ar2611>.
- [327] J. Yan, S. Yang, H. Sun, D. Guo, B. Wu, F. Ji, D. Zhou, Effects of releasing recombinant human growth and differentiation factor-5 from poly(lactic-co-glycolic acid) microspheres for repair of the rat degenerated intervertebral disc, *J. Biomater. Appl.* (2014) <https://doi.org/10.1177/0885328213515034>.
- [328] N. Suffee, C. Le Visage, H. Hlawaty, R. Aid-Launais, V. Vanneaux, J. Larghero, O. Haddad, O. Oudar, N. Charnaux, A. Sutton, Pro-Angiogenic effect of RANTES-loaded polysaccharide-based microparticles for a mouse ischemia therapy, *Sci. Rep.* (2017) <https://doi.org/10.1038/s41598-017-13444-7>.
- [329] S.M. Sinclair, J. Bhattacharyya, J.R. McDaniel, D.M. Gooden, R. Gopalaswamy, A. Chilkoti, L.A. Setton, A genetically engineered thermally responsive sustained release curcumin depot to treat neuroinflammation, *J. Control. Release* (2013) <https://doi.org/10.1016/j.jconrel.2013.06.032>.
- [330] Y.H. Cheng, S.H. Yang, F.H. Lin, Thermosensitive chitosan-gelatin-glycerol phosphate hydrogel as a controlled release system of ferulic acid for nucleus pulposus regeneration, *Biomaterials*. (2011) <https://doi.org/10.1016/j.biomaterials.2011.03.065>.
- [331] C. Pereira, G. Quelhas Teixeira, J. Rita Ferreira, M. D'Este, D. Eglin, M. Alini, S. Grad, M.A. Barbosa, R.M. Gonçalves, Stromal cell derived factor-1-mediated migration of mesenchymal stem cells enhances collagen type II expression in intervertebral disc, *Tissue Eng. Part A.* (2018) <https://doi.org/10.1089/ten.tea.2018.0131>.